From cb9de48ed2e35a66e38244f56de732f2834a40a2 Mon Sep 17 00:00:00 2001 From: Joshua McMichael Date: Wed, 19 Jul 2023 12:30:28 -0500 Subject: [PATCH] removed unused, deprecated deps, scripts --- client/e2e/protractor.conf.js | 37 - client/e2e/src/app.e2e-spec.ts | 25 - client/e2e/src/app.po.ts | 11 - client/e2e/tsconfig.json | 10 - client/package.json | 21 +- client/scripts/gql-server-data/genes.json | 6533 ------------------ client/scripts/gql-server-data/variants.json | 2088 ------ client/scripts/gql-server-mocks.js | 15 - client/scripts/gql-server-schema.js | 54 - client/scripts/gql-server.js | 25 - client/src/app/app.module.ts | 2 - client/yarn.lock | 1454 +--- 12 files changed, 41 insertions(+), 10234 deletions(-) delete mode 100644 client/e2e/protractor.conf.js delete mode 100644 client/e2e/src/app.e2e-spec.ts delete mode 100644 client/e2e/src/app.po.ts delete mode 100644 client/e2e/tsconfig.json delete mode 100644 client/scripts/gql-server-data/genes.json delete mode 100644 client/scripts/gql-server-data/variants.json delete mode 100644 client/scripts/gql-server-mocks.js delete mode 100644 client/scripts/gql-server-schema.js delete mode 100644 client/scripts/gql-server.js diff --git a/client/e2e/protractor.conf.js b/client/e2e/protractor.conf.js deleted file mode 100644 index 361e7f0cd..000000000 --- a/client/e2e/protractor.conf.js +++ /dev/null @@ -1,37 +0,0 @@ -// @ts-check -// Protractor configuration file, see link for more information -// https://github.com/angular/protractor/blob/master/lib/config.ts - -const { SpecReporter, StacktraceOption } = require('jasmine-spec-reporter'); - -/** - * @type { import("protractor").Config } - */ -exports.config = { - allScriptsTimeout: 11000, - specs: [ - './src/**/*.e2e-spec.ts' - ], - capabilities: { - browserName: 'chrome' - }, - directConnect: true, - SELENIUM_PROMISE_MANAGER: false, - baseUrl: 'http://localhost:4200/', - framework: 'jasmine', - jasmineNodeOpts: { - showColors: true, - defaultTimeoutInterval: 30000, - print: function() {} - }, - onPrepare() { - require('ts-node').register({ - project: require('path').join(__dirname, './tsconfig.json') - }); - jasmine.getEnv().addReporter(new SpecReporter({ - spec: { - displayStacktrace: StacktraceOption.PRETTY - } - })); - } -}; \ No newline at end of file diff --git a/client/e2e/src/app.e2e-spec.ts b/client/e2e/src/app.e2e-spec.ts deleted file mode 100644 index 41abb372e..000000000 --- a/client/e2e/src/app.e2e-spec.ts +++ /dev/null @@ -1,25 +0,0 @@ -import { AppPage } from './app.po' -import { browser, logging } from 'protractor' - -describe('workspace-project App', () => { - let page: AppPage - - beforeEach(() => { - page = new AppPage() - }) - - it('should display welcome message', async () => { - await page.navigateTo() - expect(await page.getTitleText()).toEqual('main app is running!') - }) - - afterEach(async () => { - // Assert that there are no errors emitted from the browser - const logs = await browser.manage().logs().get(logging.Type.BROWSER) - expect(logs).not.toContain( - jasmine.objectContaining({ - level: logging.Level.SEVERE, - } as logging.Entry) - ) - }) -}) diff --git a/client/e2e/src/app.po.ts b/client/e2e/src/app.po.ts deleted file mode 100644 index d3b92292e..000000000 --- a/client/e2e/src/app.po.ts +++ /dev/null @@ -1,11 +0,0 @@ -import { browser, by, element } from 'protractor' - -export class AppPage { - async navigateTo(): Promise { - return browser.get(browser.baseUrl) - } - - async getTitleText(): Promise { - return element(by.css('app-root .content span')).getText() - } -} diff --git a/client/e2e/tsconfig.json b/client/e2e/tsconfig.json deleted file mode 100644 index ecbd85755..000000000 --- a/client/e2e/tsconfig.json +++ /dev/null @@ -1,10 +0,0 @@ -/* To learn more about this file see: https://angular.io/config/tsconfig. */ -{ - "extends": "../tsconfig.json", - "compilerOptions": { - "outDir": "../out-tsc/e2e", - "module": "commonjs", - "target": "es2018", - "types": ["jasmine", "node"] - } -} diff --git a/client/package.json b/client/package.json index 4ec29f721..7909a433a 100644 --- a/client/package.json +++ b/client/package.json @@ -9,9 +9,6 @@ "build:watch": "ng build --watch --configuration production", "build:generate-stats": "ng build --configuration production --stats-json && webpack-bundle-analyzer ../server/public/stats.json", "build:analyze-stats": "yarn run build:generate-stats && webpack-bundle-analyzer ../server/public/stats.json", - "test": "ng test", - "lint": "ng lint", - "e2e": "ng e2e", "optimize-icon-svg": "svgo --config .svgo.config.js -f ./src/assets/icons/ -r -o ./src/assets/icons/.tmp", "generate-icon-ts": "svg-to-ts-constants", "generate-icons": "yarn run optimize-icon-svg && yarn run generate-icon-ts", @@ -37,11 +34,9 @@ "@ngrx/component": "^16.1.0", "@ngx-formly/core": "^6.1.8", "@ngx-formly/ng-zorro-antd": "^6.1.8", - "@tinkoff/ng-polymorpheus": "^4.0.10", "apollo-angular": "^5.0.0", "ng-zorro-antd": "^16.1.0", "ngx-cookie-service": "^16.0.0", - "ngx-logger": "^5.0.7", "rxjs": "^7.8.1", "rxjs-etc": "^10.6.2", "rxjs-spy": "^8.0.2", @@ -61,24 +56,10 @@ "@graphql-codegen/typescript-apollo-angular": "^3.5.6", "@graphql-codegen/typescript-apollo-client-helpers": "^2.2.6", "@graphql-codegen/typescript-operations": "^2.5.12", - "@types/jasmine": "~3.6.0", "@types/node": "^12.11.1", - "@typescript-eslint/eslint-plugin": "5.48.1", - "@typescript-eslint/parser": "5.48.1", - "casual": "^1.6.2", - "cosmiconfig-toml-loader": "^1.0.0", - "eslint": "^8.31.0", "graphql": "^16.7.1", - "jasmine-core": "^4.5.0", - "jasmine-spec-reporter": "^7.0.0", - "karma": "^6.4.1", - "karma-chrome-launcher": "^3.1.1", - "karma-coverage": "^2.2.0", - "karma-jasmine": "^5.1.0", - "karma-jasmine-html-reporter": "^2.0.0", "ngx-json-viewer": "^3.0.2", "prettier": "^2.5.1", - "protractor": "^7.0.0", "svg-to-ts": "^9.0.0", "svgo": "^3.0.2", "ts-node": "~10.9.1", @@ -92,4 +73,4 @@ "error-stack-parser": "2.0.6" } } -} \ No newline at end of file +} diff --git a/client/scripts/gql-server-data/genes.json b/client/scripts/gql-server-data/genes.json deleted file mode 100644 index 9d6226bf5..000000000 --- a/client/scripts/gql-server-data/genes.json +++ /dev/null @@ -1,6533 +0,0 @@ -{ - "records": [ - { - "id": 1, - "name": "ALK", - "entrez_id": 238, - "description": "ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.", - "flagged": false, - "variants": [ - { - "name": "CAD-ALK", - "id": 2769, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK C1156Y-L1198F", - "id": 352, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "EML4-ALK E20;A20", - "id": 500, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK L1152R", - "id": 307, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK C1156Y", - "id": 6, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 2, - "submitted_count": 7 - } - }, - { - "name": "EML4-ALK T1151INST", - "id": 173, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "EML4-ALK G1269A", - "id": 308, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "ALK FUSIONS", - "id": 499, - "evidence_items": { - "accepted_count": 31, - "rejected_count": 2, - "submitted_count": 10 - } - }, - { - "name": "ALK FUSION F1245C", - "id": 551, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK L1196M", - "id": 7, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 11 - } - }, - { - "name": "NPM-ALK", - "id": 513, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "F1245C", - "id": 549, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK V1180L", - "id": 528, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "CLTC-ALK", - "id": 520, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK E2;A20", - "id": 501, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "DEL4-11", - "id": 550, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK E6;A20", - "id": 503, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R1275Q", - "id": 9, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "F1245V", - "id": 1295, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "ALTERNATIVE TRANSCRIPT (ATI)", - "id": 839, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "HIP1-ALK I1171N", - "id": 588, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "MUTATION", - "id": 512, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK I1171S", - "id": 589, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "RANBP2-ALK", - "id": 514, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "F1174L", - "id": 8, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "STRN-ALK", - "id": 2218, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EML4-ALK", - "id": 5, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "ALK FUSION G1269A", - "id": 552, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ALK FUSION G1202R", - "id": 171, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "EML4-ALK S1206Y", - "id": 172, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "EML4-ALK and AMPLIFICATION", - "id": 170, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ALK FUSION I1171", - "id": 527, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 3 - } - } - ], - "aliases": ["ALK", "NBLST3", "CD246"], - "updated_at": "2017-03-06T00:00:15.358Z", - "type": "gene" - }, - { - "id": 2, - "name": "AKT1", - "entrez_id": 207, - "description": "AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.", - "flagged": false, - "variants": [ - { - "name": "E17K", - "id": 4, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "OVEREXPRESSION", - "id": 2360, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Q79K", - "id": 169, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "PKB-ALPHA", - "RAC-ALPHA", - "AKT1", - "RAC", - "AKT", - "PKB", - "PRKBA" - ], - "updated_at": "2017-02-09T21:58:06.184Z", - "type": "gene" - }, - { - "id": 3, - "name": "ARAF", - "entrez_id": 369, - "description": "ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.", - "flagged": false, - "variants": [ - { - "name": "S490T", - "id": 825, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "S214C", - "id": 10, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["ARAF", "RAFA1", "PKS2", "ARAF1", "A-RAF"], - "updated_at": "2015-06-21T16:49:19.894Z", - "type": "gene" - }, - { - "id": 4, - "name": "ABL1", - "entrez_id": 25, - "description": "ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.", - "flagged": false, - "variants": [ - { - "name": "ABL1-RCSD1", - "id": 2681, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL F317C", - "id": 2359, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL M244V", - "id": 1021, - "evidence_items": { - "accepted_count": 12, - "rejected_count": 1, - "submitted_count": 6 - } - }, - { - "name": "BCR-ABL E255K", - "id": 3, - "evidence_items": { - "accepted_count": 19, - "rejected_count": 2, - "submitted_count": 4 - } - }, - { - "name": "BCR-ABL E453K", - "id": 1535, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL E292L", - "id": 2887, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL Q252H", - "id": 1024, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 10 - } - }, - { - "name": "BCR-ABL N331S", - "id": 1529, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "R351W", - "id": 1656, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E98G", - "id": 2901, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL A397P", - "id": 1612, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "ETV6-ABL1", - "id": 2575, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL L387F", - "id": 1232, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL T315V", - "id": 2885, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL M244V and L364I", - "id": 2949, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL T315I", - "id": 2, - "evidence_items": { - "accepted_count": 24, - "rejected_count": 2, - "submitted_count": 18 - } - }, - { - "name": "BCR-ABL H396P", - "id": 1531, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "BCR-ABL G250E", - "id": 1023, - "evidence_items": { - "accepted_count": 13, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "BCR-ABL E450Q", - "id": 2948, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL Y253F", - "id": 2909, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL L248R", - "id": 2340, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E279K", - "id": 1526, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL", - "id": 1, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL D276G", - "id": 1027, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 1, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL L387M", - "id": 1488, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL M351T", - "id": 1029, - "evidence_items": { - "accepted_count": 12, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "BCR-ABL H396R", - "id": 1030, - "evidence_items": { - "accepted_count": 10, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "BCR-ABL E255V", - "id": 1173, - "evidence_items": { - "accepted_count": 10, - "rejected_count": 2, - "submitted_count": 7 - } - }, - { - "name": "BCR-ABL V298I", - "id": 2952, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E450V", - "id": 1534, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL D421G", - "id": 1532, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL F486S", - "id": 1152, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 1, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL V299L", - "id": 1231, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "BCR-ABL N336S", - "id": 1640, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL L248V", - "id": 1022, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 3, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL D363G", - "id": 2900, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL M343T", - "id": 1524, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL V379I", - "id": 1609, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL L364I", - "id": 2902, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Non-P-Loop Mutation", - "id": 2376, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL F359C", - "id": 1184, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 1, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL F359V", - "id": 892, - "evidence_items": { - "accepted_count": 15, - "rejected_count": 1, - "submitted_count": 3 - } - }, - { - "name": "BCR-ABL Q300R", - "id": 1527, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L298V", - "id": 1506, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL F317L", - "id": 241, - "evidence_items": { - "accepted_count": 19, - "rejected_count": 1, - "submitted_count": 9 - } - }, - { - "name": "BCR-ABL E453A", - "id": 1536, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL L364P", - "id": 1530, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E255K V299L", - "id": 2890, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E292V", - "id": 1183, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL F317S", - "id": 2343, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL G398R", - "id": 1233, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL E355G", - "id": 1487, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL P480A", - "id": 1537, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "SNX2-ABL1", - "id": 2678, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "G340L", - "id": 1657, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL L248R F359I", - "id": 2889, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL N146S", - "id": 2951, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL L384M", - "id": 1230, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 3 - } - }, - { - "name": "BCR-ABL F317I", - "id": 1625, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "BCR-ABL M388L", - "id": 2954, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y253F", - "id": 1026, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 8 - } - }, - { - "name": "C475V", - "id": 1639, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL F317V", - "id": 1525, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "BCR-ABL E453Q", - "id": 1509, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FOXP1-ABL1", - "id": 2682, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL F311L", - "id": 1528, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "P-Loop Mutation", - "id": 2375, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "TKD MUTATION", - "id": 2371, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ABL1-RCSD", - "id": 2680, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E459K", - "id": 2370, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL S438C", - "id": 2953, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL E279K", - "id": 2886, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL F317R", - "id": 2888, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL Y253H", - "id": 1025, - "evidence_items": { - "accepted_count": 13, - "rejected_count": 2, - "submitted_count": 4 - } - }, - { - "name": "BCR-ABL F311I", - "id": 1507, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 1, - "submitted_count": 2 - } - }, - { - "name": "BCR-ABL F359I", - "id": 1523, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-ABL T315A", - "id": 2335, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "S417Y", - "id": 1613, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 1, - "submitted_count": 2 - } - }, - { - "name": "Double Ph", - "id": 3009, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "CHDSKM", - "BCR-ABL", - "ABL", - "ABL1", - "v-abl", - "c-ABL", - "c-ABL1", - "JTK7", - "p150", - "bcr/abl" - ], - "updated_at": "2015-06-21T16:49:20.159Z", - "type": "gene" - }, - { - "id": 5, - "name": "BRAF", - "entrez_id": 673, - "description": "BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.\n\nOncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors.\nClass 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors.\nClass 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors.\nClass 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.", - "flagged": false, - "variants": [ - { - "name": "P731T", - "id": 2224, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D594G", - "id": 611, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G464V", - "id": 1106, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "A598V", - "id": 2826, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600E and V600M", - "id": 13, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L597S", - "id": 582, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "DEL 485-490", - "id": 522, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 399, - "evidence_items": { - "accepted_count": 12, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G596R", - "id": 1627, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "V600E and AMPLIFICATION", - "id": 14, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N486_P490del", - "id": 2794, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "K601E", - "id": 584, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "L597R", - "id": 288, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D594V", - "id": 580, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PAPSS1-BRAF", - "id": 286, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L505H", - "id": 658, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "WILD TYPE", - "id": 426, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PPFIBP2-BRAF", - "id": 617, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G596C", - "id": 694, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600_K601>E", - "id": 2820, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "intron 10 rearrangement", - "id": 2226, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ZKSCAN1-BRAF", - "id": 657, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600E/K and AMPLIFICATION", - "id": 2361, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MACF1-BRAF", - "id": 2227, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AGK-BRAF", - "id": 285, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 1269, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G469", - "id": 2822, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "WASFL-BRAF", - "id": 2228, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G606E", - "id": 2223, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G496A", - "id": 2221, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N581S", - "id": 1186, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D594A", - "id": 579, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "NRF1-BRAF", - "id": 2883, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "CUX1-BRAF", - "id": 2229, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600D", - "id": 11, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "TRIM24-BRAF", - "id": 287, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "intron 9 rearrangement", - "id": 2225, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600K", - "id": 563, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 10 - } - }, - { - "name": "AKAP9-BRAF", - "id": 184, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Non-V600", - "id": 2408, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600E", - "id": 12, - "evidence_items": { - "accepted_count": 85, - "rejected_count": 7, - "submitted_count": 79 - } - }, - { - "name": "L597V", - "id": 585, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V600", - "id": 17, - "evidence_items": { - "accepted_count": 22, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "A728V", - "id": 1198, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "KIAA1549-BRAF", - "id": 618, - "evidence_items": { - "accepted_count": 11, - "rejected_count": 1, - "submitted_count": 3 - } - }, - { - "name": "D594K", - "id": 2398, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G466V", - "id": 2222, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 15 MUTATION", - "id": 2650, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G469A", - "id": 992, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "BRAF-CUL1", - "id": 656, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K483M", - "id": 581, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G469E", - "id": 993, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "L597Q", - "id": 583, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["BRAF", "B-raf", "NS7", "RAFB1", "BRAF1", "B-RAF1"], - "updated_at": "2019-09-19T19:32:44.942Z", - "type": "gene" - }, - { - "id": 6, - "name": "BRCA1", - "entrez_id": 672, - "description": "BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", - "flagged": false, - "variants": [ - { - "name": "C61G", - "id": 1238, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Alu insertion", - "id": 709, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Q1467*", - "id": 1246, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R1495M", - "id": 1242, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R71K", - "id": 1241, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R1443*", - "id": 1245, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M1I", - "id": 1237, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "LOSS-OF-FUNCTION", - "id": 131, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "C64Y", - "id": 1239, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXPRESSION", - "id": 397, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "W1815X", - "id": 1555, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "UNDEREXPRESSION", - "id": 403, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "P968FS", - "id": 477, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E1559K", - "id": 1243, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 185, - "evidence_items": { - "accepted_count": 16, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "D1692N", - "id": 1244, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R71G", - "id": 1240, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "BROVCA1", - "BRCA1", - "RNF53", - "PSCP", - "PPP1R53", - "PNCA4", - "IRIS", - "FANCS", - "BRCC1", - "BRCAI" - ], - "updated_at": "2020-02-01T00:00:24.080Z", - "type": "gene" - }, - { - "id": 7, - "name": "BRCA2", - "entrez_id": 675, - "description": "BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.", - "flagged": false, - "variants": [ - { - "name": "R2336P", - "id": 1252, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V211I", - "id": 1251, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M1R", - "id": 1247, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "TRUNCATING MUTATION", - "id": 708, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V159M", - "id": 1249, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D3095E", - "id": 661, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R2336H", - "id": 1253, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V211L", - "id": 1250, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 186, - "evidence_items": { - "accepted_count": 17, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "M1I", - "id": 1248, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K3226*", - "id": 2871, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "LOSS-OF-FUNCTION", - "id": 132, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": [ - "FAD", - "FACD", - "BROVCA2", - "BRCC2", - "FAD1", - "PNCA2", - "BRCA2", - "XRCC11", - "GLM3", - "FANCD1", - "FANCD" - ], - "updated_at": "2020-02-01T00:00:24.148Z", - "type": "gene" - }, - { - "id": 8, - "name": "CCND1", - "entrez_id": 595, - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins, and the cyclin-dependent kinases (CDK's) they activate, have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, but currently there are no FDA-approved targeted therapies.", - "flagged": false, - "variants": [ - { - "name": "AMPLIFICATION", - "id": 18, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "OVEREXPRESSION", - "id": 20, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "EXPRESSION", - "id": 19, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["BCL1", "CCND1", "U21B31", "PRAD1", "D11S287E"], - "updated_at": "2016-11-15T15:45:36.784Z", - "type": "gene" - }, - { - "id": 9, - "name": "CCND2", - "entrez_id": 894, - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.", - "flagged": false, - "variants": [ - { - "name": "OVEREXPRESSION", - "id": 21, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PROMOTER DEMETHYLATION", - "id": 22, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["CCND2", "MPPH3", "KIAK0002"], - "updated_at": "2015-06-21T16:49:21.541Z", - "type": "gene" - }, - { - "id": 10, - "name": "CCND3", - "entrez_id": 896, - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.", - "flagged": false, - "variants": [ - { - "name": "LOSS", - "id": 23, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["CCND3"], - "updated_at": "2015-06-21T16:49:21.753Z", - "type": "gene" - }, - { - "id": 11, - "name": "CCNE1", - "entrez_id": 898, - "description": "Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.", - "flagged": false, - "variants": [ - { - "name": "AMPLIFICATION", - "id": 187, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "OVEREXPRESSION", - "id": 24, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": ["CCNE1", "pCCNE1", "CCNE"], - "updated_at": "2015-06-21T16:49:21.982Z", - "type": "gene" - }, - { - "id": 12, - "name": "CDK6", - "entrez_id": 1021, - "description": "CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.", - "flagged": false, - "variants": [ - { - "name": "OVEREXPRESSION", - "id": 602, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "EXPRESSION", - "id": 3042, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["MCPH12", "PLSTIRE", "CDK6"], - "updated_at": "2017-02-09T21:58:24.991Z", - "type": "gene" - }, - { - "id": 13, - "name": "CDK4", - "entrez_id": 1019, - "description": "CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.", - "flagged": false, - "variants": [ - { - "name": "AMPLIFICATION", - "id": 553, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXPRESSION", - "id": 25, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "R24C", - "id": 556, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["PSK-J3", "CDK4", "CMM3"], - "updated_at": "2017-02-09T21:58:24.937Z", - "type": "gene" - }, - { - "id": 14, - "name": "CDKN2A", - "entrez_id": 1029, - "description": "CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.\nAdditionally, CDKN2A (p16) expression is a surrogate marker for HPV infection. As such, CDKN2A expression is prognostic in Oropharyngeal and probably also non-oropharyngeal head and neck squamous cell carcinomas.", - "flagged": false, - "variants": [ - { - "name": "p16 EXPRESSION", - "id": 272, - "evidence_items": { - "accepted_count": 10, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "RS3814960", - "id": 641, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "DELETION", - "id": 2654, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "LOSS", - "id": 554, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "MUTATION", - "id": 2704, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PROMOTER HYPERMETHYLATION", - "id": 27, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "CDKN2A", - "TP16", - "P19ARF", - "P19", - "P16INK4A", - "P16-INK4A", - "P16", - "P14ARF", - "MTS1", - "MTS-1", - "MLM", - "INK4", - "CMM2", - "CDKN2", - "ARF", - "P16INK4", - "INK4A", - "P14", - "CDK4I" - ], - "updated_at": "2017-05-04T19:54:39.142Z", - "type": "gene" - }, - { - "id": 15, - "name": "CEBPA", - "entrez_id": 1050, - "description": "'AML with mutated CEBPA' is a provisional entity in the WHO classification of acute myeloid leukemia (AML) and is recommended to be tested for in patients with AML. CEBPA mutations are particularly associated with cytogenetically normal AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha protein while C-terminal mutations reduce the DNA-binding potential of this transcription factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.", - "flagged": false, - "variants": [ - { - "name": "BIALLELIC INACTIVATION", - "id": 594, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 29, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N-TERMINAL FRAME SHIFT", - "id": 28, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["C/EBP-alpha", "CEBP", "CEBPA"], - "updated_at": "2020-02-01T00:00:35.631Z", - "type": "gene" - }, - { - "id": 17, - "name": "PRKACA", - "entrez_id": 5566, - "description": "PRKACA has been studied in breast cancer and has been found to mediate resistance to HER2 targeted therapies. It has also been found to contain a mutation hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.", - "flagged": false, - "variants": [ - { - "name": "DNAJB1-PRKACA", - "id": 31, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["PRKACA", "PPNAD4", "PKACA"], - "updated_at": "2017-02-09T22:00:11.593Z", - "type": "gene" - }, - { - "id": 18, - "name": "DNMT3A", - "entrez_id": 1788, - "description": "DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.", - "flagged": false, - "variants": [ - { - "name": "MUTATION", - "id": 189, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R882", - "id": 32, - "evidence_items": { - "accepted_count": 28, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["DNMT3A", "HESJAS", "TBRS", "DNMT3A2", "M.HsaIIIA"], - "updated_at": "2017-02-09T21:58:41.799Z", - "type": "gene" - }, - { - "id": 19, - "name": "EGFR", - "entrez_id": 1956, - "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. \nOverproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).", - "flagged": false, - "variants": [ - { - "name": "S768I", - "id": 562, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "T785A", - "id": 1573, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G719S", - "id": 134, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "Y764_V765insHH", - "id": 1665, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "C797Y", - "id": 1574, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L747P", - "id": 1891, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EGFR-RAD51", - "id": 2203, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E734Q", - "id": 1572, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E868G", - "id": 1482, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "P753S", - "id": 460, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "H773_V774insNPH", - "id": 1513, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L858R", - "id": 33, - "evidence_items": { - "accepted_count": 37, - "rejected_count": 1, - "submitted_count": 4 - } - }, - { - "name": "S492R", - "id": 453, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "A864T", - "id": 1187, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D761Y", - "id": 712, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D770_N771insGT", - "id": 1566, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R451C", - "id": 454, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "COPY NUMBER VARIATION", - "id": 191, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXPRESSION", - "id": 354, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "A289V", - "id": 996, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K757R", - "id": 723, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R108K", - "id": 994, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "S720", - "id": 720, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T790M", - "id": 34, - "evidence_items": { - "accepted_count": 30, - "rejected_count": 2, - "submitted_count": 9 - } - }, - { - "name": "E746_T751>I", - "id": 1003, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "L747_S752delinsQ", - "id": 1580, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N842S", - "id": 1899, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G465R", - "id": 443, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "R776C", - "id": 1181, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "P772_H773insYNP", - "id": 1667, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 19 DELETION", - "id": 133, - "evidence_items": { - "accepted_count": 16, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "N826S", - "id": 1188, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L747_P753delinsS", - "id": 1012, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 8 - } - }, - { - "name": "A767_V769dupASV", - "id": 1579, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "E746G", - "id": 724, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Gain-of-function", - "id": 1765, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "W731L", - "id": 1571, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V769_770insASV", - "id": 736, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "EXON 20 INSERTION", - "id": 726, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "G719", - "id": 718, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "C797S", - "id": 415, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "V834I", - "id": 1897, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N826Y", - "id": 1896, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "A763_Y764insFQEA", - "id": 1515, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "D770_N771insSVD", - "id": 1445, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "L838V", - "id": 1018, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L861Q", - "id": 1020, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "EXON 4 DELETION", - "id": 252, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L861R", - "id": 1477, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "G719A", - "id": 999, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "D770_N771insGL", - "id": 1514, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G724S", - "id": 317, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K806E", - "id": 1895, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V774M", - "id": 1894, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T263P", - "id": 995, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 190, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "P772_V774insPHV", - "id": 1668, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V851I", - "id": 1466, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y801H", - "id": 1575, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "RARE Exon 18-21 Mutation", - "id": 1863, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K467T", - "id": 455, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "G719D", - "id": 1420, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "RARE EGRF MUT", - "id": 2334, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L838P", - "id": 1457, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R831H", - "id": 1017, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "L861", - "id": 1866, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 18 OVEREXPRESSION", - "id": 375, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E746_A750del", - "id": 1002, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 19 - } - }, - { - "name": "H773_V774insH", - "id": 1446, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "WILDTYPE", - "id": 2174, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "V774A", - "id": 1892, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 442, - "evidence_items": { - "accepted_count": 15, - "rejected_count": 1, - "submitted_count": 3 - } - }, - { - "name": "OVEREXPRESSION", - "id": 193, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 2, - "submitted_count": 3 - } - }, - { - "name": "R705K", - "id": 2333, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Ex19 del L858R", - "id": 1854, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V742A", - "id": 1001, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "T847I", - "id": 1463, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M766_A767insAI", - "id": 1664, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y1092 PHOSPHORYLATION", - "id": 390, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "VIII", - "id": 312, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "D770_N771insGY", - "id": 1666, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["ERBB1", "NISBD2", "ERBB", "EGFR", "PIG61", "mENA", "HER1"], - "updated_at": "2020-04-22T22:27:33.031Z", - "type": "gene" - }, - { - "id": 20, - "name": "ERBB2", - "entrez_id": 2064, - "description": "ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.", - "flagged": false, - "variants": [ - { - "name": "G776L", - "id": 816, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G309A", - "id": 38, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y772_A775DUP", - "id": 414, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 2, - "submitted_count": 1 - } - }, - { - "name": "P780INS", - "id": 41, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L755W", - "id": 40, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "OVEREXPRESSION", - "id": 875, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 9 - } - }, - { - "name": "L755_T759del", - "id": 37, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L866M", - "id": 496, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "R678Q", - "id": 42, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L755S", - "id": 39, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "MUTATION", - "id": 666, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D769H", - "id": 35, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V842I", - "id": 45, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "G778_P780DUP", - "id": 817, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D769Y", - "id": 36, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 306, - "evidence_items": { - "accepted_count": 61, - "rejected_count": 0, - "submitted_count": 14 - } - }, - { - "name": "KINASE DOMAIN MUTATION", - "id": 413, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T862A", - "id": 871, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "H878Y", - "id": 874, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V777L", - "id": 44, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "M774DELINSWLV", - "id": 818, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "SERUM LEVELS", - "id": 416, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N857S", - "id": 873, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R896C", - "id": 43, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "S310F/Y", - "id": 497, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "V773A", - "id": 872, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "MLN 19", - "HER-2", - "ERBB2", - "NGL", - "TKR1", - "HER2", - "CD340", - "HER-2/neu", - "NEU" - ], - "updated_at": "2018-03-30T15:23:36.367Z", - "type": "gene" - }, - { - "id": 21, - "name": "ESR1", - "entrez_id": 2099, - "description": "ESR1 has been a focus in breast cancer for quite some time, but is also clinically relevant in endometrial, ovarian and other cancer types. The identification of ER-positive breast cancers that are resistant to hormone therapy have inspired clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of ESR1 have been implicated in hormone resistance and anti-estrogen therapies. These observations have spurred efforts to develop therapeutics that stimulate ESR1 protein degradation (e.g. Fulvestrant), rather than acting as a small molecule antagonist. These agents are currently in clinical trials and have seen some success.", - "flagged": false, - "variants": [ - { - "name": "D538G", - "id": 47, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "S463P", - "id": 692, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Y537C", - "id": 48, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "L536Q", - "id": 46, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y537N", - "id": 49, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "Y537S", - "id": 50, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "OVEREXPRESSION", - "id": 607, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["ER", "ESRA", "ESR", "ESR1", "Era", "ESTRR", "NR3A1"], - "updated_at": "2015-10-10T21:01:36.620Z", - "type": "gene" - }, - { - "id": 22, - "name": "FGFR2", - "entrez_id": 2263, - "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", - "flagged": false, - "variants": [ - { - "name": "FGFR2 fusions", - "id": 2202, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "FGFR2-TACC3", - "id": 54, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 629, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "MUTATION", - "id": 511, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "FGFR2 mutations", - "id": 2206, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "FGFR2-MGEA5", - "id": 52, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FGFR2-AHCYL1", - "id": 783, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FGFR2-BICC1", - "id": 782, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N550K", - "id": 545, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "K-SAM", - "TK25", - "ECT1", - "BBDS", - "BEK", - "JWS", - "CD332", - "CEK3", - "KGFR", - "TK14", - "FGFR2", - "CFD1", - "BFR-1" - ], - "updated_at": "2015-06-21T16:49:24.914Z", - "type": "gene" - }, - { - "id": 23, - "name": "FGFR3", - "entrez_id": 2261, - "description": "The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.", - "flagged": false, - "variants": [ - { - "name": "S249C", - "id": 628, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 12 - } - }, - { - "name": "EXPRESSION", - "id": 325, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y375C", - "id": 196, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "MUTATION", - "id": 827, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FGFR3-BAIAP2L1", - "id": 53, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FGFR3-TACC3", - "id": 830, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "FGFR3 FUSIONS", - "id": 1691, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - } - ], - "aliases": ["CD333", "HSFGFR3EX", "JTK4", "CEK2", "ACH", "FGFR3"], - "updated_at": "2015-06-21T16:49:25.194Z", - "type": "gene" - }, - { - "id": 24, - "name": "FLT3", - "entrez_id": 2322, - "description": "FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.", - "flagged": false, - "variants": [ - { - "name": "D835H", - "id": 612, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "F691L", - "id": 3071, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "D835Y", - "id": 3011, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "MUTATION", - "id": 519, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "D835I", - "id": 3075, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D835", - "id": 437, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 1, - "submitted_count": 4 - } - }, - { - "name": "T227M", - "id": 540, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D835V", - "id": 1302, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "TKD MUTATION", - "id": 56, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D835H/Y", - "id": 613, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y842C", - "id": 3070, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "OVEREXPRESSION", - "id": 603, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ITD", - "id": 55, - "evidence_items": { - "accepted_count": 31, - "rejected_count": 2, - "submitted_count": 3 - } - } - ], - "aliases": ["STK1", "FLT3", "FLK-2", "CD135", "FLK2"], - "updated_at": "2020-02-01T00:00:50.690Z", - "type": "gene" - }, - { - "id": 25, - "name": "GATA2", - "entrez_id": 2624, - "description": "GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.", - "flagged": false, - "variants": [ - { - "name": "EXPRESSION", - "id": 57, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["NFE1B", "MONOMAC", "IMD21", "DCML", "GATA2"], - "updated_at": "2015-06-21T16:49:25.698Z", - "type": "gene" - }, - { - "id": 26, - "name": "IDH1", - "entrez_id": 3417, - "description": "IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.", - "flagged": false, - "variants": [ - { - "name": "R132H", - "id": 420, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "R132", - "id": 58, - "evidence_items": { - "accepted_count": 11, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "R132C", - "id": 59, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 2, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 645, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": [ - "IDH", - "IDP", - "PICD", - "HEL-216", - "IDH1", - "HEL-S-26", - "IDPC", - "IDCD" - ], - "updated_at": "2020-02-01T00:01:03.790Z", - "type": "gene" - }, - { - "id": 27, - "name": "IDH2", - "entrez_id": 3418, - "description": "IDH2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall prognosis in AML patients, its utility as a prognostic marker in MDS is still under debate. Additionally, IDH2 (R140) has been associated with improved overall survival in AML. IDH2 mutations have been associated with improved prognosis in gliomas.", - "flagged": false, - "variants": [ - { - "name": "R172", - "id": 199, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R140", - "id": 62, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R172K", - "id": 63, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 570, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 1, - "submitted_count": 2 - } - } - ], - "aliases": [ - "mNADP-IDH", - "IDPM", - "IDP", - "IDHM", - "IDH", - "ICD-M", - "D2HGA2", - "IDH2" - ], - "updated_at": "2020-02-01T00:01:03.811Z", - "type": "gene" - }, - { - "id": 28, - "name": "JAK2", - "entrez_id": 3717, - "description": "JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.", - "flagged": false, - "variants": [ - { - "name": "BCR-JAK2", - "id": 2860, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PCM1-JAK2", - "id": 571, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V617F", - "id": 64, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ZNF340-JAK2", - "id": 2977, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PPFIBP1-JAK2", - "id": 2848, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "TPR-JAK2", - "id": 2850, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ETV6-JAK2", - "id": 2859, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "SNX29-JAK2", - "id": 2976, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "c.1641+1dup", - "id": 615, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "SMU1-JAK2", - "id": 2975, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PAX5-JAK2", - "id": 2861, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "ZNF274-JAK2", - "id": 2864, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "ATF7IP-JAK2", - "id": 2846, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "SSBP2-JAK2", - "id": 2661, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "STRN3-JAK2", - "id": 2849, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "JAK2 F694L", - "id": 2587, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "GOLGA5-JAK2", - "id": 3214, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "TERF2-JAK2", - "id": 2862, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "OFD1-JAK2", - "id": 2974, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "F547 SPLICE SITE MUTATION", - "id": 1681, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "RFX3-JAK2", - "id": 2865, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EBF1-JAK2", - "id": 2847, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["JTK10", "JAK2"], - "updated_at": "2015-06-21T16:49:26.523Z", - "type": "gene" - }, - { - "id": 29, - "name": "KIT", - "entrez_id": 3815, - "description": "c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.", - "flagged": false, - "variants": [ - { - "name": "V569_L576DEL", - "id": 1551, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "K558NP", - "id": 1549, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "V555_V559DEL", - "id": 2695, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 13 MUTATION", - "id": 2643, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 388, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "S628N", - "id": 1659, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "A502_Y503insAY", - "id": 1558, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "EXPRESSION", - "id": 429, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "RS3733542", - "id": 482, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "C809G", - "id": 1264, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V654A", - "id": 73, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "N822K", - "id": 1263, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 1, - "submitted_count": 4 - } - }, - { - "name": "L576P", - "id": 72, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "D816E", - "id": 1559, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "W557_K558DELWK", - "id": 961, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 8 - } - }, - { - "name": "D816V", - "id": 65, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 9 - } - }, - { - "name": "K550_K559DEL", - "id": 2696, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "WILDTYPE", - "id": 2651, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "3' UTR MUTATION", - "id": 256, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D820A", - "id": 1265, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "D816H", - "id": 983, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "Y503_F504insAY", - "id": 946, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "V560DEL", - "id": 202, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "N822H", - "id": 987, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M541L", - "id": 201, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "K642E", - "id": 978, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 1, - "submitted_count": 2 - } - }, - { - "name": "EXON 14 MUTATION", - "id": 69, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "F506_F508DUP", - "id": 2621, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T417_D419delinsY", - "id": 2620, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "N822K", - "id": 1403, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T670I", - "id": 1267, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "P551_E554delPMYE", - "id": 1497, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "V560G", - "id": 972, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 2, - "submitted_count": 10 - } - }, - { - "name": "Y823D", - "id": 989, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V559D", - "id": 968, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 9 - } - }, - { - "name": "D820G", - "id": 1266, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "A829P", - "id": 990, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "K550_W557del", - "id": 948, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "EXON 9 MUTATION", - "id": 509, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V560_L576DEL", - "id": 1550, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "INTERNAL DUPLICATION", - "id": 67, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D820Y", - "id": 986, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "K484_G487DEL", - "id": 2622, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K550_K558del", - "id": 949, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "EXON 11 MUTATION", - "id": 66, - "evidence_items": { - "accepted_count": 13, - "rejected_count": 1, - "submitted_count": 1 - } - }, - { - "name": "D579DEL", - "id": 977, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "V560D", - "id": 971, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "AMPLIFICATION", - "id": 586, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "K558_V559del", - "id": 964, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 6 - } - } - ], - "aliases": ["KIT", "SCFR", "PBT", "CD117", "C-Kit", "MASTC"], - "updated_at": "2020-02-01T00:01:08.953Z", - "type": "gene" - }, - { - "id": 30, - "name": "KRAS", - "entrez_id": 3845, - "description": "Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.", - "flagged": false, - "variants": [ - { - "name": "G12S", - "id": 913, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 4, - "submitted_count": 21 - } - }, - { - "name": "G12/G13", - "id": 77, - "evidence_items": { - "accepted_count": 14, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "A146", - "id": 2979, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G12R", - "id": 530, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 1, - "submitted_count": 15 - } - }, - { - "name": "G13", - "id": 80, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "A146V", - "id": 322, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "A146T", - "id": 906, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "EXON 2 MUTATION", - "id": 75, - "evidence_items": { - "accepted_count": 10, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 592, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "Q61H", - "id": 907, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 7 - } - }, - { - "name": "Q22*", - "id": 479, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "RS61764370", - "id": 254, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G13D", - "id": 81, - "evidence_items": { - "accepted_count": 13, - "rejected_count": 0, - "submitted_count": 21 - } - }, - { - "name": "A146P", - "id": 905, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Wildtype", - "id": 3200, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "G13V", - "id": 1517, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "MUTATION", - "id": 336, - "evidence_items": { - "accepted_count": 43, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "G12", - "id": 76, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "G12D", - "id": 79, - "evidence_items": { - "accepted_count": 21, - "rejected_count": 1, - "submitted_count": 38 - } - }, - { - "name": "G12V", - "id": 425, - "evidence_items": { - "accepted_count": 12, - "rejected_count": 0, - "submitted_count": 21 - } - }, - { - "name": "Q61K", - "id": 910, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "G12C", - "id": 78, - "evidence_items": { - "accepted_count": 14, - "rejected_count": 0, - "submitted_count": 29 - } - }, - { - "name": "Q61", - "id": 203, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G12A", - "id": 148, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 3, - "submitted_count": 17 - } - }, - { - "name": "Q61R", - "id": 909, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "Q61L", - "id": 908, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - } - ], - "aliases": [ - "CFC2", - "c-Ki-ras", - "OES", - "K-Ras 2", - "K-Ras", - "'C-K-RAS", - "KRAS", - "c-Ki-ras2", - "RALD", - "RASK2", - "NS3", - "NS", - "KRAS2", - "KRAS1", - "KI-RAS", - "K-RAS4B", - "K-RAS4A", - "K-RAS2B", - "K-RAS2A", - "C-K-RAS" - ], - "updated_at": "2017-02-09T21:59:28.696Z", - "type": "gene" - }, - { - "id": 31, - "name": "MAP2K1", - "entrez_id": 5604, - "description": "MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian, melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe. Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.", - "flagged": false, - "variants": [ - { - "name": "Q56P", - "id": 83, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "K57N", - "id": 1272, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Q56_V60del", - "id": 655, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "C121S", - "id": 627, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "P124S", - "id": 82, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": ["MAP2K1", "MEL", "MEK1", "MKK1", "MAPKK1", "CFC3", "PRKMK1"], - "updated_at": "2016-06-28T23:24:41.889Z", - "type": "gene" - }, - { - "id": 33, - "name": "CSF1R", - "entrez_id": 1436, - "description": "", - "flagged": false, - "variants": [ - { - "name": "MEF2D-CSF1R", - "id": 30, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "BANDDOS", - "HDLS", - "CD115", - "C-FMS", - "FIM2", - "CSF1R", - "FMS", - "CSFR", - "CSF-1R", - "M-CSF-R" - ], - "updated_at": "2015-06-21T16:49:27.777Z", - "type": "gene" - }, - { - "id": 34, - "name": "MGMT", - "entrez_id": 4255, - "description": "", - "flagged": false, - "variants": [ - { - "name": "PROMOTER METHYLATION", - "id": 85, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "UNDEREXPRESSION", - "id": 1255, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "RS16906252", - "id": 338, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["MGMT"], - "updated_at": "2015-06-21T16:49:27.999Z", - "type": "gene" - }, - { - "id": 35, - "name": "NPM1", - "entrez_id": 4869, - "description": "AML with mutated NPM1 is a provisional entity in the WHO classification of AML and is recommended to be tested in patients with cytogenetically normal AML (CN-AML). FLT3 mutations should be evaluated concurrently as they have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia, indicating it may require additional mutations to promote leukemic development.", - "flagged": false, - "variants": [ - { - "name": "EXON 12 MUTATION", - "id": 86, - "evidence_items": { - "accepted_count": 30, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "W288FS", - "id": 87, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 1, - "submitted_count": 0 - } - } - ], - "aliases": ["B23", "NPM1", "NPM"], - "updated_at": "2020-02-01T00:01:19.845Z", - "type": "gene" - }, - { - "id": 36, - "name": "NRAS", - "entrez_id": 4893, - "description": "Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.", - "flagged": false, - "variants": [ - { - "name": "Q61", - "id": 94, - "evidence_items": { - "accepted_count": 8, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "G13R", - "id": 896, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 2, - "submitted_count": 2 - } - }, - { - "name": "G12D", - "id": 878, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 2, - "submitted_count": 3 - } - }, - { - "name": "MUTATION", - "id": 208, - "evidence_items": { - "accepted_count": 17, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Q61K", - "id": 427, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 3, - "submitted_count": 12 - } - }, - { - "name": "Q61L", - "id": 95, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 2, - "submitted_count": 4 - } - }, - { - "name": "Q61R", - "id": 96, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 2, - "submitted_count": 5 - } - }, - { - "name": "Q179X", - "id": 1654, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G12C", - "id": 897, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 2, - "submitted_count": 2 - } - }, - { - "name": "G12", - "id": 92, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G12/G13", - "id": 596, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Q61H", - "id": 893, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 5, - "submitted_count": 4 - } - }, - { - "name": "G13D", - "id": 93, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": ["NRAS", "NS6", "NRAS1", "NCMS", "N-ras", "CMNS", "ALPS4"], - "updated_at": "2017-07-20T14:44:02.610Z", - "type": "gene" - }, - { - "id": 37, - "name": "PIK3CA", - "entrez_id": 5290, - "description": "PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.", - "flagged": false, - "variants": [ - { - "name": "D350G", - "id": 1653, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 10 and EXON 21 MUTATIONS", - "id": 1991, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 311, - "evidence_items": { - "accepted_count": 36, - "rejected_count": 2, - "submitted_count": 4 - } - }, - { - "name": "RARE MUTATION", - "id": 3222, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 1, - "submitted_count": 0 - } - }, - { - "name": "K111N", - "id": 1234, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "H1047L", - "id": 1151, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "E81K", - "id": 1500, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G1049R", - "id": 940, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "N345K", - "id": 930, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V955I", - "id": 3001, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E545K", - "id": 104, - "evidence_items": { - "accepted_count": 16, - "rejected_count": 0, - "submitted_count": 11 - } - }, - { - "name": "Q546K", - "id": 885, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 9 - } - }, - { - "name": "S158L", - "id": 1499, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "C420R", - "id": 931, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "H1047R", - "id": 107, - "evidence_items": { - "accepted_count": 22, - "rejected_count": 2, - "submitted_count": 18 - } - }, - { - "name": "P471L", - "id": 294, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "I391M", - "id": 1235, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E545Q", - "id": 881, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 8 - } - }, - { - "name": "R93W", - "id": 1178, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "WILD TYPE", - "id": 2590, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E545G", - "id": 883, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 9 - } - }, - { - "name": "EXON 21 MUTATION", - "id": 105, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 10 MUTATION", - "id": 106, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "E542K", - "id": 103, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 10 - } - }, - { - "name": "R88Q", - "id": 929, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 212, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 8 - } - } - ], - "aliases": [ - "CWS5", - "MCAP", - "CLOVE", - "CLAPO", - "PIK3CA", - "PI3K-alpha", - "p110-alpha", - "PI3K", - "MCMTC", - "MCM" - ], - "updated_at": "2017-02-09T22:00:00.113Z", - "type": "gene" - }, - { - "id": 38, - "name": "PDGFRA", - "entrez_id": 5156, - "description": "Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.", - "flagged": false, - "variants": [ - { - "name": "PDGFRA FUSIONS", - "id": 567, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "OVEREXPRESSION", - "id": 2944, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "V561A", - "id": 247, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "AMPLIFICATION", - "id": 716, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "D842_H845DELDIMH", - "id": 943, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "P577S", - "id": 862, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "BCR-PDGFRA", - "id": 2971, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 18 MUTATION", - "id": 2623, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "V561D", - "id": 941, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D842Y", - "id": 100, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D842_I843delinsVM", - "id": 102, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D842I", - "id": 98, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D842V", - "id": 99, - "evidence_items": { - "accepted_count": 11, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "FIP1L1-PDGFRA", - "id": 574, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 1, - "submitted_count": 1 - } - }, - { - "name": "TNKS2-PDGFRA", - "id": 774, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G853D", - "id": 865, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "I843DEL", - "id": 101, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R841K", - "id": 863, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "FIP1L1-PDGFRA T674I", - "id": 577, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "H845Y", - "id": 864, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["PDGFR2", "CD140A", "PDGFR-2", "PDGFRA"], - "updated_at": "2017-02-09T21:59:56.970Z", - "type": "gene" - }, - { - "id": 39, - "name": "PML", - "entrez_id": 5371, - "description": "The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising. However, newly discovered mutations in the B2 domain of PML have started to show conferred resistance to ATRA in these patients.", - "flagged": false, - "variants": [ - { - "name": "B2 DOMAIN MUTATION", - "id": 461, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PML-RARA", - "id": 108, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "PML-RARA L218P", - "id": 463, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "PML-RARA A216V", - "id": 462, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["PP8675", "MYL", "PML", "RNF71", "TRIM19"], - "updated_at": "2020-05-28T19:30:43.832Z", - "type": "gene" - }, - { - "id": 41, - "name": "PTEN", - "entrez_id": 5728, - "description": "PTEN is a multi-functional tumor suppressor that is very commonly lost in human cancer. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss. New appoaches using microRNAs are currently being investigated.", - "flagged": false, - "variants": [ - { - "name": "R173C", - "id": 838, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 1, - "submitted_count": 1 - } - }, - { - "name": "DELETION", - "id": 213, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R130*", - "id": 636, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 510, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "LOSS", - "id": 214, - "evidence_items": { - "accepted_count": 30, - "rejected_count": 1, - "submitted_count": 11 - } - }, - { - "name": "EXPRESSION", - "id": 313, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V317FS", - "id": 605, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R233*", - "id": 110, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "CWS1", - "MHAM", - "MMAC1", - "PTEN1", - "TEP1", - "PTEN", - "PTENbeta", - "DEC", - "GLM2", - "BZS", - "10q23del" - ], - "updated_at": "2015-11-01T00:45:14.933Z", - "type": "gene" - }, - { - "id": 42, - "name": "RET", - "entrez_id": 5979, - "description": "RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.", - "flagged": false, - "variants": [ - { - "name": "RET FUSIONS", - "id": 1687, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "OVEREXPRESSION", - "id": 597, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "EXPRESSION", - "id": 295, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "CCDC6-RET", - "id": 626, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M918T", - "id": 113, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "KIF5B-RET", - "id": 273, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "C634W", - "id": 112, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "C609Y", - "id": 1260, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - } - ], - "aliases": [ - "PTC", - "MTC1", - "RET", - "RET-ELE1", - "CDHF12", - "CDHR16", - "HSCR1", - "MEN2A", - "MEN2B" - ], - "updated_at": "2015-06-21T16:49:29.989Z", - "type": "gene" - }, - { - "id": 43, - "name": "RUNX1", - "entrez_id": 861, - "description": "RUNX1 is a transcription factor that forms a complex with the cofactor CBFB. This complex provides stability to the RUNX1 protein which is involved in the generation of hematopoietic stem cells and for their differentiation into myeloid and lymphoid lines. Loss of RUNX1 function has been shown to impair differentiation between myeloid and lymphoid lines often resulting in the development of leukemia.", - "flagged": false, - "variants": [ - { - "name": "R135FSX177", - "id": 804, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "T148HFSX9", - "id": 810, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "A107P", - "id": 807, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D198Y", - "id": 806, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K83E", - "id": 802, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 155, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "Y260*", - "id": 803, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "AML1", - "AML1-EVI-1", - "AMLCR1", - "CBFA2", - "EVI-1", - "PEBP2aB", - "CBF2alpha", - "PEBP2alpha", - "RUNX1" - ], - "updated_at": "2020-02-01T00:00:31.230Z", - "type": "gene" - }, - { - "id": 44, - "name": "SF3B1", - "entrez_id": 23451, - "description": "SF3B1 mutations have been described in several myeloid malignancies, predominantly myelodysplastic syndromes (MDS), as well as other hematologic malignancies, breast cancer, and uveal melanoma (UM). SF3B1 is one of several genes involved in RNA splicing that has been identified as recurrently mutated in MDS and other malignanices. The mutations affecting SF3B1 are typically heterozygous, point mutations suspected to be functionally deleterious with R625 and K700E described as a major mutation hotspots. MDS patients with SF3B1 mutations have been reported to have better overall and event-free survival than their wildtype counterparts. Additionally, these mutations are highly associated with subtypes of MDS characterized by ringed sideroblasts (refractory anemia with ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ring sideroblasts). In UM patients, SF3B1 mutations have been reported to be associated with chromosome 3 disomy, which defines a subgroup with low risk of metastasis.", - "flagged": false, - "variants": [ - { - "name": "MUTATION", - "id": 215, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "K700E", - "id": 565, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "K666N", - "id": 114, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": [ - "MDS", - "Hsh155", - "PRP10", - "PRPF10", - "SAP155", - "SF3b155", - "SF3B1" - ], - "updated_at": "2017-02-09T22:02:31.782Z", - "type": "gene" - }, - { - "id": 45, - "name": "TP53", - "entrez_id": 7157, - "description": "TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.", - "flagged": false, - "variants": [ - { - "name": "C238Y", - "id": 2648, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "P47S", - "id": 504, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R273H", - "id": 122, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "CONSERVED DOMAIN MUT", - "id": 1300, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R280T", - "id": 1698, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R158L", - "id": 1699, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 222, - "evidence_items": { - "accepted_count": 24, - "rejected_count": 0, - "submitted_count": 14 - } - }, - { - "name": "R158H", - "id": 1695, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R249", - "id": 119, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "R213P", - "id": 1109, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y234C", - "id": 1068, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R248W", - "id": 118, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "DELETERIOUS MUTATION", - "id": 221, - "evidence_items": { - "accepted_count": 7, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G245S", - "id": 879, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "TRUNCATING MUTATION", - "id": 223, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "OVEREXPRESSION", - "id": 1306, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R273C", - "id": 121, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "ALTERATION", - "id": 1307, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "M237I", - "id": 1066, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "V157F", - "id": 1092, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R282L", - "id": 1108, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R175H", - "id": 116, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 6 - } - }, - { - "name": "R280K", - "id": 1697, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "DNA BINDING DOMAIN MUTATION", - "id": 242, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "WILD TYPE", - "id": 369, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Y220C", - "id": 922, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 3 - } - }, - { - "name": "R249S", - "id": 1696, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "P72R", - "id": 531, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 1 - } - }, - { - "name": "R282W", - "id": 916, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R248Q", - "id": 117, - "evidence_items": { - "accepted_count": 6, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "R273L", - "id": 918, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["BCC7", "P53", "TRP53", "TP53", "BMFS5", "LFS1"], - "updated_at": "2018-03-30T15:05:39.990Z", - "type": "gene" - }, - { - "id": 46, - "name": "TSC1", - "entrez_id": 7248, - "description": "", - "flagged": false, - "variants": [ - { - "name": "FRAMESHIFT TRUNCATION", - "id": 124, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R1062W", - "id": 714, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "LOSS-OF-FUNCTION", - "id": 125, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 3 - } - } - ], - "aliases": ["LAM", "TSC1", "TSC"], - "updated_at": "2020-02-01T00:01:50.929Z", - "type": "gene" - }, - { - "id": 47, - "name": "TSC2", - "entrez_id": 7249, - "description": "", - "flagged": false, - "variants": [ - { - "name": "Q1178*", - "id": 469, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["TSC4", "LAM", "PPP1R160", "TSC2"], - "updated_at": "2020-02-01T00:01:50.948Z", - "type": "gene" - }, - { - "id": 48, - "name": "U2AF1", - "entrez_id": 7307, - "description": "U2AF1 is one of several spliceosome complex genes frequently mutated in a variety of hematologic malignancies, particularly de novo myelodysplastic syndromes (MDS), as well as solid tumors such as lung and pancreatic cancers. Two hotspot mutations (S34 and Q157) occur within the two zinc-finger domains of the U2AF1 protein. These mutations have been associated with altered splicing patterns in vitro and in vivo. U2AF1 mutations in MDS have been associated with an increased risk of transformation to secondary acute myeloid leukemia, however, the impact of these mutations on overall survival has been an area of debate.", - "flagged": false, - "variants": [ - { - "name": "MUTATION", - "id": 521, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "Q157P/R", - "id": 127, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "S34Y/F", - "id": 128, - "evidence_items": { - "accepted_count": 3, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["U2AF35", "U2AF1", "RNU2AF1", "U2AFBP", "RN", "FP793"], - "updated_at": "2015-06-21T16:49:31.477Z", - "type": "gene" - }, - { - "id": 49, - "name": "WT1", - "entrez_id": 7490, - "description": "WT1 is a tumor suppressor gene associated with the development of Wilms' Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.", - "flagged": false, - "variants": [ - { - "name": "EXON 9 MUTATION", - "id": 130, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 7 MUTATION", - "id": 129, - "evidence_items": { - "accepted_count": 9, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["WAGR", "AWT1", "WT1", "WT33", "WIT-2", "NPHS4", "GUD"], - "updated_at": "2020-02-01T00:01:53.503Z", - "type": "gene" - }, - { - "id": 50, - "name": "NOTCH1", - "entrez_id": 4851, - "description": "NOTCH1 is one of four known genes encoding the NOTCH family of proteins, a group of receptors involved in the Notch signaling pathway. NOTCH proteins are characterized by N-terminal EGF-like repeats followed by LNR domains which form a complex with ligands to prevent signaling. The Notch signaling pathway is involved in processes related to cell fate specification, differentiation, proliferation, and survival. Activation of Notch has been shown to be correlative with mammary tumorgenesis in mice and increased expression of Notch receptors has been observed in a variety of cancer types including cervical, colon, head and neck, lung, renal, pancreatic, leukemia, and breast cancer. A number of treatment modalities have been explored related to Notch inhibition especially in breast cancer with mixed results.", - "flagged": false, - "variants": [ - { - "name": "AMPLIFICATION", - "id": 330, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "R2327W", - "id": 136, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "P2514FS", - "id": 207, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "LOSS-OF-FUNCTION", - "id": 601, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "V2444FS", - "id": 137, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D1642H", - "id": 135, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 206, - "evidence_items": { - "accepted_count": 4, - "rejected_count": 0, - "submitted_count": 2 - } - }, - { - "name": "S2275FS", - "id": 138, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["NOTCH1", "AOS5", "AOVD1", "TAN1", "hN1"], - "updated_at": "2020-02-01T00:01:19.640Z", - "type": "gene" - }, - { - "id": 51, - "name": "DDR2", - "entrez_id": 4921, - "description": "", - "flagged": false, - "variants": [ - { - "name": "I638F", - "id": 143, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "S768R", - "id": 145, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G253C", - "id": 141, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G774V", - "id": 144, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L63V", - "id": 139, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "L239R", - "id": 140, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "G505S", - "id": 142, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["DDR2", "TYRO10", "WRCN", "TKT", "NTRKR3", "MIG20a"], - "updated_at": "2015-06-21T16:49:32.257Z", - "type": "gene" - }, - { - "id": 52, - "name": "MET", - "entrez_id": 4233, - "description": "Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by \"skipping\" of exon 14 activates the kinase.", - "flagged": false, - "variants": [ - { - "name": "R1004G", - "id": 2774, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "MUTATION", - "id": 323, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "D1228V", - "id": 798, - "evidence_items": { - "accepted_count": 2, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 14 SKIPPING MUTATION", - "id": 324, - "evidence_items": { - "accepted_count": 11, - "rejected_count": 0, - "submitted_count": 4 - } - }, - { - "name": "MET-ATXN7L1", - "id": 2894, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EXON 14 MUTATION and AMPLIFICATION", - "id": 464, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "OVEREXPRESSION", - "id": 621, - "evidence_items": { - "accepted_count": 5, - "rejected_count": 1, - "submitted_count": 2 - } - }, - { - "name": "AMPLIFICATION", - "id": 270, - "evidence_items": { - "accepted_count": 14, - "rejected_count": 0, - "submitted_count": 5 - } - }, - { - "name": "D1228N", - "id": 649, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["MET", "c-Met", "RCCP2", "HGFR", "DFNB97", "AUTS9"], - "updated_at": "2017-03-07T22:27:58.595Z", - "type": "gene" - }, - { - "id": 53, - "name": "FLI1", - "entrez_id": 2313, - "description": "", - "flagged": false, - "variants": [ - { - "name": "EWSR1-FLI1 Type 1", - "id": 164, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - }, - { - "name": "EWSR1-FLI1", - "id": 197, - "evidence_items": { - "accepted_count": 1, - "rejected_count": 0, - "submitted_count": 0 - } - } - ], - "aliases": ["FLI1", "BDPLT21", "EWSR2", "SIC-1"], - "updated_at": "2015-06-21T16:49:32.725Z", - "type": "gene" - } - ] -} diff --git a/client/scripts/gql-server-data/variants.json b/client/scripts/gql-server-data/variants.json deleted file mode 100644 index 0d1eb6b36..000000000 --- a/client/scripts/gql-server-data/variants.json +++ /dev/null @@ -1,2088 +0,0 @@ -{ - "records": [ - { - "id": 1, - "entrez_name": "ABL1", - "entrez_id": 25, - "name": "BCR-ABL", - "description": "The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.", - "gene_id": 4, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 255.5, - "flagged": false, - "updated_at": "2020-02-08T03:53:21.874Z", - "coordinates": { - "chromosome": "22", - "start": 23522397, - "stop": 23632600, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000305877.8", - "chromosome2": "9", - "start2": 133729451, - "stop2": 133763063, - "representative_transcript2": "ENST00000318560.5", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 2, - "entrez_name": "ABL1", - "entrez_id": 25, - "name": "BCR-ABL T315I", - "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.", - "gene_id": 4, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 146, - "flagged": false, - "updated_at": "2020-08-29T00:06:08.064Z", - "coordinates": { - "chromosome": "9", - "start": 133748283, - "stop": 133748283, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000318560.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 3, - "entrez_name": "ABL1", - "entrez_id": 25, - "name": "BCR-ABL E255K", - "description": "While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.", - "gene_id": 4, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 73, - "flagged": false, - "updated_at": "2020-07-10T23:36:50.983Z", - "coordinates": { - "chromosome": "9", - "start": 133738363, - "stop": 133738363, - "reference_bases": "G", - "variant_bases": "A", - "representative_transcript": "ENST00000318560.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 4, - "entrez_name": "AKT1", - "entrez_id": 207, - "name": "E17K", - "description": "AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.", - "gene_id": 2, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 32.5, - "flagged": false, - "updated_at": "2018-11-30T14:44:59.017Z", - "coordinates": { - "chromosome": "14", - "start": 105246551, - "stop": 105246551, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000407796.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 5, - "entrez_name": "ALK", - "entrez_id": 238, - "name": "EML4-ALK", - "description": "The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.", - "gene_id": 1, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 38, - "flagged": false, - "updated_at": "2020-08-29T19:17:30.276Z", - "coordinates": { - "chromosome": "2", - "start": 42396490, - "stop": 42522656, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000318522.5", - "chromosome2": "2", - "start2": 29415640, - "stop2": 29446394, - "representative_transcript2": "ENST00000389048.3", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 6, - "entrez_name": "ALK", - "entrez_id": 238, - "name": "EML4-ALK C1156Y", - "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.", - "gene_id": 1, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 29, - "flagged": false, - "updated_at": "2020-09-04T15:14:49.656Z", - "coordinates": { - "chromosome": "2", - "start": 29445258, - "stop": 29445258, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000389048.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 7, - "entrez_name": "ALK", - "entrez_id": 238, - "name": "EML4-ALK L1196M", - "description": "In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.", - "gene_id": 1, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 21, - "flagged": false, - "updated_at": "2020-08-29T21:04:18.985Z", - "coordinates": { - "chromosome": "2", - "start": 29443631, - "stop": 29443631, - "reference_bases": "G", - "variant_bases": "T", - "representative_transcript": "ENST00000389048.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 8, - "entrez_name": "ALK", - "entrez_id": 238, - "name": "F1174L", - "description": "ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.", - "gene_id": 1, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 33.5, - "flagged": false, - "updated_at": "2018-11-30T14:45:01.672Z", - "coordinates": { - "chromosome": "2", - "start": 29443695, - "stop": 29443695, - "reference_bases": "G", - "variant_bases": "T", - "representative_transcript": "ENST00000389048.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 9, - "entrez_name": "ALK", - "entrez_id": 238, - "name": "R1275Q", - "description": "ALK R1275Q has been observed as a recurrent mutation in neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.", - "gene_id": 1, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 23, - "flagged": false, - "updated_at": "2018-11-30T14:44:59.168Z", - "coordinates": { - "chromosome": "2", - "start": 29432664, - "stop": 29432664, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000389048.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 10, - "entrez_name": "ARAF", - "entrez_id": 369, - "name": "S214C", - "description": "ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.", - "gene_id": 3, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 11, - "flagged": false, - "updated_at": "2018-11-30T14:43:04.317Z", - "coordinates": { - "chromosome": "X", - "start": 47426121, - "stop": 47426121, - "reference_bases": "C", - "variant_bases": "G", - "representative_transcript": "ENST00000377045.4", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 11, - "entrez_name": "BRAF", - "entrez_id": 673, - "name": "V600D", - "description": "Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.", - "gene_id": 5, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 47, - "flagged": false, - "updated_at": "2020-11-21T22:43:17.643Z", - "coordinates": { - "chromosome": "7", - "start": 140453135, - "stop": 140453136, - "reference_bases": "CA", - "variant_bases": "AT", - "representative_transcript": "ENST00000288602.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 12, - "entrez_name": "BRAF", - "entrez_id": 673, - "name": "V600E", - "description": "BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.", - "gene_id": 5, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 1181, - "flagged": false, - "updated_at": "2020-11-20T23:11:26.547Z", - "coordinates": { - "chromosome": "7", - "start": 140453136, - "stop": 140453136, - "reference_bases": "A", - "variant_bases": "T", - "representative_transcript": "ENST00000288602.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 13, - "entrez_name": "BRAF", - "entrez_id": 673, - "name": "V600E and V600M", - "description": "A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.", - "gene_id": 5, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 7.5, - "flagged": false, - "updated_at": "2020-05-28T20:11:12.166Z", - "coordinates": { - "chromosome": "7", - "start": 140453135, - "stop": 140453137, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000288602.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 14, - "entrez_name": "BRAF", - "entrez_id": 673, - "name": "V600E and AMPLIFICATION", - "description": "Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.", - "gene_id": 5, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 123, - "name": "transcript_amplification", - "display_name": "Transcript Amplification", - "so_id": "SO:0001889", - "description": "A feature amplification of a region containing a transcript.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001889", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 1, - "flagged": false, - "updated_at": "2020-05-28T21:34:17.648Z", - "coordinates": { - "chromosome": "7", - "start": 140434279, - "stop": 140624564, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000288602.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 17, - "entrez_name": "BRAF", - "entrez_id": 673, - "name": "V600", - "description": "BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.", - "gene_id": 5, - "type": "variant", - "variant_types": [ - { - "id": 103, - "name": "protein_altering_variant", - "display_name": "Protein Altering Variant", - "so_id": "SO:0001818", - "description": "A sequence_variant which is predicted to change the protein encoded in the coding sequence.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001818", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 470, - "flagged": false, - "updated_at": "2019-12-13T09:42:22.058Z", - "coordinates": { - "chromosome": "7", - "start": 140453136, - "stop": 140453137, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000288602.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 18, - "entrez_name": "CCND1", - "entrez_id": 595, - "name": "AMPLIFICATION", - "description": "CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.", - "gene_id": 8, - "type": "variant", - "variant_types": [ - { - "id": 123, - "name": "transcript_amplification", - "display_name": "Transcript Amplification", - "so_id": "SO:0001889", - "description": "A feature amplification of a region containing a transcript.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001889", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 47, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.673Z", - "coordinates": { - "chromosome": "11", - "start": 69455855, - "stop": 69469242, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000227507.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 19, - "entrez_name": "CCND1", - "entrez_id": 595, - "name": "EXPRESSION", - "description": "CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.", - "gene_id": 8, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 30, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.690Z", - "coordinates": { - "chromosome": "11", - "start": 69455855, - "stop": 69469242, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000227507.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 20, - "entrez_name": "CCND1", - "entrez_id": 595, - "name": "OVEREXPRESSION", - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.", - "gene_id": 8, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 116, - "flagged": false, - "updated_at": "2020-06-08T17:36:07.572Z", - "coordinates": { - "chromosome": "11", - "start": 69455855, - "stop": 69469242, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000227507.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 21, - "entrez_name": "CCND2", - "entrez_id": 894, - "name": "OVEREXPRESSION", - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.", - "gene_id": 9, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 16, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.697Z", - "coordinates": { - "chromosome": "12", - "start": 4382938, - "stop": 4414516, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000261254.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 22, - "entrez_name": "CCND2", - "entrez_id": 894, - "name": "PROMOTER DEMETHYLATION", - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.", - "gene_id": 9, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 3, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.716Z", - "coordinates": { - "chromosome": "12", - "start": 4381437, - "stop": 4382937, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000261254.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 23, - "entrez_name": "CCND3", - "entrez_id": 896, - "name": "LOSS", - "description": "Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.", - "gene_id": 10, - "type": "variant", - "variant_types": [ - { - "id": 161, - "name": "loss_of_function_variant", - "display_name": "Loss Of Function Variant", - "so_id": "SO:0002054", - "description": "A sequence variant whereby the gene product has diminished or abolished function.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002054", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 3, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.719Z", - "coordinates": { - "chromosome": "6", - "start": 41902671, - "stop": 41909586, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000372991.4", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 24, - "entrez_name": "CCNE1", - "entrez_id": 898, - "name": "OVEREXPRESSION", - "description": "Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.", - "gene_id": 11, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 62, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.720Z", - "coordinates": { - "chromosome": "19", - "start": 30302805, - "stop": 30315215, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000262643.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 25, - "entrez_name": "CDK4", - "entrez_id": 1019, - "name": "EXPRESSION", - "description": "CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.", - "gene_id": 13, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 8, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.739Z", - "coordinates": { - "chromosome": "12", - "start": 58141510, - "stop": 58146304, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000257904.6", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 27, - "entrez_name": "CDKN2A", - "entrez_id": 1029, - "name": "PROMOTER HYPERMETHYLATION", - "description": "CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.", - "gene_id": 14, - "type": "variant", - "variant_types": [ - { - "id": 183, - "name": "N/A", - "display_name": "N/A", - "so_id": "N/A", - "description": "No suitable Sequence Ontology term exists.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/N/A", - "root_concept": { - "so_id": "N/A", - "name": "N/A" - } - } - ], - "civic_actionability_score": 15, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.740Z", - "coordinates": { - "chromosome": "9", - "start": 21974827, - "stop": 21994591, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000498124.1", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 28, - "entrez_name": "CEBPA", - "entrez_id": 1050, - "name": "N-TERMINAL FRAME SHIFT", - "description": "CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.", - "gene_id": 15, - "type": "variant", - "variant_types": [ - { - "id": 134, - "name": "frameshift_truncation", - "display_name": "Frameshift Truncation", - "so_id": "SO:0001910", - "description": "A frameshift variant that causes the translational reading frame to be shortened relative to the reference feature.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001910", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 159, - "name": "dominant_negative_variant", - "display_name": "Dominant Negative Variant", - "so_id": "SO:0002052", - "description": "A variant where the mutated gene product adversely affects the other (wild type) gene product.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002052", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 3, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.740Z", - "coordinates": { - "chromosome": "19", - "start": 33792961, - "stop": 33793470, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000498907.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 29, - "entrez_name": "CEBPA", - "entrez_id": 1050, - "name": "MUTATION", - "description": "CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.", - "gene_id": 15, - "type": "variant", - "variant_types": [ - { - "id": 42, - "name": "transcript_variant", - "display_name": "Transcript Variant", - "so_id": "SO:0001576", - "description": "A sequence variant that changes the structure of the transcript.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001576", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - }, - { - "id": 161, - "name": "loss_of_function_variant", - "display_name": "Loss Of Function Variant", - "so_id": "SO:0002054", - "description": "A sequence variant whereby the gene product has diminished or abolished function.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0002054", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 105, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.762Z", - "coordinates": { - "chromosome": "19", - "start": 33790840, - "stop": 33793470, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000498907.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 30, - "entrez_name": "CSF1R", - "entrez_id": 1436, - "name": "MEF2D-CSF1R", - "description": "MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.", - "gene_id": 33, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 3, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.763Z", - "coordinates": { - "chromosome": "1", - "start": 156446804, - "stop": 156470620, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000348159.4", - "chromosome2": "5", - "start2": 149433787, - "stop2": 149441412, - "representative_transcript2": "ENST00000286301.3", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 31, - "entrez_name": "PRKACA", - "entrez_id": 5566, - "name": "DNAJB1-PRKACA", - "description": "This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.", - "gene_id": 17, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 75, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.763Z", - "coordinates": { - "chromosome": "19", - "start": 14628951, - "stop": 14629232, - "reference_bases": null, - "variant_bases": "", - "representative_transcript": "ENST00000254322.2", - "chromosome2": "19", - "start2": 14202500, - "stop2": 14218221, - "representative_transcript2": "ENST00000308677.4", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 32, - "entrez_name": "DNMT3A", - "entrez_id": 1788, - "name": "R882", - "description": "DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.", - "gene_id": 18, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 525, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.787Z", - "coordinates": { - "chromosome": "2", - "start": 25457241, - "stop": 25457243, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000264709.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 33, - "entrez_name": "EGFR", - "entrez_id": 1956, - "name": "L858R", - "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.", - "gene_id": 19, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 362.5, - "flagged": false, - "updated_at": "2020-11-23T21:07:21.207Z", - "coordinates": { - "chromosome": "7", - "start": 55259515, - "stop": 55259515, - "reference_bases": "T", - "variant_bases": "G", - "representative_transcript": "ENST00000275493.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 34, - "entrez_name": "EGFR", - "entrez_id": 1956, - "name": "T790M", - "description": "EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.", - "gene_id": 19, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 376.25, - "flagged": false, - "updated_at": "2018-11-30T14:45:31.788Z", - "coordinates": { - "chromosome": "7", - "start": 55249071, - "stop": 55249071, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000275493.2", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 35, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "D769H", - "description": "ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 4, - "flagged": false, - "updated_at": "2018-11-30T14:44:12.903Z", - "coordinates": { - "chromosome": "17", - "start": 37880261, - "stop": 37880261, - "reference_bases": "G", - "variant_bases": "C", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 36, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "D769Y", - "description": "ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 4, - "flagged": false, - "updated_at": "2018-11-30T14:44:52.082Z", - "coordinates": { - "chromosome": "17", - "start": 37880261, - "stop": 37880261, - "reference_bases": "G", - "variant_bases": "T", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 37, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "L755_T759del", - "description": "ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 107, - "name": "inframe_deletion", - "display_name": "Inframe Deletion", - "so_id": "SO:0001822", - "description": "An inframe non synonymous variant that deletes bases from the coding sequence.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001822", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2020-07-24T18:54:58.616Z", - "coordinates": { - "chromosome": "17", - "start": 37880219, - "stop": 37880233, - "reference_bases": "TTGAGGGAAAACACA", - "variant_bases": null, - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 38, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "G309A", - "description": "ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2018-11-30T14:43:04.469Z", - "coordinates": { - "chromosome": "17", - "start": 37868205, - "stop": 37868205, - "reference_bases": "G", - "variant_bases": "C", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 39, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "L755S", - "description": "ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 21.5, - "flagged": false, - "updated_at": "2019-10-11T18:55:54.236Z", - "coordinates": { - "chromosome": "17", - "start": 37880220, - "stop": 37880220, - "reference_bases": "T", - "variant_bases": "C", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 40, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "L755W", - "description": "ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2018-11-30T14:43:24.474Z", - "coordinates": { - "chromosome": "17", - "start": 37880220, - "stop": 37880220, - "reference_bases": "T", - "variant_bases": "G", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 41, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "P780INS", - "description": "ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 106, - "name": "inframe_insertion", - "display_name": "Inframe Insertion", - "so_id": "SO:0001821", - "description": "An inframe non synonymous variant that inserts bases into in the coding sequence.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001821", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 12.5, - "flagged": true, - "updated_at": "2020-12-03T18:33:03.528Z", - "coordinates": { - "chromosome": "17", - "start": 37881011, - "stop": 37881012, - "reference_bases": null, - "variant_bases": "GGCTCCCCA", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 42, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "R678Q", - "description": "ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2018-11-30T14:43:31.275Z", - "coordinates": { - "chromosome": "17", - "start": 37879658, - "stop": 37879658, - "reference_bases": "G", - "variant_bases": "A", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 43, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "R896C", - "description": "ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2018-11-30T14:43:04.621Z", - "coordinates": { - "chromosome": "17", - "start": 37881616, - "stop": 37881616, - "reference_bases": "C", - "variant_bases": "T", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 44, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "V777L", - "description": "ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 9, - "flagged": false, - "updated_at": "2018-11-30T14:43:13.235Z", - "coordinates": { - "chromosome": "17", - "start": 37881000, - "stop": 37881000, - "reference_bases": "G", - "variant_bases": "T", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 45, - "entrez_name": "ERBB2", - "entrez_id": 2064, - "name": "V842I", - "description": "ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.", - "gene_id": 20, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 9, - "flagged": false, - "updated_at": "2018-11-30T14:43:19.716Z", - "coordinates": { - "chromosome": "17", - "start": 37881332, - "stop": 37881332, - "reference_bases": "G", - "variant_bases": "A", - "representative_transcript": "ENST00000269571.5", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 46, - "entrez_name": "ESR1", - "entrez_id": 2099, - "name": "L536Q", - "description": "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.", - "gene_id": 21, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 8, - "flagged": false, - "updated_at": "2018-11-30T14:45:01.835Z", - "coordinates": { - "chromosome": "6", - "start": 152419920, - "stop": 152419921, - "reference_bases": "TC", - "variant_bases": "AG", - "representative_transcript": "ENST00000440973.1", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 47, - "entrez_name": "ESR1", - "entrez_id": 2099, - "name": "D538G", - "description": "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.", - "gene_id": 21, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 18, - "flagged": false, - "updated_at": "2018-11-30T14:45:02.936Z", - "coordinates": { - "chromosome": "6", - "start": 152419926, - "stop": 152419926, - "reference_bases": "A", - "variant_bases": "G", - "representative_transcript": "ENST00000206249.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 48, - "entrez_name": "ESR1", - "entrez_id": 2099, - "name": "Y537C", - "description": "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.", - "gene_id": 21, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 8, - "flagged": false, - "updated_at": "2018-11-30T14:45:04.364Z", - "coordinates": { - "chromosome": "6", - "start": 152419923, - "stop": 152419923, - "reference_bases": "A", - "variant_bases": "G", - "representative_transcript": "ENST00000206249.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 49, - "entrez_name": "ESR1", - "entrez_id": 2099, - "name": "Y537N", - "description": "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.", - "gene_id": 21, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 8, - "flagged": false, - "updated_at": "2018-11-30T14:45:01.993Z", - "coordinates": { - "chromosome": "6", - "start": 152419922, - "stop": 152419922, - "reference_bases": "T", - "variant_bases": "A", - "representative_transcript": "ENST00000206249.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 50, - "entrez_name": "ESR1", - "entrez_id": 2099, - "name": "Y537S", - "description": "ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.", - "gene_id": 21, - "type": "variant", - "variant_types": [ - { - "id": 47, - "name": "missense_variant", - "display_name": "Missense Variant", - "so_id": "SO:0001583", - "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 8, - "flagged": false, - "updated_at": "2018-11-30T14:45:03.142Z", - "coordinates": { - "chromosome": "6", - "start": 152419923, - "stop": 152419923, - "reference_bases": "A", - "variant_bases": "C", - "representative_transcript": "ENST00000206249.3", - "chromosome2": null, - "start2": null, - "stop2": null, - "representative_transcript2": null, - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 52, - "entrez_name": "FGFR2", - "entrez_id": 2263, - "name": "FGFR2-MGEA5", - "description": "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.", - "gene_id": 22, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 5, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.944Z", - "coordinates": { - "chromosome": "10", - "start": 123243212, - "stop": 123357917, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000457416.2", - "chromosome2": "10", - "start2": 103544209, - "stop2": 103552700, - "representative_transcript2": "ENST00000361464.3", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 53, - "entrez_name": "FGFR3", - "entrez_id": 2261, - "name": "FGFR3-BAIAP2L1", - "description": "In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.", - "gene_id": 23, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 3, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.949Z", - "coordinates": { - "chromosome": "4", - "start": 1795039, - "stop": 1810599, - "reference_bases": null, - "variant_bases": null, - "representative_transcript": "ENST00000340107.4", - "chromosome2": "7", - "start2": 97991744, - "stop2": 97920963, - "representative_transcript2": "ENST00000005260.8", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - }, - { - "id": 54, - "entrez_name": "FGFR2", - "entrez_id": 2263, - "name": "FGFR2-TACC3", - "description": "In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.", - "gene_id": 22, - "type": "variant", - "variant_types": [ - { - "id": 120, - "name": "transcript_fusion", - "display_name": "Transcript Fusion", - "so_id": "SO:0001886", - "description": "A feature fusion where the deletion brings together transcript regions.", - "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886", - "root_concept": { - "so_id": "SO:0001060", - "name": "Sequence Variant" - } - } - ], - "civic_actionability_score": 7.5, - "flagged": false, - "updated_at": "2017-12-01T14:40:28.946Z", - "coordinates": { - "chromosome": "4", - "start": 123243212, - "stop": 123357598, - "reference_bases": null, - "variant_bases": "", - "representative_transcript": "ENST00000358487.5", - "chromosome2": "4", - "start2": 1723266, - "stop2": 1741505, - "representative_transcript2": "ENST00000313288.4", - "ensembl_version": 75, - "reference_build": "GRCh37" - } - } - ] -} diff --git a/client/scripts/gql-server-mocks.js b/client/scripts/gql-server-mocks.js deleted file mode 100644 index 91a9927a4..000000000 --- a/client/scripts/gql-server-mocks.js +++ /dev/null @@ -1,15 +0,0 @@ -import casual from 'casual'; -import RandExp from 'randexp'; -import {MockList} from 'graphql-tools'; -import {startCase} from 'lodash'; - - -export default { - Int: () => casual.integer(0), - - Gene: () => ({ - id: casual.integer(1,2000), - type: "GENE", - name: "GENE NAME" - }), -}; diff --git a/client/scripts/gql-server-schema.js b/client/scripts/gql-server-schema.js deleted file mode 100644 index 9aeac767e..000000000 --- a/client/scripts/gql-server-schema.js +++ /dev/null @@ -1,54 +0,0 @@ -// This example demonstrates a simple server with some relational data: Posts and Authors. You can get the posts for a particular author, -// and vice-versa Read the complete docs for graphql-tools here: http://dev.apollodata.com/tools/graphql-tools/generate-schema.html - -import { - makeExecutableSchema, - addMockFunctionsToSchema -} from 'graphql-tools'; - -import { - schema as authorpostsSchema, - resolvers as authorpostsResolvers -} from './authorposts'; - -import { - schema as myLittleTypoSchema, - resolvers as myLittleTypeResolvers -} from './myLittleDomain'; - -import { - merge -} from 'lodash'; - -import mocks from './mocks' - -const baseSchema = [ - ` - type Query { - domain: String - } - type Mutation { - domain: String - } - schema { - query: Query, - mutation: Mutation - }` -] - -// Put schema together into one array of schema strings and one map of resolvers, like makeExecutableSchema expects -const schema = [...baseSchema, ...authorpostsSchema, ...myLittleTypoSchema] - -const options = { - typeDefs: schema, - resolvers: merge(authorpostsResolvers, myLittleTypeResolvers) -} - -const executableSchema = makeExecutableSchema(options); - -addMockFunctionsToSchema({ - schema: executableSchema, - mocks: mocks, -}) - -export default executableSchema; diff --git a/client/scripts/gql-server.js b/client/scripts/gql-server.js deleted file mode 100644 index dd924b0e3..000000000 --- a/client/scripts/gql-server.js +++ /dev/null @@ -1,25 +0,0 @@ -const fs = require("fs"); -const path = require("path"); -const express = require("express"); -const { graphqlHTTP } = require("express-graphql"); -const { makeExecutableSchema, - addMockFunctionsToSchema } = require("graphql-tools"); - - -const schemaFile = path.join(__dirname, "../generated/server.model.graphql"); -const typeDefs = fs.readFileSync(schemaFile, "utf8"); - -const schema = makeExecutableSchema({ typeDefs }); - -addMockFunctionsToSchema({ schema: schema }); - -var app = express(); -app.use( - "/api", - graphqlHTTP({ - schema: schema, - graphiql: true, - }) -); -app.listen(4000); -console.log("Running a GraphQL API server at localhost:4000/api"); diff --git a/client/src/app/app.module.ts b/client/src/app/app.module.ts index 9df4f6e8a..2d51729ad 100644 --- a/client/src/app/app.module.ts +++ b/client/src/app/app.module.ts @@ -12,14 +12,12 @@ import { BrowserAnimationsModule } from '@angular/platform-browser/animations' import { LetDirective, PushPipe } from '@ngrx/component' import { CookieService } from 'ngx-cookie-service' import { civicIcons } from '@app/icons-provider.module' -import { LoggerModule, NgxLoggerLevel } from 'ngx-logger' import { NgxJsonViewerModule } from 'ngx-json-viewer' import { NZ_I18N } from 'ng-zorro-antd/i18n' import { en_US } from 'ng-zorro-antd/i18n' import { AppRoutingModule } from './app-routing.module' import { AppComponent } from './app.component' import { GraphQLModule } from '@app/graphql/graphql.module' -import { environment } from 'environments/environment' import { NzIconModule } from 'ng-zorro-antd/icon' import { CvcNetworkErrorAlertModule } from './components/app/network-error-alert/network-error-alert.module' import { Observable } from 'rxjs' diff --git a/client/yarn.lock b/client/yarn.lock index 5a5bf2d7f..5a673a28b 100644 --- a/client/yarn.lock +++ b/client/yarn.lock @@ -1754,11 +1754,6 @@ "@babel/helper-validator-identifier" "^7.22.5" to-fast-properties "^2.0.0" -"@colors/colors@1.5.0": - version "1.5.0" - resolved "https://registry.yarnpkg.com/@colors/colors/-/colors-1.5.0.tgz#bb504579c1cae923e6576a4f5da43d25f97bdbd9" - integrity sha512-ooWCrlZP11i8GImSjTHYHLkvFDP48nS4+204nGb1RiX/WXYHmJA2III9/e2DWVabCESdW7hBAEzHRqUn9OUVvQ== - "@cspotcode/source-map-support@^0.8.0": version "0.8.1" resolved "https://registry.yarnpkg.com/@cspotcode/source-map-support/-/source-map-support-0.8.1.tgz#00629c35a688e05a88b1cda684fb9d5e73f000a1" @@ -1886,21 +1881,6 @@ resolved "https://registry.yarnpkg.com/@esbuild/win32-x64/-/win32-x64-0.17.19.tgz#8cfaf2ff603e9aabb910e9c0558c26cf32744061" integrity sha512-lAhycmKnVOuRYNtRtatQR1LPQf2oYCkRGkSFnseDAKPl8lu5SOsK/e1sXe5a0Pc5kHIHe6P2I/ilntNv2xf3cA== -"@eslint/eslintrc@^1.4.1": - version "1.4.1" - resolved "https://registry.yarnpkg.com/@eslint/eslintrc/-/eslintrc-1.4.1.tgz#af58772019a2d271b7e2d4c23ff4ddcba3ccfb3e" - integrity sha512-XXrH9Uarn0stsyldqDYq8r++mROmWRI1xKMXa640Bb//SY1+ECYX6VzT6Lcx5frD0V30XieqJ0oX9I2Xj5aoMA== - dependencies: - ajv "^6.12.4" - debug "^4.3.2" - espree "^9.4.0" - globals "^13.19.0" - ignore "^5.2.0" - import-fresh "^3.2.1" - js-yaml "^4.1.0" - minimatch "^3.1.2" - strip-json-comments "^3.1.1" - "@gar/promisify@^1.1.3": version "1.1.3" resolved "https://registry.yarnpkg.com/@gar/promisify/-/promisify-1.1.3.tgz#555193ab2e3bb3b6adc3d551c9c030d9e860daf6" @@ -2401,30 +2381,6 @@ resolved "https://registry.yarnpkg.com/@graphql-typed-document-node/core/-/core-3.1.1.tgz#076d78ce99822258cf813ecc1e7fa460fa74d052" integrity sha512-NQ17ii0rK1b34VZonlmT2QMJFI70m0TRwbknO/ihlbatXyaktDhN/98vBiUU6kNBPljqGqyIrl2T4nY2RpFANg== -"@humanwhocodes/config-array@^0.11.8": - version "0.11.8" - resolved "https://registry.yarnpkg.com/@humanwhocodes/config-array/-/config-array-0.11.8.tgz#03595ac2075a4dc0f191cc2131de14fbd7d410b9" - integrity sha512-UybHIJzJnR5Qc/MsD9Kr+RpO2h+/P1GhOwdiLPXK5TWk5sgTdu88bTD9UP+CKbPPh5Rni1u0GjAdYQLemG8g+g== - dependencies: - "@humanwhocodes/object-schema" "^1.2.1" - debug "^4.1.1" - minimatch "^3.0.5" - -"@humanwhocodes/module-importer@^1.0.1": - version "1.0.1" - resolved "https://registry.yarnpkg.com/@humanwhocodes/module-importer/-/module-importer-1.0.1.tgz#af5b2691a22b44be847b0ca81641c5fb6ad0172c" - integrity sha512-bxveV4V8v5Yb4ncFTT3rPSgZBOpCkjfK0y4oVVVJwIuDVBRMDXrPyXRL988i5ap9m9bnyEEjWfm5WkBmtffLfA== - -"@humanwhocodes/object-schema@^1.2.1": - version "1.2.1" - resolved "https://registry.yarnpkg.com/@humanwhocodes/object-schema/-/object-schema-1.2.1.tgz#b520529ec21d8e5945a1851dfd1c32e94e39ff45" - integrity sha512-ZnQMnLV4e7hDlUvw8H+U8ASL02SS2Gn6+9Ac3wGGLIe7+je2AeAOxPY+izIPJDfFDb7eDjev0Us8MO1iFRN8hA== - -"@iarna/toml@^2.2.5": - version "2.2.5" - resolved "https://registry.yarnpkg.com/@iarna/toml/-/toml-2.2.5.tgz#b32366c89b43c6f8cefbdefac778b9c828e3ba8c" - integrity sha512-trnsAYxU3xnS1gPHPyU961coFyLkh4gAD/0zQ5mymY4yOZ+CYvsPqUbOFSw0aDM4y0tV7tiFxL/1XfXPNC6IPg== - "@isaacs/cliui@^8.0.2": version "8.0.2" resolved "https://registry.yarnpkg.com/@isaacs/cliui/-/cliui-8.0.2.tgz#b37667b7bc181c168782259bab42474fbf52b550" @@ -2573,7 +2529,7 @@ resolved "https://registry.yarnpkg.com/@nodelib/fs.stat/-/fs.stat-2.0.5.tgz#5bd262af94e9d25bd1e71b05deed44876a222e8b" integrity sha512-RkhPPp2zrqDAQA/2jNhnztcPAlv64XdhIp7a7454A5ovI7Bukxgt7MX7udwAu3zg1DcpPU0rz3VV1SeaqvY4+A== -"@nodelib/fs.walk@^1.2.3", "@nodelib/fs.walk@^1.2.8": +"@nodelib/fs.walk@^1.2.3": version "1.2.8" resolved "https://registry.yarnpkg.com/@nodelib/fs.walk/-/fs.walk-1.2.8.tgz#e95737e8bb6746ddedf69c556953494f196fe69a" integrity sha512-oGB+UxlgWcgQkgwo8GcEGwemoTFt3FIO9ababBmaGwXIoBKZ+GTy0pP185beGg7Llih/NSHSV2XAs1lnznocSg== @@ -2714,18 +2670,6 @@ "@sigstore/protobuf-specs" "^0.1.0" tuf-js "^1.1.7" -"@socket.io/component-emitter@~3.1.0": - version "3.1.0" - resolved "https://registry.yarnpkg.com/@socket.io/component-emitter/-/component-emitter-3.1.0.tgz#96116f2a912e0c02817345b3c10751069920d553" - integrity sha512-+9jVqKhRSpsc591z5vX+X5Yyw+he/HCB4iQ/RYxw35CEPaY1gnsNE43nf9n9AaYjAQrTiI/mOwKUKdUs9vf7Xg== - -"@tinkoff/ng-polymorpheus@^4.0.10": - version "4.0.10" - resolved "https://registry.yarnpkg.com/@tinkoff/ng-polymorpheus/-/ng-polymorpheus-4.0.10.tgz#373fe145b8b82497e8f3e1972898c6cb03f8601b" - integrity sha512-BxHSwj9CertJ3qiamZ52NTpsKn81EZHjDwiph8mXiEeKXpuPaDn6e5wmTWdW8mYexLPtBsxmCRvZ9vapw4F1kA== - dependencies: - tslib "^2.0.0" - "@tootallnate/once@2": version "2.0.0" resolved "https://registry.yarnpkg.com/@tootallnate/once/-/once-2.0.0.tgz#f544a148d3ab35801c1f633a7441fd87c2e484bf" @@ -2804,18 +2748,6 @@ dependencies: "@types/node" "*" -"@types/cookie@^0.4.1": - version "0.4.1" - resolved "https://registry.yarnpkg.com/@types/cookie/-/cookie-0.4.1.tgz#bfd02c1f2224567676c1545199f87c3a861d878d" - integrity sha512-XW/Aa8APYr6jSVVA1y/DEIZX0/GMKLEVekNG727R8cs56ahETkRAy/3DR7+fJyh7oUgGwNQaRfXCun0+KbWY7Q== - -"@types/cors@^2.8.12": - version "2.8.13" - resolved "https://registry.yarnpkg.com/@types/cors/-/cors-2.8.13.tgz#b8ade22ba455a1b8cb3b5d3f35910fd204f84f94" - integrity sha512-RG8AStHlUiV5ysZQKq97copd2UmVYw3/pRMLefISZ3S1hK104Cwm7iLQ3fTKx+lsUH2CE8FlLaYeEA2LSeqYUA== - dependencies: - "@types/node" "*" - "@types/eslint-scope@^3.7.3": version "3.7.4" resolved "https://registry.yarnpkg.com/@types/eslint-scope/-/eslint-scope-3.7.4.tgz#37fc1223f0786c39627068a12e94d6e6fc61de16" @@ -2868,11 +2800,6 @@ dependencies: "@types/node" "*" -"@types/jasmine@~3.6.0": - version "3.6.11" - resolved "https://registry.yarnpkg.com/@types/jasmine/-/jasmine-3.6.11.tgz#4b1d77aa9dfc757407cb9e277216d8e83553f09d" - integrity sha512-S6pvzQDvMZHrkBz2Mcn/8Du7cpr76PlRJBAoHnSDNbulULsH5dp0Gns+WRyNX5LHejz/ljxK4/vIHK/caHt6SQ== - "@types/js-yaml@^4.0.0": version "4.0.5" resolved "https://registry.yarnpkg.com/@types/js-yaml/-/js-yaml-4.0.5.tgz#738dd390a6ecc5442f35e7f03fa1431353f7e138" @@ -2900,7 +2827,7 @@ resolved "https://registry.yarnpkg.com/@types/mime/-/mime-3.0.1.tgz#5f8f2bca0a5863cb69bc0b0acd88c96cb1d4ae10" integrity sha512-Y4XFY5VJAuw0FgAqPNd6NNoV44jbq9Bz2L7Rh/J6jLTiHBSBJa9fxqQIvkIld4GsoDOcCbvzOUAbLPsSKKg+uA== -"@types/node@*", "@types/node@>=10.0.0": +"@types/node@*": version "18.11.18" resolved "https://registry.yarnpkg.com/@types/node/-/node-18.11.18.tgz#8dfb97f0da23c2293e554c5a50d61ef134d7697f" integrity sha512-DHQpWGjyQKSHj3ebjFI/wRKcqQcdR+MoFBygntYOZytCqNfkd2ZC4ARDJ2DQqhjH5p85Nnd3jhUJIXrszFX/JA== @@ -2915,11 +2842,6 @@ resolved "https://registry.yarnpkg.com/@types/parse-json/-/parse-json-4.0.0.tgz#2f8bb441434d163b35fb8ffdccd7138927ffb8c0" integrity sha512-//oorEZjL6sbPcKUaCdIGlIUeH26mgzimjBB77G6XRgnDl/L5wOnpyBGRe/Mmf5CVW3PwEBE1NjiMZ/ssFh4wA== -"@types/q@^0.0.32": - version "0.0.32" - resolved "https://registry.yarnpkg.com/@types/q/-/q-0.0.32.tgz#bd284e57c84f1325da702babfc82a5328190c0c5" - integrity sha512-qYi3YV9inU/REEfxwVcGZzbS3KG/Xs90lv0Pr+lDtuVjBPGd1A+eciXzVSaRvLify132BfcvhvEjeVahrUl0Ug== - "@types/qs@*": version "6.9.7" resolved "https://registry.yarnpkg.com/@types/qs/-/qs-6.9.7.tgz#63bb7d067db107cc1e457c303bc25d511febf6cb" @@ -2935,16 +2857,6 @@ resolved "https://registry.yarnpkg.com/@types/retry/-/retry-0.12.0.tgz#2b35eccfcee7d38cd72ad99232fbd58bffb3c84d" integrity sha512-wWKOClTTiizcZhXnPY4wikVAwmdYHp8q6DmC+EJUzAMsycb7HB32Kh9RN4+0gExjmPmZSAQjgURXIGATPegAvA== -"@types/selenium-webdriver@^3.0.0": - version "3.0.20" - resolved "https://registry.yarnpkg.com/@types/selenium-webdriver/-/selenium-webdriver-3.0.20.tgz#448771a0608ebf1c86cb5885914da6311e323c3a" - integrity sha512-6d8Q5fqS9DWOXEhMDiF6/2FjyHdmP/jSTAUyeQR7QwrFeNmYyzmvGxD5aLIHL445HjWgibs0eAig+KPnbaesXA== - -"@types/semver@^7.3.12": - version "7.3.13" - resolved "https://registry.yarnpkg.com/@types/semver/-/semver-7.3.13.tgz#da4bfd73f49bd541d28920ab0e2bf0ee80f71c91" - integrity sha512-21cFJr9z3g5dW8B0CVI9g2O9beqaThGQ6ZFBqHfwhzLDKUxaqTIy3vnfah/UPkfOiF2pLq+tGz+W8RyCskuslw== - "@types/serve-index@^1.9.1": version "1.9.1" resolved "https://registry.yarnpkg.com/@types/serve-index/-/serve-index-1.9.1.tgz#1b5e85370a192c01ec6cec4735cf2917337a6278" @@ -2979,89 +2891,6 @@ dependencies: "@types/node" "*" -"@typescript-eslint/eslint-plugin@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/eslint-plugin/-/eslint-plugin-5.48.1.tgz#deee67e399f2cb6b4608c935777110e509d8018c" - integrity sha512-9nY5K1Rp2ppmpb9s9S2aBiF3xo5uExCehMDmYmmFqqyxgenbHJ3qbarcLt4ITgaD6r/2ypdlcFRdcuVPnks+fQ== - dependencies: - "@typescript-eslint/scope-manager" "5.48.1" - "@typescript-eslint/type-utils" "5.48.1" - "@typescript-eslint/utils" "5.48.1" - debug "^4.3.4" - ignore "^5.2.0" - natural-compare-lite "^1.4.0" - regexpp "^3.2.0" - semver "^7.3.7" - tsutils "^3.21.0" - -"@typescript-eslint/parser@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/parser/-/parser-5.48.1.tgz#d0125792dab7e232035434ab8ef0658154db2f10" - integrity sha512-4yg+FJR/V1M9Xoq56SF9Iygqm+r5LMXvheo6DQ7/yUWynQ4YfCRnsKuRgqH4EQ5Ya76rVwlEpw4Xu+TgWQUcdA== - dependencies: - "@typescript-eslint/scope-manager" "5.48.1" - "@typescript-eslint/types" "5.48.1" - "@typescript-eslint/typescript-estree" "5.48.1" - debug "^4.3.4" - -"@typescript-eslint/scope-manager@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/scope-manager/-/scope-manager-5.48.1.tgz#39c71e4de639f5fe08b988005beaaf6d79f9d64d" - integrity sha512-S035ueRrbxRMKvSTv9vJKIWgr86BD8s3RqoRZmsSh/s8HhIs90g6UlK8ZabUSjUZQkhVxt7nmZ63VJ9dcZhtDQ== - dependencies: - "@typescript-eslint/types" "5.48.1" - "@typescript-eslint/visitor-keys" "5.48.1" - -"@typescript-eslint/type-utils@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/type-utils/-/type-utils-5.48.1.tgz#5d94ac0c269a81a91ad77c03407cea2caf481412" - integrity sha512-Hyr8HU8Alcuva1ppmqSYtM/Gp0q4JOp1F+/JH5D1IZm/bUBrV0edoewQZiEc1r6I8L4JL21broddxK8HAcZiqQ== - dependencies: - "@typescript-eslint/typescript-estree" "5.48.1" - "@typescript-eslint/utils" "5.48.1" - debug "^4.3.4" - tsutils "^3.21.0" - -"@typescript-eslint/types@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/types/-/types-5.48.1.tgz#efd1913a9aaf67caf8a6e6779fd53e14e8587e14" - integrity sha512-xHyDLU6MSuEEdIlzrrAerCGS3T7AA/L8Hggd0RCYBi0w3JMvGYxlLlXHeg50JI9Tfg5MrtsfuNxbS/3zF1/ATg== - -"@typescript-eslint/typescript-estree@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/typescript-estree/-/typescript-estree-5.48.1.tgz#9efa8ee2aa471c6ab62e649f6e64d8d121bc2056" - integrity sha512-Hut+Osk5FYr+sgFh8J/FHjqX6HFcDzTlWLrFqGoK5kVUN3VBHF/QzZmAsIXCQ8T/W9nQNBTqalxi1P3LSqWnRA== - dependencies: - "@typescript-eslint/types" "5.48.1" - "@typescript-eslint/visitor-keys" "5.48.1" - debug "^4.3.4" - globby "^11.1.0" - is-glob "^4.0.3" - semver "^7.3.7" - tsutils "^3.21.0" - -"@typescript-eslint/utils@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/utils/-/utils-5.48.1.tgz#20f2f4e88e9e2a0961cbebcb47a1f0f7da7ba7f9" - integrity sha512-SmQuSrCGUOdmGMwivW14Z0Lj8dxG1mOFZ7soeJ0TQZEJcs3n5Ndgkg0A4bcMFzBELqLJ6GTHnEU+iIoaD6hFGA== - dependencies: - "@types/json-schema" "^7.0.9" - "@types/semver" "^7.3.12" - "@typescript-eslint/scope-manager" "5.48.1" - "@typescript-eslint/types" "5.48.1" - "@typescript-eslint/typescript-estree" "5.48.1" - eslint-scope "^5.1.1" - eslint-utils "^3.0.0" - semver "^7.3.7" - -"@typescript-eslint/visitor-keys@5.48.1": - version "5.48.1" - resolved "https://registry.yarnpkg.com/@typescript-eslint/visitor-keys/-/visitor-keys-5.48.1.tgz#79fd4fb9996023ef86849bf6f904f33eb6c8fccb" - integrity sha512-Ns0XBwmfuX7ZknznfXozgnydyR8F6ev/KEGePP4i74uL3ArsKbEhJ7raeKr1JSa997DBDwol/4a0Y+At82c9dA== - dependencies: - "@typescript-eslint/types" "5.48.1" - eslint-visitor-keys "^3.3.0" - "@vitejs/plugin-basic-ssl@1.0.1": version "1.0.1" resolved "https://registry.yarnpkg.com/@vitejs/plugin-basic-ssl/-/plugin-basic-ssl-1.0.1.tgz#48c46eab21e0730921986ce742563ae83fe7fe34" @@ -3291,17 +3120,12 @@ acorn-import-assertions@^1.9.0: resolved "https://registry.yarnpkg.com/acorn-import-assertions/-/acorn-import-assertions-1.9.0.tgz#507276249d684797c84e0734ef84860334cfb1ac" integrity sha512-cmMwop9x+8KFhxvKrKfPYmN6/pKTYYHBqLa0DfvVZcKMJWNyWLnaqND7dx/qn66R7ewM1UX5XMaDVP5wlVTaVA== -acorn-jsx@^5.3.2: - version "5.3.2" - resolved "https://registry.yarnpkg.com/acorn-jsx/-/acorn-jsx-5.3.2.tgz#7ed5bb55908b3b2f1bc55c6af1653bada7f07937" - integrity sha512-rq9s+JNhf0IChjtDXxllJ7g41oZk5SlXtp0LHwyA5cejwn7vKmKp4pPri6YEePv2PU65sAsegbXtIinmDFDXgQ== - acorn-walk@^8.0.0, acorn-walk@^8.1.1: version "8.2.0" resolved "https://registry.yarnpkg.com/acorn-walk/-/acorn-walk-8.2.0.tgz#741210f2e2426454508853a2f44d0ab83b7f69c1" integrity sha512-k+iyHEuPgSw6SbuDpGQM+06HQUa04DZ3o+F6CSzXMvvI5KMvnaEqXe+YVe555R9nn6GPt404fos4wcgpw12SDA== -acorn@^8.0.4, acorn@^8.4.1, acorn@^8.7.1, acorn@^8.8.0: +acorn@^8.0.4, acorn@^8.4.1, acorn@^8.7.1: version "8.8.1" resolved "https://registry.yarnpkg.com/acorn/-/acorn-8.8.1.tgz#0a3f9cbecc4ec3bea6f0a80b66ae8dd2da250b73" integrity sha512-7zFpHzhnqYKrkYdUjF1HI1bzd0VygEGX8lFk4k5zVMqHEoES+P+7TKI+EvLO9WVMJ8eekdO0aDEK044xTXwPPA== @@ -3319,11 +3143,6 @@ adjust-sourcemap-loader@^4.0.0: loader-utils "^2.0.0" regex-parser "^2.2.11" -adm-zip@^0.4.9: - version "0.4.16" - resolved "https://registry.yarnpkg.com/adm-zip/-/adm-zip-0.4.16.tgz#cf4c508fdffab02c269cbc7f471a875f05570365" - integrity sha512-TFi4HBKSGfIKsK5YCkKaaFG2m4PEDyViZmEwof3MTIgzimHLto6muaHVpbrljdIvIrFZzEq/p4nafOeLcYegrg== - agent-base@6, agent-base@^6.0.2: version "6.0.2" resolved "https://registry.yarnpkg.com/agent-base/-/agent-base-6.0.2.tgz#49fff58577cfee3f37176feab4c22e00f86d7f77" @@ -3331,13 +3150,6 @@ agent-base@6, agent-base@^6.0.2: dependencies: debug "4" -agent-base@^4.3.0: - version "4.3.0" - resolved "https://registry.yarnpkg.com/agent-base/-/agent-base-4.3.0.tgz#8165f01c436009bccad0b1d122f05ed770efc6ee" - integrity sha512-salcGninV0nPrwpGNn4VTXBb1SOuXQBiqbrNXoeizJsHrsL6ERFM2Ne3JUSBWRE6aeNJI2ROP/WEEIDUiDe3cg== - dependencies: - es6-promisify "^5.0.0" - agentkeepalive@^4.2.1: version "4.2.1" resolved "https://registry.yarnpkg.com/agentkeepalive/-/agentkeepalive-4.2.1.tgz#a7975cbb9f83b367f06c90cc51ff28fe7d499717" @@ -3384,7 +3196,7 @@ ajv@8.12.0, ajv@^8.0.0, ajv@^8.8.0: require-from-string "^2.0.2" uri-js "^4.2.2" -ajv@^6.10.0, ajv@^6.12.3, ajv@^6.12.4, ajv@^6.12.5: +ajv@^6.12.5: version "6.12.6" resolved "https://registry.yarnpkg.com/ajv/-/ajv-6.12.6.tgz#baf5a62e802b07d977034586f8c3baf5adf26df4" integrity sha512-j3fVLgvTo527anyYyJOGTYJbG+vnnQYvE0m5mmkc1TK+nxAppkCLMIL0aZ4dblVCNoGShhm+kzE4ZUykBoMg4g== @@ -3411,11 +3223,6 @@ ansi-html-community@^0.0.8: resolved "https://registry.yarnpkg.com/ansi-html-community/-/ansi-html-community-0.0.8.tgz#69fbc4d6ccbe383f9736934ae34c3f8290f1bf41" integrity sha512-1APHAyr3+PCamwNw3bXCPp4HFLONZt/yIH0sZp0/469KWNTEy+qN5jQ3GVX6DMZ1UXAi34yVwtTeaG/HpBuuzw== -ansi-regex@^2.0.0: - version "2.1.1" - resolved "https://registry.yarnpkg.com/ansi-regex/-/ansi-regex-2.1.1.tgz#c3b33ab5ee360d86e0e628f0468ae7ef27d654df" - integrity sha512-TIGnTpdo+E3+pCyAluZvtED5p5wCqLdezCyhPZzKPcxvFplEt4i+W7OONCKgeZFT3+y5NZZfOOS/Bdcanm1MYA== - ansi-regex@^5.0.1: version "5.0.1" resolved "https://registry.yarnpkg.com/ansi-regex/-/ansi-regex-5.0.1.tgz#082cb2c89c9fe8659a311a53bd6a4dc5301db304" @@ -3426,11 +3233,6 @@ ansi-regex@^6.0.1: resolved "https://registry.yarnpkg.com/ansi-regex/-/ansi-regex-6.0.1.tgz#3183e38fae9a65d7cb5e53945cd5897d0260a06a" integrity sha512-n5M855fKb2SsfMIiFFoVrABHJC8QtHwVx+mHWP3QcEqBHYienj5dHSgjbxtC0WEZXYt4wcD6zrQElDPhFuZgfA== -ansi-styles@^2.2.1: - version "2.2.1" - resolved "https://registry.yarnpkg.com/ansi-styles/-/ansi-styles-2.2.1.tgz#b432dd3358b634cf75e1e4664368240533c1ddbe" - integrity sha512-kmCevFghRiWM7HB5zTPULl4r9bVFSWjz62MhqizDGUrq2NWuNMQyuv4tHHoKJHs69M/MF64lEcHdYIocrdWQYA== - ansi-styles@^3.2.1: version "3.2.1" resolved "https://registry.yarnpkg.com/ansi-styles/-/ansi-styles-3.2.1.tgz#41fbb20243e50b12be0f04b8dedbf07520ce841d" @@ -3505,40 +3307,16 @@ array-flatten@^2.1.2: resolved "https://registry.yarnpkg.com/array-flatten/-/array-flatten-2.1.2.tgz#24ef80a28c1a893617e2149b0c6d0d788293b099" integrity sha512-hNfzcOV8W4NdualtqBFPyVO+54DSJuZGY9qT4pRroB6S9e3iiido2ISIC5h9R2sPJ8H3FHCIiEnsv1lPXO3KtQ== -array-union@^1.0.1: - version "1.0.2" - resolved "https://registry.yarnpkg.com/array-union/-/array-union-1.0.2.tgz#9a34410e4f4e3da23dea375be5be70f24778ec39" - integrity sha512-Dxr6QJj/RdU/hCaBjOfxW+q6lyuVE6JFWIrAUpuOOhoJJoQ99cUn3igRaHVB5P9WrgFVN0FfArM3x0cueOU8ng== - dependencies: - array-uniq "^1.0.1" - array-union@^2.1.0: version "2.1.0" resolved "https://registry.yarnpkg.com/array-union/-/array-union-2.1.0.tgz#b798420adbeb1de828d84acd8a2e23d3efe85e8d" integrity sha512-HGyxoOTYUyCM6stUe6EJgnd4EoewAI7zMdfqO+kGjnlZmBDz/cR5pf8r/cR4Wq60sL/p0IkcjUEEPwS3GFrIyw== -array-uniq@^1.0.1: - version "1.0.3" - resolved "https://registry.yarnpkg.com/array-uniq/-/array-uniq-1.0.3.tgz#af6ac877a25cc7f74e058894753858dfdb24fdb6" - integrity sha512-MNha4BWQ6JbwhFhj03YK552f7cb3AzoE8SzeljgChvL1dl3IcvggXVz1DilzySZkCja+CXuZbdW7yATchWn8/Q== - -arrify@^1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/arrify/-/arrify-1.0.1.tgz#898508da2226f380df904728456849c1501a4b0d" - integrity sha512-3CYzex9M9FGQjCGMGyi6/31c8GJbgb0qGyrx5HWxPd0aCwh4cB2YjMb2Xf9UuoogrMrlO9cTqnB5rI5GHZTcUA== - asap@~2.0.3: version "2.0.6" resolved "https://registry.yarnpkg.com/asap/-/asap-2.0.6.tgz#e50347611d7e690943208bbdafebcbc2fb866d46" integrity sha512-BSHWgDSAiKs50o2Re8ppvp3seVHXSRM44cdSsT9FfNEUUZLOGWVCsiWaRPWM1Znn+mqZ1OfVZ3z3DWEzSp7hRA== -asn1@~0.2.3: - version "0.2.6" - resolved "https://registry.yarnpkg.com/asn1/-/asn1-0.2.6.tgz#0d3a7bb6e64e02a90c0303b31f292868ea09a08d" - integrity sha512-ix/FxPn0MDjeyJ7i/yoHGFt/EX6LyNbxSEhPPXODPL+KB0VPk86UYfL0lMdy+KCnv+fmvIzySwaK5COwqVbWTQ== - dependencies: - safer-buffer "~2.1.0" - asn1js@^3.0.1, asn1js@^3.0.5: version "3.0.5" resolved "https://registry.yarnpkg.com/asn1js/-/asn1js-3.0.5.tgz#5ea36820443dbefb51cc7f88a2ebb5b462114f38" @@ -3548,11 +3326,6 @@ asn1js@^3.0.1, asn1js@^3.0.5: pvutils "^1.1.3" tslib "^2.4.0" -assert-plus@1.0.0, assert-plus@^1.0.0: - version "1.0.0" - resolved "https://registry.yarnpkg.com/assert-plus/-/assert-plus-1.0.0.tgz#f12e0f3c5d77b0b1cdd9146942e4e96c1e4dd525" - integrity sha512-NfJ4UzBCcQGLDlQq7nHxH+tv3kyZ0hHQqF5BO6J7tNJeP5do1llPr8dZ8zHonfhAu0PHAdMkSo+8o0wxg9lZWw== - astral-regex@^2.0.0: version "2.0.0" resolved "https://registry.yarnpkg.com/astral-regex/-/astral-regex-2.0.0.tgz#483143c567aeed4785759c0865786dc77d7d2e31" @@ -3580,16 +3353,6 @@ autoprefixer@10.4.14: picocolors "^1.0.0" postcss-value-parser "^4.2.0" -aws-sign2@~0.7.0: - version "0.7.0" - resolved "https://registry.yarnpkg.com/aws-sign2/-/aws-sign2-0.7.0.tgz#b46e890934a9591f2d2f6f86d7e6a9f1b3fe76a8" - integrity sha512-08kcGqnYf/YmjoRhfxyu+CLxBjUtHLXLXX/vUfx9l2LYzG3c1m61nrpyFUZI6zeS+Li/wWMMidD9KgrqtGq3mA== - -aws4@^1.8.0: - version "1.12.0" - resolved "https://registry.yarnpkg.com/aws4/-/aws4-1.12.0.tgz#ce1c9d143389679e253b314241ea9aa5cec980d3" - integrity sha512-NmWvPnx0F1SfrQbYwOi7OeaNGokp9XhzNioJ/CSBs8Qa4vxug81mhJEAVZwxXuBmYB5KDRfMq/F3RR0BIU7sWg== - babel-loader@9.1.2: version "9.1.2" resolved "https://registry.yarnpkg.com/babel-loader/-/babel-loader-9.1.2.tgz#a16a080de52d08854ee14570469905a5fc00d39c" @@ -3681,23 +3444,11 @@ base64-js@^1.2.0, base64-js@^1.3.1: resolved "https://registry.yarnpkg.com/base64-js/-/base64-js-1.5.1.tgz#1b1b440160a5bf7ad40b650f095963481903930a" integrity sha512-AKpaYlHn8t4SVbOHCy+b5+KKgvR4vrsD8vbvrbiQJps7fKDTkjkDry6ji0rUJjC0kzbNePLwzxq8iypo41qeWA== -base64id@2.0.0, base64id@~2.0.0: - version "2.0.0" - resolved "https://registry.yarnpkg.com/base64id/-/base64id-2.0.0.tgz#2770ac6bc47d312af97a8bf9a634342e0cd25cb6" - integrity sha512-lGe34o6EHj9y3Kts9R4ZYs/Gr+6N7MCaMlIFA3F1R2O5/m7K06AxfSeO5530PEERE6/WyEg3lsuyw4GHlPZHog== - batch@0.6.1: version "0.6.1" resolved "https://registry.yarnpkg.com/batch/-/batch-0.6.1.tgz#dc34314f4e679318093fc760272525f94bf25c16" integrity sha512-x+VAiMRL6UPkx+kudNvxTl6hB2XNNCG2r+7wixVfIYwu/2HKRXimwQyaumLjMveWvT2Hkd/cAJw+QBMfJ/EKVw== -bcrypt-pbkdf@^1.0.0: - version "1.0.2" - resolved "https://registry.yarnpkg.com/bcrypt-pbkdf/-/bcrypt-pbkdf-1.0.2.tgz#a4301d389b6a43f9b67ff3ca11a3f6637e360e9e" - integrity sha512-qeFIXtP4MSoi6NLqO12WfqARWWuCKi2Rn/9hJLEmtB5yTNr9DqFWkJRCf2qShWzPeAMRnOgCrq0sg/KLv5ES9w== - dependencies: - tweetnacl "^0.14.3" - bent@~7.3.6: version "7.3.12" resolved "https://registry.yarnpkg.com/bent/-/bent-7.3.12.tgz#e0a2775d4425e7674c64b78b242af4f49da6b035" @@ -3726,14 +3477,7 @@ bl@^4.1.0: inherits "^2.0.4" readable-stream "^3.4.0" -blocking-proxy@^1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/blocking-proxy/-/blocking-proxy-1.0.1.tgz#81d6fd1fe13a4c0d6957df7f91b75e98dac40cb2" - integrity sha512-KE8NFMZr3mN2E0HcvCgRtX7DjhiIQrwle+nSVJVC/yqFb9+xznHl2ZcoBp2L9qzkI4t4cBFJ1efXF8Dwi132RA== - dependencies: - minimist "^1.2.0" - -body-parser@1.20.1, body-parser@^1.19.0: +body-parser@1.20.1: version "1.20.1" resolved "https://registry.yarnpkg.com/body-parser/-/body-parser-1.20.1.tgz#b1812a8912c195cd371a3ee5e66faa2338a5c668" integrity sha512-jWi7abTbYwajOytWCQc37VulmWiRae5RyTpaCyDcS5/lMdtwSz5lOpDE67srw/HYe35f1z3fDQw+3txg7gNtWw== @@ -3808,13 +3552,6 @@ browserslist@^4.21.5, browserslist@^4.21.9: node-releases "^2.0.12" update-browserslist-db "^1.0.11" -browserstack@^1.5.1: - version "1.6.1" - resolved "https://registry.yarnpkg.com/browserstack/-/browserstack-1.6.1.tgz#e051f9733ec3b507659f395c7a4765a1b1e358b3" - integrity sha512-GxtFjpIaKdbAyzHfFDKixKO8IBT7wR3NjbzrGc78nNs/Ciys9wU3/nBtsqsWv5nDSrdI5tz0peKuzCPuNXNUiw== - dependencies: - https-proxy-agent "^2.2.1" - bser@2.1.1: version "2.1.1" resolved "https://registry.yarnpkg.com/bser/-/bser-2.1.1.tgz#e6787da20ece9d07998533cfd9de6f5c38f4bc05" @@ -3985,25 +3722,6 @@ caseless@~0.12.0: resolved "https://registry.yarnpkg.com/caseless/-/caseless-0.12.0.tgz#1b681c21ff84033c826543090689420d187151dc" integrity sha512-4tYFyifaFfGacoiObjJegolkwSU4xQNGbVgUiNYVUxbQ2x2lUsFvY4hVgVzGiIe6WLOPqycWXA40l+PWsxthUw== -casual@^1.6.2: - version "1.6.2" - resolved "https://registry.yarnpkg.com/casual/-/casual-1.6.2.tgz#f56b87113ae99a6bba45e04bdfa068ca443f9e85" - integrity sha512-NQObL800rg32KZ9bBajHbyDjxLXxxuShChQg7A4tbSeG3n1t7VYGOSkzFSI9gkSgOHp+xilEJ7G0L5l6M30KYA== - dependencies: - mersenne-twister "^1.0.1" - moment "^2.15.2" - -chalk@^1.1.1, chalk@^1.1.3: - version "1.1.3" - resolved "https://registry.yarnpkg.com/chalk/-/chalk-1.1.3.tgz#a8115c55e4a702fe4d150abd3872822a7e09fc98" - integrity sha512-U3lRVLMSlsCfjqYPbLyVv11M9CPW4I728d6TCKMAOJueEeB9/8o+eSsMnxPJD+Q+K909sdESg7C+tIkoH6on1A== - dependencies: - ansi-styles "^2.2.1" - escape-string-regexp "^1.0.2" - has-ansi "^2.0.0" - strip-ansi "^3.0.0" - supports-color "^2.0.0" - chalk@^2.0.0, chalk@^2.3.0: version "2.4.2" resolved "https://registry.yarnpkg.com/chalk/-/chalk-2.4.2.tgz#cd42541677a54333cf541a49108c1432b44c9424" @@ -4084,7 +3802,7 @@ chardet@^0.7.0: resolved "https://registry.yarnpkg.com/chardet/-/chardet-0.7.0.tgz#90094849f0937f2eedc2425d0d28a9e5f0cbad9e" integrity sha512-mT8iDcrh03qDGRRmoA2hmBJnxpllMR+0/0qlzjqZES6NdiWDcZkCNAk4rPFZ9Q85r27unkiNNg8ZOiwZXBHwcA== -chokidar@3.5.3, "chokidar@>=3.0.0 <4.0.0", chokidar@^3.0.0, chokidar@^3.5.1, chokidar@^3.5.2, chokidar@^3.5.3: +chokidar@3.5.3, "chokidar@>=3.0.0 <4.0.0", chokidar@^3.0.0, chokidar@^3.5.2, chokidar@^3.5.3: version "3.5.3" resolved "https://registry.yarnpkg.com/chokidar/-/chokidar-3.5.3.tgz#1cf37c8707b932bd1af1ae22c0432e2acd1903bd" integrity sha512-Dr3sfKRP6oTcjf2JmUmFJfeVMvXBdegxB0iVQ5eb2V10uFJUCAS8OByZdVAyVb8xXNz3GjjTgj9kLWsZTqE6kw== @@ -4153,15 +3871,6 @@ cliui@^6.0.0: strip-ansi "^6.0.0" wrap-ansi "^6.2.0" -cliui@^7.0.2: - version "7.0.4" - resolved "https://registry.yarnpkg.com/cliui/-/cliui-7.0.4.tgz#a0265ee655476fc807aea9df3df8df7783808b4f" - integrity sha512-OcRE68cOsVMXp1Yvonl/fzkQOyjLSu/8bhPDfQt0e0/Eb283TKP20Fs2MqoPsr9SwA595rRCA+QMzYc9nBP+JQ== - dependencies: - string-width "^4.2.0" - strip-ansi "^6.0.0" - wrap-ansi "^7.0.0" - cliui@^8.0.1: version "8.0.1" resolved "https://registry.yarnpkg.com/cliui/-/cliui-8.0.1.tgz#0c04b075db02cbfe60dc8e6cf2f5486b1a3608aa" @@ -4219,12 +3928,7 @@ colorette@^2.0.10, colorette@^2.0.16: resolved "https://registry.yarnpkg.com/colorette/-/colorette-2.0.19.tgz#cdf044f47ad41a0f4b56b3a0d5b4e6e1a2d5a798" integrity sha512-3tlv/dIP7FWvj3BsbHrGLJ6l/oKh1O3TcgBqMn+yyCagOxc23fyzDS6HypQbgxWbkpDnf52p1LuR4eWDQ/K9WQ== -colors@1.4.0: - version "1.4.0" - resolved "https://registry.yarnpkg.com/colors/-/colors-1.4.0.tgz#c50491479d4c1bdaed2c9ced32cf7c7dc2360f78" - integrity sha512-a+UqTh4kgZg/SlGvfbzDHpgRu7AAQOmmqRHJnxhRZICKFUT91brVhNNt58CMWU9PsBbv3PDCZUHbVxuDiH2mtA== - -combined-stream@^1.0.6, combined-stream@^1.0.8, combined-stream@~1.0.6: +combined-stream@^1.0.8: version "1.0.8" resolved "https://registry.yarnpkg.com/combined-stream/-/combined-stream-1.0.8.tgz#c3d45a8b34fd730631a110a8a2520682b31d5a7f" integrity sha512-FQN4MRfuJeHf7cBbBMJFXhKSDq+2kAArBlmRBvcvFE5BB1HZKXtSFASDhdlz9zOYwxh8lDdnvmMOe/+5cdoEdg== @@ -4286,16 +3990,6 @@ connect-history-api-fallback@^2.0.0: resolved "https://registry.yarnpkg.com/connect-history-api-fallback/-/connect-history-api-fallback-2.0.0.tgz#647264845251a0daf25b97ce87834cace0f5f1c8" integrity sha512-U73+6lQFmfiNPrYbXqr6kZ1i1wiRqXnp2nhMsINseWXO8lDau0LGEffJ8kQi4EjLZympVgRdvqjAgiZ1tgzDDA== -connect@^3.7.0: - version "3.7.0" - resolved "https://registry.yarnpkg.com/connect/-/connect-3.7.0.tgz#5d49348910caa5e07a01800b030d0c35f20484f8" - integrity sha512-ZqRXc+tZukToSNmh5C2iWMSoV3X1YUcPbqEM4DkEG5tNQXrQUZCNVGGv3IuicnkMtPfGf3Xtp8WCXs295iQ1pQ== - dependencies: - debug "2.6.9" - finalhandler "1.1.2" - parseurl "~1.3.3" - utils-merge "1.0.1" - console-control-strings@^1.1.0: version "1.1.0" resolved "https://registry.yarnpkg.com/console-control-strings/-/console-control-strings-1.1.0.tgz#3d7cf4464db6446ea644bf4b39507f9851008e8e" @@ -4337,11 +4031,6 @@ cookie@0.5.0: resolved "https://registry.yarnpkg.com/cookie/-/cookie-0.5.0.tgz#d1f5d71adec6558c58f389987c366aa47e994f8b" integrity sha512-YZ3GUyn/o8gfKJlnlX7g7xq4gyO6OSuhGPKaaGssGB2qgDUS0gPgtTvoyZLTt9Ab6dC4hfc9dV5arkvc/OCmrw== -cookie@~0.4.1: - version "0.4.2" - resolved "https://registry.yarnpkg.com/cookie/-/cookie-0.4.2.tgz#0e41f24de5ecf317947c82fc789e06a884824432" - integrity sha512-aSWTXFzaKWkvHO1Ny/s+ePFpvKsPnjc551iI41v3ny/ow6tBG5Vd+FuqGNhh1LxOmVzOlGUriIlOaokOvhaStA== - copy-anything@^2.0.1: version "2.0.6" resolved "https://registry.yarnpkg.com/copy-anything/-/copy-anything-2.0.6.tgz#092454ea9584a7b7ad5573062b2a87f5900fc480" @@ -4368,31 +4057,11 @@ core-js-compat@^3.30.2, core-js-compat@^3.31.0: dependencies: browserslist "^4.21.9" -core-util-is@1.0.2: - version "1.0.2" - resolved "https://registry.yarnpkg.com/core-util-is/-/core-util-is-1.0.2.tgz#b5fd54220aa2bc5ab57aab7140c940754503c1a7" - integrity sha512-3lqz5YjWTYnW6dlDa5TLaTCcShfar1e40rmcJVwCBJC6mWlFuj0eCHIElmG1g5kyuJ/GD+8Wn4FFCcz4gJPfaQ== - core-util-is@~1.0.0: version "1.0.3" resolved "https://registry.yarnpkg.com/core-util-is/-/core-util-is-1.0.3.tgz#a6042d3634c2b27e9328f837b965fac83808db85" integrity sha512-ZQBvi1DcpJ4GDqanjucZ2Hj3wEO5pZDS89BWbkcrvdxksJorwUDDZamX9ldFkp9aw2lmBDLgkObEA4DWNJ9FYQ== -cors@~2.8.5: - version "2.8.5" - resolved "https://registry.yarnpkg.com/cors/-/cors-2.8.5.tgz#eac11da51592dd86b9f06f6e7ac293b3df875d29" - integrity sha512-KIHbLJqu73RGr/hnbrO9uBeixNGuvSQjul/jdFvS/KFSIH1hWVd1ng7zOHx+YrEfInLG7q4n6GHQ9cDtxv/P6g== - dependencies: - object-assign "^4" - vary "^1" - -cosmiconfig-toml-loader@^1.0.0: - version "1.0.0" - resolved "https://registry.yarnpkg.com/cosmiconfig-toml-loader/-/cosmiconfig-toml-loader-1.0.0.tgz#0681383651cceff918177debe9084c0d3769509b" - integrity sha512-H/2gurFWVi7xXvCyvsWRLCMekl4tITJcX0QEsDMpzxtuxDyM59xLatYNg4s/k9AA/HdtCYfj2su8mgA0GSDLDA== - dependencies: - "@iarna/toml" "^2.2.5" - cosmiconfig-typescript-loader@4.3.0: version "4.3.0" resolved "https://registry.yarnpkg.com/cosmiconfig-typescript-loader/-/cosmiconfig-typescript-loader-4.3.0.tgz#c4259ce474c9df0f32274ed162c0447c951ef073" @@ -4465,7 +4134,7 @@ cross-fetch@^3.1.5: dependencies: node-fetch "2.6.7" -cross-spawn@^7.0.0, cross-spawn@^7.0.2, cross-spawn@^7.0.3: +cross-spawn@^7.0.0, cross-spawn@^7.0.3: version "7.0.3" resolved "https://registry.yarnpkg.com/cross-spawn/-/cross-spawn-7.0.3.tgz#f73a85b9d5d41d045551c177e2882d4ac85728a6" integrity sha512-iRDPJKUPVEND7dHPO8rkbOnPpyDygcDFtWjpeWNCgy8WP2rXcxXL8TskReQl6OrB2G7+UJrags1q15Fudc7G6w== @@ -4558,18 +4227,6 @@ csso@^5.0.5: dependencies: css-tree "~2.2.0" -custom-event@~1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/custom-event/-/custom-event-1.0.1.tgz#5d02a46850adf1b4a317946a3928fccb5bfd0425" - integrity sha512-GAj5FOq0Hd+RsCGVJxZuKaIDXDf3h6GQoNEjFgbLLI/trgtavwUbSnZ5pVfg27DVCaWjIohryS0JFwIJyT2cMg== - -dashdash@^1.12.0: - version "1.14.1" - resolved "https://registry.yarnpkg.com/dashdash/-/dashdash-1.14.1.tgz#853cfa0f7cbe2fed5de20326b8dd581035f6e2f0" - integrity sha512-jRFi8UDGo6j+odZiEpjazZaWqEal3w/basFjQHQEwVtZJGDpxbH1MeYluwCS8Xq5wmLJooDlMgvVarmWfGM44g== - dependencies: - assert-plus "^1.0.0" - dataloader@2.1.0: version "2.1.0" resolved "https://registry.yarnpkg.com/dataloader/-/dataloader-2.1.0.tgz#c69c538235e85e7ac6c6c444bae8ecabf5de9df7" @@ -4580,11 +4237,6 @@ date-fns@^2.16.1: resolved "https://registry.yarnpkg.com/date-fns/-/date-fns-2.29.3.tgz#27402d2fc67eb442b511b70bbdf98e6411cd68a8" integrity sha512-dDCnyH2WnnKusqvZZ6+jA1O51Ibt8ZMRNkDZdyAyK4YfbDwa/cEmuztzG5pk6hqlp9aSBPYcjOlktquahGwGeA== -date-format@^4.0.14: - version "4.0.14" - resolved "https://registry.yarnpkg.com/date-format/-/date-format-4.0.14.tgz#7a8e584434fb169a521c8b7aa481f355810d9400" - integrity sha512-39BOQLs9ZjKh0/patS9nrT8wc3ioX3/eA/zgbKNopnF2wCqJEoxywwwElATYvRsXdnOxA/OQeQoFZ3rFjVajhg== - debounce@^1.2.0: version "1.2.1" resolved "https://registry.yarnpkg.com/debounce/-/debounce-1.2.1.tgz#38881d8f4166a5c5848020c11827b834bcb3e0a5" @@ -4597,14 +4249,14 @@ debug@2.6.9: dependencies: ms "2.0.0" -debug@4, debug@^4.1.0, debug@^4.1.1, debug@^4.3.1, debug@^4.3.2, debug@^4.3.3, debug@^4.3.4, debug@~4.3.1, debug@~4.3.2: +debug@4, debug@^4.1.0, debug@^4.1.1, debug@^4.3.1, debug@^4.3.3, debug@^4.3.4: version "4.3.4" resolved "https://registry.yarnpkg.com/debug/-/debug-4.3.4.tgz#1319f6579357f2338d3337d2cdd4914bb5dcc865" integrity sha512-PRWFHuSU3eDtQJPvnNY7Jcket1j0t5OuOsFzPPzsekD52Zl8qUfFIPEiswXqIvHWGVHOgX+7G/vCNNhehwxfkQ== dependencies: ms "2.1.2" -debug@^3.1.0, debug@^3.2.6: +debug@^3.2.6: version "3.2.7" resolved "https://registry.yarnpkg.com/debug/-/debug-3.2.7.tgz#72580b7e9145fb39b6676f9c5e5fb100b934179a" integrity sha512-CFjzYYAi4ThfiQvizrFQevTTXHtnCqWfe7x1AhgEscTz6ZbLbfoLRLPugTQyBth6f8ZERVUSyWHFD/7Wu4t1XQ== @@ -4616,11 +4268,6 @@ decamelize@^1.2.0: resolved "https://registry.yarnpkg.com/decamelize/-/decamelize-1.2.0.tgz#f6534d15148269b20352e7bee26f501f9a191290" integrity sha512-z2S+W9X73hAUUki+N+9Za2lBlun89zigOyGrsax+KUQ6wKW4ZoWpEYBkGhQjwAjjDCkWxhY0VKEhk8wzY7F5cA== -deep-is@^0.1.3: - version "0.1.4" - resolved "https://registry.yarnpkg.com/deep-is/-/deep-is-0.1.4.tgz#a6f2dce612fadd2ef1f519b73551f17e85199831" - integrity sha512-oIPzksmTg4/MriiaYGO+okXDT7ztn/w3Eptv/+gSIdMdKsJo0u4CfYNFJPy+4SKMuCqGw2wxnA+URMg3t8a/bQ== - default-gateway@^6.0.3: version "6.0.3" resolved "https://registry.yarnpkg.com/default-gateway/-/default-gateway-6.0.3.tgz#819494c888053bdb743edbf343d6cdf7f2943a71" @@ -4640,19 +4287,6 @@ define-lazy-prop@^2.0.0: resolved "https://registry.yarnpkg.com/define-lazy-prop/-/define-lazy-prop-2.0.0.tgz#3f7ae421129bcaaac9bc74905c98a0009ec9ee7f" integrity sha512-Ds09qNh8yw3khSjiJjiUInaGX9xlqZDY7JVryGxdxV7NPeuqQfplOpQ66yJFZut3jLa5zOwkXw1g9EI2uKh4Og== -del@^2.2.0: - version "2.2.2" - resolved "https://registry.yarnpkg.com/del/-/del-2.2.2.tgz#c12c981d067846c84bcaf862cff930d907ffd1a8" - integrity sha512-Z4fzpbIRjOu7lO5jCETSWoqUDVe0IPOlfugBsF6suen2LKDlVb4QZpKEM9P+buNJ4KI1eN7I083w/pbKUpsrWQ== - dependencies: - globby "^5.0.0" - is-path-cwd "^1.0.0" - is-path-in-cwd "^1.0.0" - object-assign "^4.0.1" - pify "^2.0.0" - pinkie-promise "^2.0.0" - rimraf "^2.2.8" - delayed-stream@~1.0.0: version "1.0.0" resolved "https://registry.yarnpkg.com/delayed-stream/-/delayed-stream-1.0.0.tgz#df3ae199acadfb7d440aaae0b29e2272b24ec619" @@ -4693,11 +4327,6 @@ detect-node@^2.0.4: resolved "https://registry.yarnpkg.com/detect-node/-/detect-node-2.1.0.tgz#c9c70775a49c3d03bc2c06d9a73be550f978f8b1" integrity sha512-T0NIuQpnTvFDATNuHN5roPwSBG83rFsuO+MXXH9/3N1eFbn4wcPjttvjMLEPWJ0RGUYgQE7cGgS3tNxbqCGM7g== -di@^0.0.1: - version "0.0.1" - resolved "https://registry.yarnpkg.com/di/-/di-0.0.1.tgz#806649326ceaa7caa3306d75d985ea2748ba913c" - integrity sha512-uJaamHkagcZtHPqCIHZxnFrXlunQXgBOsZSUOWwFw31QJCAbyTBoHMW75YOTur5ZNx8pIeAKgf6GWIgaqqiLhA== - diff@^4.0.1: version "4.0.2" resolved "https://registry.yarnpkg.com/diff/-/diff-4.0.2.tgz#60f3aecb89d5fae520c11aa19efc2bb982aade7d" @@ -4722,23 +4351,6 @@ dns-packet@^5.2.2: dependencies: "@leichtgewicht/ip-codec" "^2.0.1" -doctrine@^3.0.0: - version "3.0.0" - resolved "https://registry.yarnpkg.com/doctrine/-/doctrine-3.0.0.tgz#addebead72a6574db783639dc87a121773973961" - integrity sha512-yS+Q5i3hBf7GBkd4KG8a7eBNNWNGLTaEwwYWUijIYM7zrlYDM0BFXHjjPWlWZ1Rg7UaddZeIDmi9jF3HmqiQ2w== - dependencies: - esutils "^2.0.2" - -dom-serialize@^2.2.1: - version "2.2.1" - resolved "https://registry.yarnpkg.com/dom-serialize/-/dom-serialize-2.2.1.tgz#562ae8999f44be5ea3076f5419dcd59eb43ac95b" - integrity sha512-Yra4DbvoW7/Z6LBN560ZwXMjoNOSAN2wRsKFGc4iBeso+mpIA6qj1vfdf9HpMaKAqG6wXTy+1SYEzmNpKXOSsQ== - dependencies: - custom-event "~1.0.0" - ent "~2.2.0" - extend "^3.0.0" - void-elements "^2.0.0" - dom-serializer@^1.0.1: version "1.4.1" resolved "https://registry.yarnpkg.com/dom-serializer/-/dom-serializer-1.4.1.tgz#de5d41b1aea290215dc45a6dae8adcf1d32e2d30" @@ -4822,14 +4434,6 @@ eastasianwidth@^0.2.0: resolved "https://registry.yarnpkg.com/eastasianwidth/-/eastasianwidth-0.2.0.tgz#696ce2ec0aa0e6ea93a397ffcf24aa7840c827cb" integrity sha512-I88TYZWc9XiYHRQ4/3c5rjjfgkjhLyW2luGIheGERbNQ6OY7yTybanSpDXZa8y7VUP9YmDcYa+eyq4ca7iLqWA== -ecc-jsbn@~0.1.1: - version "0.1.2" - resolved "https://registry.yarnpkg.com/ecc-jsbn/-/ecc-jsbn-0.1.2.tgz#3a83a904e54353287874c564b7549386849a98c9" - integrity sha512-eh9O+hwRHNbG4BLTjEl3nw044CkGm5X6LoaCf7LPp7UU8Qrt47JYNi6nPX8xjW97TKGKm1ouctg0QSpZe9qrnw== - dependencies: - jsbn "~0.1.0" - safer-buffer "^2.1.0" - ecdsa-sig-formatter@1.0.11: version "1.0.11" resolved "https://registry.yarnpkg.com/ecdsa-sig-formatter/-/ecdsa-sig-formatter-1.0.11.tgz#ae0f0fa2d85045ef14a817daa3ce9acd0489e5bf" @@ -4879,27 +4483,6 @@ encoding@^0.1.13: dependencies: iconv-lite "^0.6.2" -engine.io-parser@~5.0.3: - version "5.0.5" - resolved "https://registry.yarnpkg.com/engine.io-parser/-/engine.io-parser-5.0.5.tgz#c6fa52e57d8d2dc68b24754348f779aa6e44f886" - integrity sha512-mjEyaa4zhuuRhaSLOdjEb57X0XPP9JEsnXI4E+ivhwT0GgzUogARx4MqoY1jQyB+4Bkz3BUOmzL7t9RMKmlG3g== - -engine.io@~6.2.1: - version "6.2.1" - resolved "https://registry.yarnpkg.com/engine.io/-/engine.io-6.2.1.tgz#e3f7826ebc4140db9bbaa9021ad6b1efb175878f" - integrity sha512-ECceEFcAaNRybd3lsGQKas3ZlMVjN3cyWwMP25D2i0zWfyiytVbTpRPa34qrr+FHddtpBVOmq4H/DCv1O0lZRA== - dependencies: - "@types/cookie" "^0.4.1" - "@types/cors" "^2.8.12" - "@types/node" ">=10.0.0" - accepts "~1.3.4" - base64id "2.0.0" - cookie "~0.4.1" - cors "~2.8.5" - debug "~4.3.1" - engine.io-parser "~5.0.3" - ws "~8.2.3" - enhanced-resolve@^5.14.1: version "5.15.0" resolved "https://registry.yarnpkg.com/enhanced-resolve/-/enhanced-resolve-5.15.0.tgz#1af946c7d93603eb88e9896cee4904dc012e9c35" @@ -4908,11 +4491,6 @@ enhanced-resolve@^5.14.1: graceful-fs "^4.2.4" tapable "^2.2.0" -ent@~2.2.0: - version "2.2.0" - resolved "https://registry.yarnpkg.com/ent/-/ent-2.2.0.tgz#e964219325a21d05f44466a2f686ed6ce5f5dd1d" - integrity sha512-GHrMyVZQWvTIdDtpiEXdHZnFQKzeO09apj8Cbl4pKWy4i0Oprcq17usfDt5aO63swf0JOeMWjWQE/LzgSRuWpA== - entities@^2.0.0: version "2.2.0" resolved "https://registry.yarnpkg.com/entities/-/entities-2.2.0.tgz#098dc90ebb83d8dffa089d55256b351d34c4da55" @@ -4964,18 +4542,6 @@ es-module-lexer@^1.2.1: resolved "https://registry.yarnpkg.com/es-module-lexer/-/es-module-lexer-1.3.0.tgz#6be9c9e0b4543a60cd166ff6f8b4e9dae0b0c16f" integrity sha512-vZK7T0N2CBmBOixhmjdqx2gWVbFZ4DXZ/NyRMZVlJXPa7CyFS+/a4QQsDGDQy9ZfEzxFuNEsMLeQJnKP2p5/JA== -es6-promise@^4.0.3: - version "4.2.8" - resolved "https://registry.yarnpkg.com/es6-promise/-/es6-promise-4.2.8.tgz#4eb21594c972bc40553d276e510539143db53e0a" - integrity sha512-HJDGx5daxeIvxdBxvG2cb9g4tEvwIk3i8+nhX0yGrYmZUzbkdg8QbDevheDB8gd0//uPj4c1EQua8Q+MViT0/w== - -es6-promisify@^5.0.0: - version "5.0.0" - resolved "https://registry.yarnpkg.com/es6-promisify/-/es6-promisify-5.0.0.tgz#5109d62f3e56ea967c4b63505aef08291c8a5203" - integrity sha512-C+d6UdsYDk0lMebHNR4S2NybQMMngAOnOwYBQjTOiv0MkoJMP0Myw2mgpDLBcpfCmRLxyFqYhS/CfOENq4SJhQ== - dependencies: - es6-promise "^4.0.3" - esbuild-wasm@0.17.19: version "0.17.19" resolved "https://registry.yarnpkg.com/esbuild-wasm/-/esbuild-wasm-0.17.19.tgz#c528495c5363c34a4671fa55404e2b0ba85566ba" @@ -5019,17 +4585,12 @@ escape-html@~1.0.3: resolved "https://registry.yarnpkg.com/escape-html/-/escape-html-1.0.3.tgz#0258eae4d3d0c0974de1c169188ef0051d1d1988" integrity sha512-NiSupZ4OeuGwr68lGIeym/ksIZMJodUGOSCZ/FSnTxcrekbvqrgdUxlJOMpijaKZVjAJrWrGs/6Jy8OMuyj9ow== -escape-string-regexp@^1.0.2, escape-string-regexp@^1.0.5: +escape-string-regexp@^1.0.5: version "1.0.5" resolved "https://registry.yarnpkg.com/escape-string-regexp/-/escape-string-regexp-1.0.5.tgz#1b61c0562190a8dff6ae3bb2cf0200ca130b86d4" integrity sha512-vbRorB5FUQWvla16U8R/qgaFIya2qGzwDrNmCZuYKrbdSUMG6I1ZCGQRefkRVhuOkIGVne7BQ35DSfo1qvJqFg== -escape-string-regexp@^4.0.0: - version "4.0.0" - resolved "https://registry.yarnpkg.com/escape-string-regexp/-/escape-string-regexp-4.0.0.tgz#14ba83a5d373e3d311e5afca29cf5bfad965bf34" - integrity sha512-TtpcNJ3XAzx3Gq8sWRzJaVajRs0uVxA2YAkdb1jm2YkPz4G6egUFAyA3n5vtEIZefPk5Wa4UXbKuS5fKkJWdgA== - -eslint-scope@5.1.1, eslint-scope@^5.1.1: +eslint-scope@5.1.1: version "5.1.1" resolved "https://registry.yarnpkg.com/eslint-scope/-/eslint-scope-5.1.1.tgz#e786e59a66cb92b3f6c1fb0d508aab174848f48c" integrity sha512-2NxwbF/hZ0KpepYN0cNbo+FN6XoK7GaHlQhgx/hIZl6Va0bF45RQOOwhLIy8lQDbuCiadSLCBnH2CFYquit5bw== @@ -5037,97 +4598,11 @@ eslint-scope@5.1.1, eslint-scope@^5.1.1: esrecurse "^4.3.0" estraverse "^4.1.1" -eslint-scope@^7.1.1: - version "7.1.1" - resolved "https://registry.yarnpkg.com/eslint-scope/-/eslint-scope-7.1.1.tgz#fff34894c2f65e5226d3041ac480b4513a163642" - integrity sha512-QKQM/UXpIiHcLqJ5AOyIW7XZmzjkzQXYE54n1++wb0u9V/abW3l9uQnxX8Z5Xd18xyKIMTUAyQ0k1e8pz6LUrw== - dependencies: - esrecurse "^4.3.0" - estraverse "^5.2.0" - -eslint-utils@^3.0.0: - version "3.0.0" - resolved "https://registry.yarnpkg.com/eslint-utils/-/eslint-utils-3.0.0.tgz#8aebaface7345bb33559db0a1f13a1d2d48c3672" - integrity sha512-uuQC43IGctw68pJA1RgbQS8/NP7rch6Cwd4j3ZBtgo4/8Flj4eGE7ZYSZRN3iq5pVUv6GPdW5Z1RFleo84uLDA== - dependencies: - eslint-visitor-keys "^2.0.0" - -eslint-visitor-keys@^2.0.0: - version "2.1.0" - resolved "https://registry.yarnpkg.com/eslint-visitor-keys/-/eslint-visitor-keys-2.1.0.tgz#f65328259305927392c938ed44eb0a5c9b2bd303" - integrity sha512-0rSmRBzXgDzIsD6mGdJgevzgezI534Cer5L/vyMX0kHzT/jiB43jRhd9YUlMGYLQy2zprNmoT8qasCGtY+QaKw== - -eslint-visitor-keys@^3.3.0: - version "3.3.0" - resolved "https://registry.yarnpkg.com/eslint-visitor-keys/-/eslint-visitor-keys-3.3.0.tgz#f6480fa6b1f30efe2d1968aa8ac745b862469826" - integrity sha512-mQ+suqKJVyeuwGYHAdjMFqjCyfl8+Ldnxuyp3ldiMBFKkvytrXUZWaiPCEav8qDHKty44bD+qV1IP4T+w+xXRA== - -eslint@^8.31.0: - version "8.32.0" - resolved "https://registry.yarnpkg.com/eslint/-/eslint-8.32.0.tgz#d9690056bb6f1a302bd991e7090f5b68fbaea861" - integrity sha512-nETVXpnthqKPFyuY2FNjz/bEd6nbosRgKbkgS/y1C7LJop96gYHWpiguLecMHQ2XCPxn77DS0P+68WzG6vkZSQ== - dependencies: - "@eslint/eslintrc" "^1.4.1" - "@humanwhocodes/config-array" "^0.11.8" - "@humanwhocodes/module-importer" "^1.0.1" - "@nodelib/fs.walk" "^1.2.8" - ajv "^6.10.0" - chalk "^4.0.0" - cross-spawn "^7.0.2" - debug "^4.3.2" - doctrine "^3.0.0" - escape-string-regexp "^4.0.0" - eslint-scope "^7.1.1" - eslint-utils "^3.0.0" - eslint-visitor-keys "^3.3.0" - espree "^9.4.0" - esquery "^1.4.0" - esutils "^2.0.2" - fast-deep-equal "^3.1.3" - file-entry-cache "^6.0.1" - find-up "^5.0.0" - glob-parent "^6.0.2" - globals "^13.19.0" - grapheme-splitter "^1.0.4" - ignore "^5.2.0" - import-fresh "^3.0.0" - imurmurhash "^0.1.4" - is-glob "^4.0.0" - is-path-inside "^3.0.3" - js-sdsl "^4.1.4" - js-yaml "^4.1.0" - json-stable-stringify-without-jsonify "^1.0.1" - levn "^0.4.1" - lodash.merge "^4.6.2" - minimatch "^3.1.2" - natural-compare "^1.4.0" - optionator "^0.9.1" - regexpp "^3.2.0" - strip-ansi "^6.0.1" - strip-json-comments "^3.1.0" - text-table "^0.2.0" - -espree@^9.4.0: - version "9.4.1" - resolved "https://registry.yarnpkg.com/espree/-/espree-9.4.1.tgz#51d6092615567a2c2cff7833445e37c28c0065bd" - integrity sha512-XwctdmTO6SIvCzd9810yyNzIrOrqNYV9Koizx4C/mRhf9uq0o4yHoCEU/670pOxOL/MSraektvSAji79kX90Vg== - dependencies: - acorn "^8.8.0" - acorn-jsx "^5.3.2" - eslint-visitor-keys "^3.3.0" - esprima@^4.0.0: version "4.0.1" resolved "https://registry.yarnpkg.com/esprima/-/esprima-4.0.1.tgz#13b04cdb3e6c5d19df91ab6987a8695619b0aa71" integrity sha512-eGuFFw7Upda+g4p+QHvnW0RyTX/SVeJBDM/gCtMARO0cLuT2HcEKnTPvhjV6aGeqrCB/sbNop0Kszm0jsaWU4A== -esquery@^1.4.0: - version "1.4.0" - resolved "https://registry.yarnpkg.com/esquery/-/esquery-1.4.0.tgz#2148ffc38b82e8c7057dfed48425b3e61f0f24a5" - integrity sha512-cCDispWt5vHHtwMY2YrAQ4ibFkAL8RbH5YGBnZBc90MolvvfkkQcJro/aZiAQUlQ3qgrYS6D6v8Gc5G5CQsc9w== - dependencies: - estraverse "^5.1.0" - esrecurse@^4.3.0: version "4.3.0" resolved "https://registry.yarnpkg.com/esrecurse/-/esrecurse-4.3.0.tgz#7ad7964d679abb28bee72cec63758b1c5d2c9921" @@ -5140,7 +4615,7 @@ estraverse@^4.1.1: resolved "https://registry.yarnpkg.com/estraverse/-/estraverse-4.3.0.tgz#398ad3f3c5a24948be7725e83d11a7de28cdbd1d" integrity sha512-39nnKffWz8xN1BU/2c79n9nB9HDzo0niYUqx6xyqUnyoAnQyyWpOTdZEeiCch8BBu515t4wp9ZmgVfVhn9EBpw== -estraverse@^5.1.0, estraverse@^5.2.0: +estraverse@^5.2.0: version "5.3.0" resolved "https://registry.yarnpkg.com/estraverse/-/estraverse-5.3.0.tgz#2eea5290702f26ab8fe5370370ff86c965d21123" integrity sha512-MMdARuVEQziNTeJD8DgMqmhwR11BRQ/cBP+pLtYdSTnf3MIO8fFeiINEbX36ZdNlfU/7A9f3gUw49B3oQsvwBA== @@ -5190,11 +4665,6 @@ execa@^5.0.0: signal-exit "^3.0.3" strip-final-newline "^2.0.0" -exit@^0.1.2: - version "0.1.2" - resolved "https://registry.yarnpkg.com/exit/-/exit-0.1.2.tgz#0632638f8d877cc82107d30a0fff1a17cba1cd0c" - integrity sha512-Zk/eNKV2zbjpKzrsQ+n1G6poVbErQxJ0LBOJXaKZ1EViLzH+hrLu9cdXI4zw9dBQJslwBEpbQ2P1oS7nDxs6jQ== - express@^4.17.3: version "4.18.2" resolved "https://registry.yarnpkg.com/express/-/express-4.18.2.tgz#3fabe08296e930c796c19e3c516979386ba9fd59" @@ -5232,11 +4702,6 @@ express@^4.17.3: utils-merge "1.0.1" vary "~1.1.2" -extend@^3.0.0, extend@~3.0.2: - version "3.0.2" - resolved "https://registry.yarnpkg.com/extend/-/extend-3.0.2.tgz#f8b1136b4071fbd8eb140aff858b1019ec2915fa" - integrity sha512-fjquC59cD7CyW6urNXK0FBufkZcoiGG80wTuPujX590cB5Ttln20E2UB4S/WARVqhXffZl2LNgS+gQdPIIim/g== - external-editor@^3.0.3: version "3.1.0" resolved "https://registry.yarnpkg.com/external-editor/-/external-editor-3.1.0.tgz#cb03f740befae03ea4d283caed2741a83f335495" @@ -5256,16 +4721,6 @@ extract-files@^9.0.0: resolved "https://registry.yarnpkg.com/extract-files/-/extract-files-9.0.0.tgz#8a7744f2437f81f5ed3250ed9f1550de902fe54a" integrity sha512-CvdFfHkC95B4bBBk36hcEmvdR2awOdhhVUYH6S/zrVj3477zven/fJMYg7121h4T1xHZC+tetUpubpAhxwI7hQ== -extsprintf@1.3.0: - version "1.3.0" - resolved "https://registry.yarnpkg.com/extsprintf/-/extsprintf-1.3.0.tgz#96918440e3041a7a414f8c52e3c574eb3c3e1e05" - integrity sha512-11Ndz7Nv+mvAC1j0ktTa7fAb0vLyGGX+rMHNBYQviQDGU0Hw7lhctJANqbPhu9nV9/izT/IntTgZ7Im/9LJs9g== - -extsprintf@^1.2.0: - version "1.4.1" - resolved "https://registry.yarnpkg.com/extsprintf/-/extsprintf-1.4.1.tgz#8d172c064867f235c0c84a596806d279bf4bcc07" - integrity sha512-Wrk35e8ydCKDj/ArClo1VrPVmN8zph5V4AtHwIuHhvMXsKf73UT3BOD+azBIW+3wOJ4FhEH7zyaJCFvChjYvMA== - fast-deep-equal@^3.1.1, fast-deep-equal@^3.1.3: version "3.1.3" resolved "https://registry.yarnpkg.com/fast-deep-equal/-/fast-deep-equal-3.1.3.tgz#3a7d56b559d6cbc3eb512325244e619a65c6c525" @@ -5287,11 +4742,6 @@ fast-json-stable-stringify@^2.0.0: resolved "https://registry.yarnpkg.com/fast-json-stable-stringify/-/fast-json-stable-stringify-2.1.0.tgz#874bf69c6f404c2b5d99c481341399fd55892633" integrity sha512-lhd/wF+Lk98HZoTCtlVraHtfh5XYijIjalXck7saUtuanSDyLMxnHhSXEDJqHxD7msR8D0uCmqlkwjCV8xvwHw== -fast-levenshtein@^2.0.6: - version "2.0.6" - resolved "https://registry.yarnpkg.com/fast-levenshtein/-/fast-levenshtein-2.0.6.tgz#3d8a5c66883a16a30ca8643e851f19baa7797917" - integrity sha512-DCXu6Ifhqcks7TZKY3Hxp3y6qphY5SJZmrWMDrKcERSOXWQdMhU9Ig/PYrzyw/ul9jOIyh0N4M0tbC5hodg8dw== - fastq@^1.6.0: version "1.15.0" resolved "https://registry.yarnpkg.com/fastq/-/fastq-1.15.0.tgz#d04d07c6a2a68fe4599fea8d2e103a937fae6b3a" @@ -5338,13 +4788,6 @@ figures@^3.0.0: dependencies: escape-string-regexp "^1.0.5" -file-entry-cache@^6.0.1: - version "6.0.1" - resolved "https://registry.yarnpkg.com/file-entry-cache/-/file-entry-cache-6.0.1.tgz#211b2dd9659cb0394b073e7323ac3c933d522027" - integrity sha512-7Gps/XWymbLk2QLYK4NzpMOrYjMhdIxXuIvy2QBsLE6ljuodKvdkWs/cpyJJ3CVIVpH0Oi1Hvg1ovbMzLdFBBg== - dependencies: - flat-cache "^3.0.4" - fill-range@^7.0.1: version "7.0.1" resolved "https://registry.yarnpkg.com/fill-range/-/fill-range-7.0.1.tgz#1919a6a7c75fe38b2c7c77e5198535da9acdda40" @@ -5352,19 +4795,6 @@ fill-range@^7.0.1: dependencies: to-regex-range "^5.0.1" -finalhandler@1.1.2: - version "1.1.2" - resolved "https://registry.yarnpkg.com/finalhandler/-/finalhandler-1.1.2.tgz#b7e7d000ffd11938d0fdb053506f6ebabe9f587d" - integrity sha512-aAWcW57uxVNrQZqFXjITpW3sIUQmHGG3qSb9mUah9MgMC4NeWhNOlNjXEYq3HjRAvL6arUviZGGJsBg6z0zsWA== - dependencies: - debug "2.6.9" - encodeurl "~1.0.2" - escape-html "~1.0.3" - on-finished "~2.3.0" - parseurl "~1.3.3" - statuses "~1.5.0" - unpipe "~1.0.0" - finalhandler@1.2.0: version "1.2.0" resolved "https://registry.yarnpkg.com/finalhandler/-/finalhandler-1.2.0.tgz#7d23fe5731b207b4640e4fcd00aec1f9207a7b32" @@ -5395,27 +4825,6 @@ find-up@^4.0.0, find-up@^4.1.0: locate-path "^5.0.0" path-exists "^4.0.0" -find-up@^5.0.0: - version "5.0.0" - resolved "https://registry.yarnpkg.com/find-up/-/find-up-5.0.0.tgz#4c92819ecb7083561e4f4a240a86be5198f536fc" - integrity sha512-78/PXT1wlLLDgTzDs7sjq9hzz0vXD+zn+7wypEe4fXQxCmdmqfGsEPQxmiCSQI3ajFV91bVSsvNtrJRiW6nGng== - dependencies: - locate-path "^6.0.0" - path-exists "^4.0.0" - -flat-cache@^3.0.4: - version "3.0.4" - resolved "https://registry.yarnpkg.com/flat-cache/-/flat-cache-3.0.4.tgz#61b0338302b2fe9f957dcc32fc2a87f1c3048b11" - integrity sha512-dm9s5Pw7Jc0GvMYbshN6zchCA9RgQlzzEZX3vylR9IqFfS8XciblUXOKfW6SiuJ0e13eDYZoZV5wdrev7P3Nwg== - dependencies: - flatted "^3.1.0" - rimraf "^3.0.2" - -flatted@^3.1.0, flatted@^3.2.7: - version "3.2.7" - resolved "https://registry.yarnpkg.com/flatted/-/flatted-3.2.7.tgz#609f39207cb614b89d0765b477cb2d437fbf9787" - integrity sha512-5nqDSxl8nn5BSNxyR3n4I6eDmbolI6WT+QqR547RwxQapgjQBmtktdP+HTBb/a/zLsbzERTONyUB5pefh5TtjQ== - follow-redirects@^1.0.0: version "1.15.2" resolved "https://registry.yarnpkg.com/follow-redirects/-/follow-redirects-1.15.2.tgz#b460864144ba63f2681096f274c4e57026da2c13" @@ -5429,11 +4838,6 @@ foreground-child@^3.1.0: cross-spawn "^7.0.0" signal-exit "^4.0.1" -forever-agent@~0.6.1: - version "0.6.1" - resolved "https://registry.yarnpkg.com/forever-agent/-/forever-agent-0.6.1.tgz#fbc71f0c41adeb37f96c577ad1ed42d8fdacca91" - integrity sha512-j0KLYPhm6zeac4lz3oJ3o65qvgQCcPubiyotZrXqEaG4hNagNYO8qdlUrX5vwqv9ohqeT/Z3j6+yW067yWWdUw== - form-data-encoder@^1.7.1: version "1.7.2" resolved "https://registry.yarnpkg.com/form-data-encoder/-/form-data-encoder-1.7.2.tgz#1f1ae3dccf58ed4690b86d87e4f57c654fbab040" @@ -5448,15 +4852,6 @@ form-data@^3.0.0: combined-stream "^1.0.8" mime-types "^2.1.12" -form-data@~2.3.2: - version "2.3.3" - resolved "https://registry.yarnpkg.com/form-data/-/form-data-2.3.3.tgz#dcce52c05f644f298c6a7ab936bd724ceffbf3a6" - integrity sha512-1lLKB2Mu3aGP1Q/2eCOx0fNbRMe7XdwktwOruhfqqd0rIJWwN4Dh+E3hrPSlDCXnSR7UtZ1N38rVXm+6+MEhJQ== - dependencies: - asynckit "^0.4.0" - combined-stream "^1.0.6" - mime-types "^2.1.12" - formdata-node@^4.3.1: version "4.4.1" resolved "https://registry.yarnpkg.com/formdata-node/-/formdata-node-4.4.1.tgz#23f6a5cb9cb55315912cbec4ff7b0f59bbd191e2" @@ -5480,15 +4875,6 @@ fresh@0.5.2: resolved "https://registry.yarnpkg.com/fresh/-/fresh-0.5.2.tgz#3d8cadd90d976569fa835ab1f8e4b23a105605a7" integrity sha512-zJ2mQYM18rEFOudeV4GShTGIQ7RbzA7ozbU9I/XBpm7kqgMywgmylMwXHxZJmkVoYkna9d2pVXVXPdYTP9ej8Q== -fs-extra@^8.1.0: - version "8.1.0" - resolved "https://registry.yarnpkg.com/fs-extra/-/fs-extra-8.1.0.tgz#49d43c45a88cd9677668cb7be1b46efdb8d2e1c0" - integrity sha512-yhlQgA6mnOJUKOsRUFsgJdQCvkKhcz8tlZG5HBQfReYZy46OwLcY+Zia0mtdHsOo9y/hP+CxMN0TU9QxoOtG4g== - dependencies: - graceful-fs "^4.2.0" - jsonfile "^4.0.0" - universalify "^0.1.0" - fs-minipass@^2.0.0, fs-minipass@^2.1.0: version "2.1.0" resolved "https://registry.yarnpkg.com/fs-minipass/-/fs-minipass-2.1.0.tgz#7f5036fdbf12c63c169190cbe4199c852271f9fb" @@ -5566,13 +4952,6 @@ get-stream@^6.0.0: resolved "https://registry.yarnpkg.com/get-stream/-/get-stream-6.0.1.tgz#a262d8eef67aced57c2852ad6167526a43cbf7b7" integrity sha512-ts6Wi+2j3jQjqi70w5AlN8DFnkSwC+MqmxEzdEALB2qXZYV3X/b1CTfgPLGJNMeAWxdPfU8FO1ms3NUfaHCPYg== -getpass@^0.1.1: - version "0.1.7" - resolved "https://registry.yarnpkg.com/getpass/-/getpass-0.1.7.tgz#5eff8e3e684d569ae4cb2b1282604e8ba62149fa" - integrity sha512-0fzj9JxOLfJ+XGLhR8ze3unN0KZCgZwiSSDz168VERjK8Wl8kVSdcu2kspd4s4wtAa1y/qrVRiAA0WclVsu0ng== - dependencies: - assert-plus "^1.0.0" - glob-parent@^5.1.2, glob-parent@~5.1.2: version "5.1.2" resolved "https://registry.yarnpkg.com/glob-parent/-/glob-parent-5.1.2.tgz#869832c58034fe68a4093c17dc15e8340d8401c4" @@ -5580,7 +4959,7 @@ glob-parent@^5.1.2, glob-parent@~5.1.2: dependencies: is-glob "^4.0.1" -glob-parent@^6.0.1, glob-parent@^6.0.2: +glob-parent@^6.0.1: version "6.0.2" resolved "https://registry.yarnpkg.com/glob-parent/-/glob-parent-6.0.2.tgz#6d237d99083950c79290f24c7642a3de9a28f9e3" integrity sha512-XxwI8EOhVQgWp6iDL+3b0r86f4d6AX6zSU55HfB4ydCEuXLXc5FcYeOu+nnGftS4TEju/11rt4KJPTMgbfmv4A== @@ -5603,7 +4982,7 @@ glob@^10.2.2: minipass "^5.0.0 || ^6.0.2 || ^7.0.0" path-scurry "^1.10.1" -glob@^7.0.3, glob@^7.0.6, glob@^7.1.1, glob@^7.1.3, glob@^7.1.4, glob@^7.1.6, glob@^7.1.7, glob@~7.2.0: +glob@^7.1.1, glob@^7.1.3, glob@^7.1.4, glob@^7.1.6, glob@~7.2.0: version "7.2.3" resolved "https://registry.yarnpkg.com/glob/-/glob-7.2.3.tgz#b8df0fb802bbfa8e89bd1d938b4e16578ed44f2b" integrity sha512-nFR0zLpU2YCaRxwoCJvL6UvCH2JFyFVIvwTLsIf21AuHlMskA1hhTdk+LlYJtOlYt9v6dvszD2BGRqBL+iQK9Q== @@ -5631,14 +5010,7 @@ globals@^11.1.0: resolved "https://registry.yarnpkg.com/globals/-/globals-11.12.0.tgz#ab8795338868a0babd8525758018c2a7eb95c42e" integrity sha512-WOBp/EEGUiIsJSp7wcv/y6MO+lV9UoncWqxuFfm8eBwzWNgyfBd6Gz+IeKQ9jCmyhoH99g15M3T+QaVHFjizVA== -globals@^13.19.0: - version "13.19.0" - resolved "https://registry.yarnpkg.com/globals/-/globals-13.19.0.tgz#7a42de8e6ad4f7242fbcca27ea5b23aca367b5c8" - integrity sha512-dkQ957uSRWHw7CFXLUtUHQI3g3aWApYhfNR2O6jn/907riyTYKVBmxYVROkBcY614FSSeSJh7Xm7SrUWCxvJMQ== - dependencies: - type-fest "^0.20.2" - -globby@^11.0.3, globby@^11.1.0: +globby@^11.0.3: version "11.1.0" resolved "https://registry.yarnpkg.com/globby/-/globby-11.1.0.tgz#bd4be98bb042f83d796f7e3811991fbe82a0d34b" integrity sha512-jhIXaOzy1sb8IyocaruWSn1TjmnBVs8Ayhcy83rmxNJ8q2uWKCAj3CnJY+KpGSXCueAPc0i05kVvVKtP1t9S3g== @@ -5661,28 +5033,11 @@ globby@^13.1.1: merge2 "^1.4.1" slash "^4.0.0" -globby@^5.0.0: - version "5.0.0" - resolved "https://registry.yarnpkg.com/globby/-/globby-5.0.0.tgz#ebd84667ca0dbb330b99bcfc68eac2bc54370e0d" - integrity sha512-HJRTIH2EeH44ka+LWig+EqT2ONSYpVlNfx6pyd592/VF1TbfljJ7elwie7oSwcViLGqOdWocSdu2txwBF9bjmQ== - dependencies: - array-union "^1.0.1" - arrify "^1.0.0" - glob "^7.0.3" - object-assign "^4.0.1" - pify "^2.0.0" - pinkie-promise "^2.0.0" - -graceful-fs@^4.1.2, graceful-fs@^4.1.6, graceful-fs@^4.2.0, graceful-fs@^4.2.4, graceful-fs@^4.2.6, graceful-fs@^4.2.9: +graceful-fs@^4.1.2, graceful-fs@^4.2.4, graceful-fs@^4.2.6, graceful-fs@^4.2.9: version "4.2.10" resolved "https://registry.yarnpkg.com/graceful-fs/-/graceful-fs-4.2.10.tgz#147d3a006da4ca3ce14728c7aefc287c367d7a6c" integrity sha512-9ByhssR2fPVsNZj478qUUbKfmL0+t5BDVyjShtyZZLiK7ZDAArFFfopyOTj0M05wE2tJPisA4iTnnXl2YoPvOA== -grapheme-splitter@^1.0.4: - version "1.0.4" - resolved "https://registry.yarnpkg.com/grapheme-splitter/-/grapheme-splitter-1.0.4.tgz#9cf3a665c6247479896834af35cf1dbb4400767e" - integrity sha512-bzh50DW9kTPM00T8y4o8vQg89Di9oLJVLW/KaOGIXJWP/iqCN6WKYkbNOF04vFLJhwcpYUh9ydh/+5vpOqV4YQ== - graphql-config@4.4.0: version "4.4.0" resolved "https://registry.yarnpkg.com/graphql-config/-/graphql-config-4.4.0.tgz#4b2d34d846bd4b9a40afbadfc5a4426668963c43" @@ -5738,26 +5093,6 @@ handle-thing@^2.0.0: resolved "https://registry.yarnpkg.com/handle-thing/-/handle-thing-2.0.1.tgz#857f79ce359580c340d43081cc648970d0bb234e" integrity sha512-9Qn4yBxelxoh2Ow62nP+Ka/kMnOXRi8BXnRaUwezLNhqelnN49xKz4F/dPP8OYLxLxq6JDtZb2i9XznUQbNPTg== -har-schema@^2.0.0: - version "2.0.0" - resolved "https://registry.yarnpkg.com/har-schema/-/har-schema-2.0.0.tgz#a94c2224ebcac04782a0d9035521f24735b7ec92" - integrity sha512-Oqluz6zhGX8cyRaTQlFMPw80bSJVG2x/cFb8ZPhUILGgHka9SsokCCOQgpveePerqidZOrT14ipqfJb7ILcW5Q== - -har-validator@~5.1.3: - version "5.1.5" - resolved "https://registry.yarnpkg.com/har-validator/-/har-validator-5.1.5.tgz#1f0803b9f8cb20c0fa13822df1ecddb36bde1efd" - integrity sha512-nmT2T0lljbxdQZfspsno9hgrG3Uir6Ks5afism62poxqBM6sDnMEuPmzTq8XN0OEwqKLLdh1jQI3qyE66Nzb3w== - dependencies: - ajv "^6.12.3" - har-schema "^2.0.0" - -has-ansi@^2.0.0: - version "2.0.0" - resolved "https://registry.yarnpkg.com/has-ansi/-/has-ansi-2.0.0.tgz#34f5049ce1ecdf2b0649af3ef24e45ed35416d91" - integrity sha512-C8vBJ8DwUCx19vhm7urhTuUsr4/IyP6l4VzNQDv+ryHQObW3TTTp9yB68WpYgRe2bbaGuZ/se74IqFeVnMnLZg== - dependencies: - ansi-regex "^2.0.0" - has-flag@^3.0.0: version "3.0.0" resolved "https://registry.yarnpkg.com/has-flag/-/has-flag-3.0.0.tgz#b5d454dc2199ae225699f3467e5a07f3b955bafd" @@ -5836,11 +5171,6 @@ html-entities@^2.3.2: resolved "https://registry.yarnpkg.com/html-entities/-/html-entities-2.3.3.tgz#117d7626bece327fc8baace8868fa6f5ef856e46" integrity sha512-DV5Ln36z34NNTDgnz0EWGBLZENelNAtkiFA4kyNOG2tDI6Mz1uSWiq1wAKdyjnJwyDiDO7Fa2SO1CTxPXL8VxA== -html-escaper@^2.0.0: - version "2.0.2" - resolved "https://registry.yarnpkg.com/html-escaper/-/html-escaper-2.0.2.tgz#dfd60027da36a36dfcbe236262c00a5822681453" - integrity sha512-H2iMtd0I4Mt5eYiapRdIDjp+XzelXQ0tFE4JS7YFwFevXXMmOp9myNrUvCg0D6ws8iqkRPBfKHgbwig1SmlLfg== - htmlparser2@^8.0.2: version "8.0.2" resolved "https://registry.yarnpkg.com/htmlparser2/-/htmlparser2-8.0.2.tgz#f002151705b383e62433b5cf466f5b716edaec21" @@ -5916,15 +5246,6 @@ http-proxy@^1.18.1: follow-redirects "^1.0.0" requires-port "^1.0.0" -http-signature@~1.2.0: - version "1.2.0" - resolved "https://registry.yarnpkg.com/http-signature/-/http-signature-1.2.0.tgz#9aecd925114772f3d95b65a60abb8f7c18fbace1" - integrity sha512-CAbnr6Rz4CYQkLYUtSNXxQPUH2gK8f3iWexVlsnMeD+GjlsQ0Xsy1cOX+mN3dtxYomRy21CiOzU8Uhw6OwncEQ== - dependencies: - assert-plus "^1.0.0" - jsprim "^1.2.2" - sshpk "^1.7.0" - https-proxy-agent@5.0.1, https-proxy-agent@^5.0.0: version "5.0.1" resolved "https://registry.yarnpkg.com/https-proxy-agent/-/https-proxy-agent-5.0.1.tgz#c59ef224a04fe8b754f3db0063a25ea30d0005d6" @@ -5933,14 +5254,6 @@ https-proxy-agent@5.0.1, https-proxy-agent@^5.0.0: agent-base "6" debug "4" -https-proxy-agent@^2.2.1: - version "2.2.4" - resolved "https://registry.yarnpkg.com/https-proxy-agent/-/https-proxy-agent-2.2.4.tgz#4ee7a737abd92678a293d9b34a1af4d0d08c787b" - integrity sha512-OmvfoQ53WLjtA9HeYP9RNrWMJzzAz1JGaSFr1nijg0PVR1JaD/xbJq1mdEIIlxGpXp9eSe/O2LgU9DJmTPd0Eg== - dependencies: - agent-base "^4.3.0" - debug "^3.1.0" - human-signals@^2.1.0: version "2.1.0" resolved "https://registry.yarnpkg.com/human-signals/-/human-signals-2.1.0.tgz#dc91fcba42e4d06e4abaed33b3e7a3c02f514ea0" @@ -5994,11 +5307,6 @@ image-size@~0.5.0: resolved "https://registry.yarnpkg.com/image-size/-/image-size-0.5.5.tgz#09dfd4ab9d20e29eb1c3e80b8990378df9e3cb9c" integrity sha512-6TDAlDPZxUFCv+fuOkIoXT/V/f3Qbq8e37p+YOiYrUv3v9cc3/6x78VdfPgFVaB9dZYeLUfKgHRebpkm/oP2VQ== -immediate@~3.0.5: - version "3.0.6" - resolved "https://registry.yarnpkg.com/immediate/-/immediate-3.0.6.tgz#9db1dbd0faf8de6fbe0f5dd5e56bb606280de69b" - integrity sha512-XXOFtyqDjNDAQxVfYxuF7g9Il/IbWmmlQg2MYKOH8ExIT1qg6xc4zyS3HaEEATgs1btfzxq15ciUiY7gjSXRGQ== - immutable@^4.0.0: version "4.2.2" resolved "https://registry.yarnpkg.com/immutable/-/immutable-4.2.2.tgz#2da9ff4384a4330c36d4d1bc88e90f9e0b0ccd16" @@ -6009,7 +5317,7 @@ immutable@~3.7.6: resolved "https://registry.yarnpkg.com/immutable/-/immutable-3.7.6.tgz#13b4d3cb12befa15482a26fe1b2ebae640071e4b" integrity sha512-AizQPcaofEtO11RZhPPHBOJRdo/20MKQF9mBLnVkBoyHi1/zXK8fzVdnEpSV9gxqtnh6Qomfp3F0xT5qP/vThw== -import-fresh@^3.0.0, import-fresh@^3.1.0, import-fresh@^3.2.1: +import-fresh@^3.1.0, import-fresh@^3.2.1: version "3.3.0" resolved "https://registry.yarnpkg.com/import-fresh/-/import-fresh-3.3.0.tgz#37162c25fcb9ebaa2e6e53d5b4d88ce17d9e0c2b" integrity sha512-veYYhQa+D1QBKznvhUHxb8faxlrwUnxseDAbAp457E0wLNio2bOSKnjYDhMj+YiAq61xrMGhQk9iXVk5FzgQMw== @@ -6060,11 +5368,6 @@ ini@4.1.1: resolved "https://registry.yarnpkg.com/ini/-/ini-4.1.1.tgz#d95b3d843b1e906e56d6747d5447904ff50ce7a1" integrity sha512-QQnnxNyfvmHFIsj7gkPcYymR8Jdw/o7mp5ZFihxn6h8Ci6fh3Dx4E1gPjpQEpIuPo9XVNY/ZUwh4BPMjGyL01g== -ini@^1.3.4: - version "1.3.8" - resolved "https://registry.yarnpkg.com/ini/-/ini-1.3.8.tgz#a29da425b48806f34767a4efce397269af28432c" - integrity sha512-JV/yugV2uzW5iMRSiZAyDtQd+nxtUnjeLt0acNdw98kKLrvuRVyB80tsREOE7yvGVgalhZ6RNXCmEHkUKBKxew== - inquirer@8.2.4: version "8.2.4" resolved "https://registry.yarnpkg.com/inquirer/-/inquirer-8.2.4.tgz#ddbfe86ca2f67649a67daa6f1051c128f684f0b4" @@ -6178,7 +5481,7 @@ is-fullwidth-code-point@^3.0.0: resolved "https://registry.yarnpkg.com/is-fullwidth-code-point/-/is-fullwidth-code-point-3.0.0.tgz#f116f8064fe90b3f7844a38997c0b75051269f1d" integrity sha512-zymm5+u+sCsSWyD9qNaejV3DFvhCKclKdizYaJUuHA83RLjb7nSuGnddCHGv0hk+KY7BMAlsWeK4Ueg6EV6XQg== -is-glob@4.0.3, is-glob@^4.0.0, is-glob@^4.0.1, is-glob@^4.0.3, is-glob@~4.0.1: +is-glob@4.0.3, is-glob@^4.0.1, is-glob@^4.0.3, is-glob@~4.0.1: version "4.0.3" resolved "https://registry.yarnpkg.com/is-glob/-/is-glob-4.0.3.tgz#64f61e42cbbb2eec2071a9dac0b28ba1e65d5084" integrity sha512-xelSayHH36ZgE7ZWhli7pW34hNbNl8Ojv5KVmkJD4hBdD3th8Tfk9vYasLM+mXWOZhFkgZfxhLSnrwRr4elSSg== @@ -6207,30 +5510,6 @@ is-number@^7.0.0: resolved "https://registry.yarnpkg.com/is-number/-/is-number-7.0.0.tgz#7535345b896734d5f80c4d06c50955527a14f12b" integrity sha512-41Cifkg6e8TylSpdtTpeLVMqvSBEVzTttHvERD741+pnZ8ANv0004MRL43QKPDlK9cGvNp6NZWZUBlbGXYxxng== -is-path-cwd@^1.0.0: - version "1.0.0" - resolved "https://registry.yarnpkg.com/is-path-cwd/-/is-path-cwd-1.0.0.tgz#d225ec23132e89edd38fda767472e62e65f1106d" - integrity sha512-cnS56eR9SPAscL77ik76ATVqoPARTqPIVkMDVxRaWH06zT+6+CzIroYRJ0VVvm0Z1zfAvxvz9i/D3Ppjaqt5Nw== - -is-path-in-cwd@^1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/is-path-in-cwd/-/is-path-in-cwd-1.0.1.tgz#5ac48b345ef675339bd6c7a48a912110b241cf52" - integrity sha512-FjV1RTW48E7CWM7eE/J2NJvAEEVektecDBVBE5Hh3nM1Jd0kvhHtX68Pr3xsDf857xt3Y4AkwVULK1Vku62aaQ== - dependencies: - is-path-inside "^1.0.0" - -is-path-inside@^1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/is-path-inside/-/is-path-inside-1.0.1.tgz#8ef5b7de50437a3fdca6b4e865ef7aa55cb48036" - integrity sha512-qhsCR/Esx4U4hg/9I19OVUAJkGWtjRYHMRgUMZE2TDdj+Ag+kttZanLupfddNyglzz50cUlmWzUaI37GDfNx/g== - dependencies: - path-is-inside "^1.0.1" - -is-path-inside@^3.0.3: - version "3.0.3" - resolved "https://registry.yarnpkg.com/is-path-inside/-/is-path-inside-3.0.3.tgz#d231362e53a07ff2b0e0ea7fed049161ffd16283" - integrity sha512-Fd4gABb+ycGAmKou8eMftCupSir5lRxqf4aD/vd0cD2qc4HL07OjCeuHMr8Ro4CoMaeCKDB0/ECBOVWjTwUvPQ== - is-plain-obj@^3.0.0: version "3.0.0" resolved "https://registry.yarnpkg.com/is-plain-obj/-/is-plain-obj-3.0.0.tgz#af6f2ea14ac5a646183a5bbdb5baabbc156ad9d7" @@ -6255,11 +5534,6 @@ is-stream@^2.0.0: resolved "https://registry.yarnpkg.com/is-stream/-/is-stream-2.0.1.tgz#fac1e3d53b97ad5a9d0ae9cef2389f5810a5c077" integrity sha512-hFoiJiTl63nn+kstHGBtewWSKnQLpyb155KHheA1l39uvtO9nWIop1p3udqPcUd/xbF1VLMO4n7OI6p7RbngDg== -is-typedarray@~1.0.0: - version "1.0.0" - resolved "https://registry.yarnpkg.com/is-typedarray/-/is-typedarray-1.0.0.tgz#e479c80858df0c1b11ddda6940f96011fcda4a9a" - integrity sha512-cyA56iCMHAh5CdzjJIa4aohJyeO1YbwLi3Jc35MmRU6poroFjIGZzUzupGiRPOjgHg9TLu43xbpwXk523fMxKA== - is-unc-path@^1.0.0: version "1.0.0" resolved "https://registry.yarnpkg.com/is-unc-path/-/is-unc-path-1.0.0.tgz#d731e8898ed090a12c352ad2eaed5095ad322c9d" @@ -6301,11 +5575,6 @@ isarray@~1.0.0: resolved "https://registry.yarnpkg.com/isarray/-/isarray-1.0.0.tgz#bb935d48582cba168c06834957a54a3e07124f11" integrity sha512-VLghIWNM6ELQzo7zwmcg0NmTVyWKYjvIeM83yjp0wRDTmUnrM678fQbcKBo6n2CJEF0szoG//ytg+TKla89ALQ== -isbinaryfile@^4.0.8: - version "4.0.10" - resolved "https://registry.yarnpkg.com/isbinaryfile/-/isbinaryfile-4.0.10.tgz#0c5b5e30c2557a2f06febd37b7322946aaee42b3" - integrity sha512-iHrqe5shvBUcFbmZq9zOQHBoeOhZJu6RQGrDpBgenUm/Am+F3JM2MgQj+rK3Z601fzrL5gLZWtAPH2OBaSVcyw== - isexe@^2.0.0: version "2.0.0" resolved "https://registry.yarnpkg.com/isexe/-/isexe-2.0.0.tgz#e8fbf374dc556ff8947a10dcb0572d633f2cfa10" @@ -6329,17 +5598,12 @@ isomorphic-ws@5.0.0: resolved "https://registry.yarnpkg.com/isomorphic-ws/-/isomorphic-ws-5.0.0.tgz#e5529148912ecb9b451b46ed44d53dae1ce04bbf" integrity sha512-muId7Zzn9ywDsyXgTIafTry2sV3nySZeUDe6YedVd1Hvuuep5AsIlqK+XefWpYTyJG5e503F2xIuT2lcU6rCSw== -isstream@~0.1.2: - version "0.1.2" - resolved "https://registry.yarnpkg.com/isstream/-/isstream-0.1.2.tgz#47e63f7af55afa6f92e1500e690eb8b8529c099a" - integrity sha512-Yljz7ffyPbrLpLngrMtZ7NduUgVvi6wG9RJ9IUcyCd59YQ911PBJphODUcbOVbqYfxe1wuYf/LJ8PauMRwsM/g== - -istanbul-lib-coverage@^3.0.0, istanbul-lib-coverage@^3.2.0: +istanbul-lib-coverage@^3.2.0: version "3.2.0" resolved "https://registry.yarnpkg.com/istanbul-lib-coverage/-/istanbul-lib-coverage-3.2.0.tgz#189e7909d0a39fa5a3dfad5b03f71947770191d3" integrity sha512-eOeJ5BHCmHYvQK7xt9GkdHuzuCGS1Y6g9Gvnx3Ym33fz/HpLRYxiS0wHNr+m/MBC8B647Xt608vCDEvhl9c6Mw== -istanbul-lib-instrument@^5.0.4, istanbul-lib-instrument@^5.1.0: +istanbul-lib-instrument@^5.0.4: version "5.2.1" resolved "https://registry.yarnpkg.com/istanbul-lib-instrument/-/istanbul-lib-instrument-5.2.1.tgz#d10c8885c2125574e1c231cacadf955675e1ce3d" integrity sha512-pzqtp31nLv/XFOzXGuvhCb8qhjmTVo5vjVk19XE4CRlSWz0KoeJ3bw9XsA7nOp9YBf4qHjwBxkDzKcME/J29Yg== @@ -6350,32 +5614,6 @@ istanbul-lib-instrument@^5.0.4, istanbul-lib-instrument@^5.1.0: istanbul-lib-coverage "^3.2.0" semver "^6.3.0" -istanbul-lib-report@^3.0.0: - version "3.0.0" - resolved "https://registry.yarnpkg.com/istanbul-lib-report/-/istanbul-lib-report-3.0.0.tgz#7518fe52ea44de372f460a76b5ecda9ffb73d8a6" - integrity sha512-wcdi+uAKzfiGT2abPpKZ0hSU1rGQjUQnLvtY5MpQ7QCTahD3VODhcu4wcfY1YtkGaDD5yuydOLINXsfbus9ROw== - dependencies: - istanbul-lib-coverage "^3.0.0" - make-dir "^3.0.0" - supports-color "^7.1.0" - -istanbul-lib-source-maps@^4.0.1: - version "4.0.1" - resolved "https://registry.yarnpkg.com/istanbul-lib-source-maps/-/istanbul-lib-source-maps-4.0.1.tgz#895f3a709fcfba34c6de5a42939022f3e4358551" - integrity sha512-n3s8EwkdFIJCG3BPKBYvskgXGoy88ARzvegkitk60NxRdwltLOTaH7CUiMRXvwYorl0Q712iEjcWB+fK/MrWVw== - dependencies: - debug "^4.1.1" - istanbul-lib-coverage "^3.0.0" - source-map "^0.6.1" - -istanbul-reports@^3.0.5: - version "3.1.5" - resolved "https://registry.yarnpkg.com/istanbul-reports/-/istanbul-reports-3.1.5.tgz#cc9a6ab25cb25659810e4785ed9d9fb742578bae" - integrity sha512-nUsEMa9pBt/NOHqbcbeJEgqIlY/K7rVWUX6Lql2orY5e9roQOthbR3vtY4zzf2orPELg80fnxxk9zUyPlgwD1w== - dependencies: - html-escaper "^2.0.0" - istanbul-lib-report "^3.0.0" - jackspeak@^2.0.3: version "2.2.1" resolved "https://registry.yarnpkg.com/jackspeak/-/jackspeak-2.2.1.tgz#655e8cf025d872c9c03d3eb63e8f0c024fef16a6" @@ -6385,37 +5623,6 @@ jackspeak@^2.0.3: optionalDependencies: "@pkgjs/parseargs" "^0.11.0" -jasmine-core@^4.1.0, jasmine-core@^4.5.0: - version "4.5.0" - resolved "https://registry.yarnpkg.com/jasmine-core/-/jasmine-core-4.5.0.tgz#1a6bd0bde3f60996164311c88a0995d67ceda7c3" - integrity sha512-9PMzyvhtocxb3aXJVOPqBDswdgyAeSB81QnLop4npOpbqnheaTEwPc9ZloQeVswugPManznQBjD8kWDTjlnHuw== - -jasmine-core@~2.8.0: - version "2.8.0" - resolved "https://registry.yarnpkg.com/jasmine-core/-/jasmine-core-2.8.0.tgz#bcc979ae1f9fd05701e45e52e65d3a5d63f1a24e" - integrity sha512-SNkOkS+/jMZvLhuSx1fjhcNWUC/KG6oVyFUGkSBEr9n1axSNduWU8GlI7suaHXr4yxjet6KjrUZxUTE5WzzWwQ== - -jasmine-spec-reporter@^7.0.0: - version "7.0.0" - resolved "https://registry.yarnpkg.com/jasmine-spec-reporter/-/jasmine-spec-reporter-7.0.0.tgz#94b939448e63d4e2bd01668142389f20f0a8ea49" - integrity sha512-OtC7JRasiTcjsaCBPtMO0Tl8glCejM4J4/dNuOJdA8lBjz4PmWjYQ6pzb0uzpBNAWJMDudYuj9OdXJWqM2QTJg== - dependencies: - colors "1.4.0" - -jasmine@2.8.0: - version "2.8.0" - resolved "https://registry.yarnpkg.com/jasmine/-/jasmine-2.8.0.tgz#6b089c0a11576b1f16df11b80146d91d4e8b8a3e" - integrity sha512-KbdGQTf5jbZgltoHs31XGiChAPumMSY64OZMWLNYnEnMfG5uwGBhffePwuskexjT+/Jea/gU3qAU8344hNohSw== - dependencies: - exit "^0.1.2" - glob "^7.0.6" - jasmine-core "~2.8.0" - -jasminewd2@^2.1.0: - version "2.2.0" - resolved "https://registry.yarnpkg.com/jasminewd2/-/jasminewd2-2.2.0.tgz#e37cf0b17f199cce23bea71b2039395246b4ec4e" - integrity sha512-Rn0nZe4rfDhzA63Al3ZGh0E+JTmM6ESZYXJGKuqKGZObsAB9fwXPD03GjtIEvJBDOhN94T5MzbwZSqzFHSQPzg== - jest-worker@^27.4.5: version "27.5.1" resolved "https://registry.yarnpkg.com/jest-worker/-/jest-worker-27.5.1.tgz#8d146f0900e8973b106b6f73cc1e9a8cb86f8db0" @@ -6430,11 +5637,6 @@ jiti@^1.18.2: resolved "https://registry.yarnpkg.com/jiti/-/jiti-1.19.1.tgz#fa99e4b76a23053e0e7cde098efe1704a14c16f1" integrity sha512-oVhqoRDaBXf7sjkll95LHVS6Myyyb1zaunVwk4Z0+WPSW4gjS0pl01zYKHScTuyEhQsFxV5L4DR5r+YqSyqyyg== -js-sdsl@^4.1.4: - version "4.2.0" - resolved "https://registry.yarnpkg.com/js-sdsl/-/js-sdsl-4.2.0.tgz#278e98b7bea589b8baaf048c20aeb19eb7ad09d0" - integrity sha512-dyBIzQBDkCqCu+0upx25Y2jGdbTGxE9fshMsCdK0ViOongpV+n5tXRcZY9v7CaVQ79AGS9KA1KHtojxiM7aXSQ== - "js-tokens@^3.0.0 || ^4.0.0", js-tokens@^4.0.0: version "4.0.0" resolved "https://registry.yarnpkg.com/js-tokens/-/js-tokens-4.0.0.tgz#19203fb59991df98e3a287050d4647cdeaf32499" @@ -6455,11 +5657,6 @@ js-yaml@^4.0.0, js-yaml@^4.1.0: dependencies: argparse "^2.0.1" -jsbn@~0.1.0: - version "0.1.1" - resolved "https://registry.yarnpkg.com/jsbn/-/jsbn-0.1.1.tgz#a5e654c2e5a2deb5f201d96cefbca80c0ef2f513" - integrity sha512-UVU9dibq2JcFWxQPA6KCqj5O42VOmAY3zQUfEKxU0KpTGXwNoCjkX1e13eHNvw/xPynt6pU0rZ1htjWTNTSXsg== - jsesc@^2.5.1: version "2.5.2" resolved "https://registry.yarnpkg.com/jsesc/-/jsesc-2.5.2.tgz#80564d2e483dacf6e8ef209650a67df3f0c283a4" @@ -6490,16 +5687,6 @@ json-schema-traverse@^1.0.0: resolved "https://registry.yarnpkg.com/json-schema-traverse/-/json-schema-traverse-1.0.0.tgz#ae7bcb3656ab77a73ba5c49bf654f38e6b6860e2" integrity sha512-NM8/P9n3XjXhIZn1lLhkFaACTOURQXjWhV4BA/RnOv8xvgqtqpAX9IO4mRQxSx1Rlo4tqzeqb0sOlruaOy3dug== -json-schema@0.4.0: - version "0.4.0" - resolved "https://registry.yarnpkg.com/json-schema/-/json-schema-0.4.0.tgz#f7de4cf6efab838ebaeb3236474cbba5a1930ab5" - integrity sha512-es94M3nTIfsEPisRafak+HDLfHXnKBhV3vU5eqPcS3flIWqcxJWgXHXiey3YrpaNsanY5ei1VoYEbOzijuq9BA== - -json-stable-stringify-without-jsonify@^1.0.1: - version "1.0.1" - resolved "https://registry.yarnpkg.com/json-stable-stringify-without-jsonify/-/json-stable-stringify-without-jsonify-1.0.1.tgz#9db7b59496ad3f3cfef30a75142d2d930ad72651" - integrity sha512-Bdboy+l7tA3OGW6FjyFHWkP5LuByj1Tk33Ljyq0axyzdk9//JSi2u3fP1QSmd1KNwq6VOKYGlAu87CisVir6Pw== - json-stable-stringify@^1.0.1: version "1.0.2" resolved "https://registry.yarnpkg.com/json-stable-stringify/-/json-stable-stringify-1.0.2.tgz#e06f23128e0bbe342dc996ed5a19e28b57b580e0" @@ -6507,11 +5694,6 @@ json-stable-stringify@^1.0.1: dependencies: jsonify "^0.0.1" -json-stringify-safe@~5.0.1: - version "5.0.1" - resolved "https://registry.yarnpkg.com/json-stringify-safe/-/json-stringify-safe-5.0.1.tgz#1296a2d58fd45f19a0f6ce01d65701e2c735b6eb" - integrity sha512-ZClg6AaYvamvYEE82d3Iyd3vSSIjQ+odgjaTzRuO3s7toCdFKczob2i0zCh7JE8kWn17yvAWhUVxvqGwUalsRA== - json-to-pretty-yaml@^1.2.2: version "1.2.2" resolved "https://registry.yarnpkg.com/json-to-pretty-yaml/-/json-to-pretty-yaml-1.2.2.tgz#f4cd0bd0a5e8fe1df25aaf5ba118b099fd992d5b" @@ -6530,13 +5712,6 @@ jsonc-parser@3.2.0: resolved "https://registry.yarnpkg.com/jsonc-parser/-/jsonc-parser-3.2.0.tgz#31ff3f4c2b9793f89c67212627c51c6394f88e76" integrity sha512-gfFQZrcTc8CnKXp6Y4/CBT3fTc0OVuDofpre4aEeEpSBPV5X5v4+Vmx+8snU7RLPrNHPKSgLxGo9YuQzz20o+w== -jsonfile@^4.0.0: - version "4.0.0" - resolved "https://registry.yarnpkg.com/jsonfile/-/jsonfile-4.0.0.tgz#8771aae0799b64076b76640fca058f9c10e33ecb" - integrity sha512-m6F1R3z8jjlf2imQHS2Qez5sjKWQzbuuhuJ/FKYFRZvPE3PuHcSMVZzfsLhGVOkfd20obL5SWEBew5ShlquNxg== - optionalDependencies: - graceful-fs "^4.1.6" - jsonify@^0.0.1: version "0.0.1" resolved "https://registry.yarnpkg.com/jsonify/-/jsonify-0.0.1.tgz#2aa3111dae3d34a0f151c63f3a45d995d9420978" @@ -6557,26 +5732,6 @@ jsonwebtoken@^9.0.0: ms "^2.1.1" semver "^7.3.8" -jsprim@^1.2.2: - version "1.4.2" - resolved "https://registry.yarnpkg.com/jsprim/-/jsprim-1.4.2.tgz#712c65533a15c878ba59e9ed5f0e26d5b77c5feb" - integrity sha512-P2bSOMAc/ciLz6DzgjVlGJP9+BrJWu5UDGK70C2iweC5QBIeFf0ZXRvGjEj2uYgrY2MkAAhsSWHDWlFtEroZWw== - dependencies: - assert-plus "1.0.0" - extsprintf "1.3.0" - json-schema "0.4.0" - verror "1.10.0" - -jszip@^3.1.3: - version "3.10.1" - resolved "https://registry.yarnpkg.com/jszip/-/jszip-3.10.1.tgz#34aee70eb18ea1faec2f589208a157d1feb091c2" - integrity sha512-xXDvecyTpGLrqFrvkrUSoxxfJI5AH7U8zxxtVclpsUtMCq4JQ290LY8AW5c7Ggnr/Y/oK+bQMbqK2qmtk3pN4g== - dependencies: - lie "~3.3.0" - pako "~1.0.2" - readable-stream "~2.3.6" - setimmediate "^1.0.5" - jwa@^1.4.1: version "1.4.1" resolved "https://registry.yarnpkg.com/jwa/-/jwa-1.4.1.tgz#743c32985cb9e98655530d53641b66c8645b039a" @@ -6594,37 +5749,6 @@ jws@^3.2.2: jwa "^1.4.1" safe-buffer "^5.0.1" -karma-chrome-launcher@^3.1.1: - version "3.1.1" - resolved "https://registry.yarnpkg.com/karma-chrome-launcher/-/karma-chrome-launcher-3.1.1.tgz#baca9cc071b1562a1db241827257bfe5cab597ea" - integrity sha512-hsIglcq1vtboGPAN+DGCISCFOxW+ZVnIqhDQcCMqqCp+4dmJ0Qpq5QAjkbA0X2L9Mi6OBkHi2Srrbmm7pUKkzQ== - dependencies: - which "^1.2.1" - -karma-coverage@^2.2.0: - version "2.2.0" - resolved "https://registry.yarnpkg.com/karma-coverage/-/karma-coverage-2.2.0.tgz#64f838b66b71327802e7f6f6c39d569b7024e40c" - integrity sha512-gPVdoZBNDZ08UCzdMHHhEImKrw1+PAOQOIiffv1YsvxFhBjqvo/SVXNk4tqn1SYqX0BJZT6S/59zgxiBe+9OuA== - dependencies: - istanbul-lib-coverage "^3.2.0" - istanbul-lib-instrument "^5.1.0" - istanbul-lib-report "^3.0.0" - istanbul-lib-source-maps "^4.0.1" - istanbul-reports "^3.0.5" - minimatch "^3.0.4" - -karma-jasmine-html-reporter@^2.0.0: - version "2.0.0" - resolved "https://registry.yarnpkg.com/karma-jasmine-html-reporter/-/karma-jasmine-html-reporter-2.0.0.tgz#76c26ce40e217dc36a630fbcd7b31c3462948bf2" - integrity sha512-SB8HNNiazAHXM1vGEzf8/tSyEhkfxuDdhYdPBX2Mwgzt0OuF2gicApQ+uvXLID/gXyJQgvrM9+1/2SxZFUUDIA== - -karma-jasmine@^5.1.0: - version "5.1.0" - resolved "https://registry.yarnpkg.com/karma-jasmine/-/karma-jasmine-5.1.0.tgz#3af4558a6502fa16856a0f346ec2193d4b884b2f" - integrity sha512-i/zQLFrfEpRyQoJF9fsCdTMOF5c2dK7C7OmsuKg2D0YSsuZSfQDiLuaiktbuio6F2wiCsZSnSnieIQ0ant/uzQ== - dependencies: - jasmine-core "^4.1.0" - karma-source-map-support@1.4.0: version "1.4.0" resolved "https://registry.yarnpkg.com/karma-source-map-support/-/karma-source-map-support-1.4.0.tgz#58526ceccf7e8730e56effd97a4de8d712ac0d6b" @@ -6632,36 +5756,6 @@ karma-source-map-support@1.4.0: dependencies: source-map-support "^0.5.5" -karma@^6.4.1: - version "6.4.1" - resolved "https://registry.yarnpkg.com/karma/-/karma-6.4.1.tgz#f2253716dd3a41aaa813fa9f54b6ee047e1127d9" - integrity sha512-Cj57NKOskK7wtFWSlMvZf459iX+kpYIPXmkNUzP2WAFcA7nhr/ALn5R7sw3w+1udFDcpMx/tuB8d5amgm3ijaA== - dependencies: - "@colors/colors" "1.5.0" - body-parser "^1.19.0" - braces "^3.0.2" - chokidar "^3.5.1" - connect "^3.7.0" - di "^0.0.1" - dom-serialize "^2.2.1" - glob "^7.1.7" - graceful-fs "^4.2.6" - http-proxy "^1.18.1" - isbinaryfile "^4.0.8" - lodash "^4.17.21" - log4js "^6.4.1" - mime "^2.5.2" - minimatch "^3.0.4" - mkdirp "^0.5.5" - qjobs "^1.2.0" - range-parser "^1.2.1" - rimraf "^3.0.2" - socket.io "^4.4.1" - source-map "^0.6.1" - tmp "^0.2.1" - ua-parser-js "^0.7.30" - yargs "^16.1.1" - kind-of@^6.0.2: version "6.0.3" resolved "https://registry.yarnpkg.com/kind-of/-/kind-of-6.0.3.tgz#07c05034a6c349fa06e24fa35aa76db4580ce4dd" @@ -6714,14 +5808,6 @@ less@4.1.3: needle "^3.1.0" source-map "~0.6.0" -levn@^0.4.1: - version "0.4.1" - resolved "https://registry.yarnpkg.com/levn/-/levn-0.4.1.tgz#ae4562c007473b932a6200d403268dd2fffc6ade" - integrity sha512-+bT2uH4E5LGE7h/n3evcS/sQlJXCpIp6ym8OWJ5eV6+67Dsql/LaaT7qJBAt2rzfoa/5QBGBhxDix1dMt2kQKQ== - dependencies: - prelude-ls "^1.2.1" - type-check "~0.4.0" - license-webpack-plugin@4.0.2: version "4.0.2" resolved "https://registry.yarnpkg.com/license-webpack-plugin/-/license-webpack-plugin-4.0.2.tgz#1e18442ed20b754b82f1adeff42249b81d11aec6" @@ -6729,13 +5815,6 @@ license-webpack-plugin@4.0.2: dependencies: webpack-sources "^3.0.0" -lie@~3.3.0: - version "3.3.0" - resolved "https://registry.yarnpkg.com/lie/-/lie-3.3.0.tgz#dcf82dee545f46074daf200c7c1c5a08e0f40f6a" - integrity sha512-UaiMJzeWRlEujzAuw5LokY1L5ecNQYZKfmyZ9L7wDHb/p5etKaxXhohBcrw0EYby+G/NA52vRSN4N39dxHAIwQ== - dependencies: - immediate "~3.0.5" - lines-and-columns@^1.1.6: version "1.2.4" resolved "https://registry.yarnpkg.com/lines-and-columns/-/lines-and-columns-1.2.4.tgz#eca284f75d2965079309dc0ad9255abb2ebc1632" @@ -6781,13 +5860,6 @@ locate-path@^5.0.0: dependencies: p-locate "^4.1.0" -locate-path@^6.0.0: - version "6.0.0" - resolved "https://registry.yarnpkg.com/locate-path/-/locate-path-6.0.0.tgz#55321eb309febbc59c4801d931a72452a681d286" - integrity sha512-iPZK6eYjbxRu3uB4/WZ3EsEIMJFMqAoopl3R+zuq0UjcAm/MO6KCweDgPfP3elTztoKP3KtnVHxTn2NHBSDVUw== - dependencies: - p-locate "^5.0.0" - lodash.camelcase@^4.3.0: version "4.3.0" resolved "https://registry.yarnpkg.com/lodash.camelcase/-/lodash.camelcase-4.3.0.tgz#b28aa6288a2b9fc651035c7711f65ab6190331a6" @@ -6803,11 +5875,6 @@ lodash.kebabcase@^4.1.1: resolved "https://registry.yarnpkg.com/lodash.kebabcase/-/lodash.kebabcase-4.1.1.tgz#8489b1cb0d29ff88195cceca448ff6d6cc295c36" integrity sha512-N8XRTIMMqqDgSy4VLKPnJ/+hpGZN+PHQiJnSenYqPaVV/NCqEogTnAdZLQiGKhxX+JCs8waWq2t1XHWKOmlY8g== -lodash.merge@^4.6.2: - version "4.6.2" - resolved "https://registry.yarnpkg.com/lodash.merge/-/lodash.merge-4.6.2.tgz#558aa53b43b661e1925a0afdfa36a9a1085fe57a" - integrity sha512-0KpjqXRVvrYyCsX1swR/XTK0va6VQkQM6MNo7PqW77ByjAhoARA8EfrP1N4+KlKj8YS0ZUCtRT/YUuhyYDujIQ== - lodash.snakecase@^4.1.1: version "4.1.1" resolved "https://registry.yarnpkg.com/lodash.snakecase/-/lodash.snakecase-4.1.1.tgz#39d714a35357147837aefd64b5dcbb16becd8f8d" @@ -6836,17 +5903,6 @@ log-update@^4.0.0: slice-ansi "^4.0.0" wrap-ansi "^6.2.0" -log4js@^6.4.1: - version "6.7.1" - resolved "https://registry.yarnpkg.com/log4js/-/log4js-6.7.1.tgz#06e12b1ac915dd1067146ffad8215f666f7d2c51" - integrity sha512-lzbd0Eq1HRdWM2abSD7mk6YIVY0AogGJzb/z+lqzRk+8+XJP+M6L1MS5FUSc3jjGru4dbKjEMJmqlsoYYpuivQ== - dependencies: - date-format "^4.0.14" - debug "^4.3.4" - flatted "^3.2.7" - rfdc "^1.3.0" - streamroller "^3.1.3" - loose-envify@^1.0.0, loose-envify@^1.4.0: version "1.4.0" resolved "https://registry.yarnpkg.com/loose-envify/-/loose-envify-1.4.0.tgz#71ee51fa7be4caec1a63839f7e682d8132d30caf" @@ -6907,7 +5963,7 @@ make-dir@^2.1.0: pify "^4.0.1" semver "^5.6.0" -make-dir@^3.0.0, make-dir@^3.0.2: +make-dir@^3.0.2: version "3.1.0" resolved "https://registry.yarnpkg.com/make-dir/-/make-dir-3.1.0.tgz#415e967046b3a7f1d185277d84aa58203726a13f" integrity sha512-g3FeP20LNwhALb/6Cz6Dd4F2ngze0jz7tbzrD2wAV+o9FeNHe4rL+yK2md0J/fiSf1sa1ADhXqi5+oVwOM/eGw== @@ -7041,11 +6097,6 @@ meros@1.2.1: resolved "https://registry.yarnpkg.com/meros/-/meros-1.2.1.tgz#056f7a76e8571d0aaf3c7afcbe7eb6407ff7329e" integrity sha512-R2f/jxYqCAGI19KhAvaxSOxALBMkaXWH2a7rOyqQw+ZmizX5bKkEYWLzdhC+U82ZVVPVp6MCXe3EkVligh+12g== -mersenne-twister@^1.0.1: - version "1.1.0" - resolved "https://registry.yarnpkg.com/mersenne-twister/-/mersenne-twister-1.1.0.tgz#f916618ee43d7179efcf641bec4531eb9670978a" - integrity sha512-mUYWsMKNrm4lfygPkL3OfGzOPTR2DBlTkBNHM//F6hGp8cLThY897crAlk3/Jo17LEOOjQUrNAx6DvgO77QJkA== - methods@~1.1.2: version "1.1.2" resolved "https://registry.yarnpkg.com/methods/-/methods-1.1.2.tgz#5529a4d67654134edcc5266656835b0f851afcee" @@ -7064,7 +6115,7 @@ mime-db@1.52.0, "mime-db@>= 1.43.0 < 2": resolved "https://registry.yarnpkg.com/mime-db/-/mime-db-1.52.0.tgz#bbabcdc02859f4987301c856e3387ce5ec43bf70" integrity sha512-sPU4uV7dYlvtWJxwwxHD0PuihVNiE7TyAbQ5SWxDCB9mUYvOgroQOwYQQOKPJ8CIbE+1ETVlOoK1UC2nU3gYvg== -mime-types@^2.1.12, mime-types@^2.1.27, mime-types@^2.1.31, mime-types@~2.1.17, mime-types@~2.1.19, mime-types@~2.1.24, mime-types@~2.1.34: +mime-types@^2.1.12, mime-types@^2.1.27, mime-types@^2.1.31, mime-types@~2.1.17, mime-types@~2.1.24, mime-types@~2.1.34: version "2.1.35" resolved "https://registry.yarnpkg.com/mime-types/-/mime-types-2.1.35.tgz#381a871b62a734450660ae3deee44813f70d959a" integrity sha512-ZDY+bPm5zTTF+YpCrAU9nK0UgICYPT0QtT1NZWFv4s++TNkcgVaT0g6+4R2uI4MjQjzysHB1zxuWL50hzaeXiw== @@ -7076,11 +6127,6 @@ mime@1.6.0, mime@^1.4.1: resolved "https://registry.yarnpkg.com/mime/-/mime-1.6.0.tgz#32cd9e5c64553bd58d19a568af452acff04981b1" integrity sha512-x0Vn8spI+wuJ1O6S7gnbaQg8Pxh4NNHb7KSINmEWKiPE4RKOplvijn+NkmYmmRgP68mc70j2EbeTFRsrswaQeg== -mime@^2.5.2: - version "2.6.0" - resolved "https://registry.yarnpkg.com/mime/-/mime-2.6.0.tgz#a2a682a95cd4d0cb1d6257e28f83da7e35800367" - integrity sha512-USPkMeET31rOMiarsBNIHZKLGgvKc/LrjofAnBlOttf5ajRvqiRA8QsenbcooctK6d6Ts6aqZXBA+XbkKthiQg== - mimic-fn@^2.1.0: version "2.1.0" resolved "https://registry.yarnpkg.com/mimic-fn/-/mimic-fn-2.1.0.tgz#7ed2c2ccccaf84d3ffcb7a69b57711fc2083401b" @@ -7105,7 +6151,7 @@ minimatch@4.2.1: dependencies: brace-expansion "^1.1.7" -minimatch@^3.0.4, minimatch@^3.0.5, minimatch@^3.1.1, minimatch@^3.1.2: +minimatch@^3.0.4, minimatch@^3.1.1: version "3.1.2" resolved "https://registry.yarnpkg.com/minimatch/-/minimatch-3.1.2.tgz#19cd194bfd3e428f049a70817c038d89ab4be35b" integrity sha512-J7p63hRiAjw1NDEww1W7i37+ByIrOWO5XQQAzZ3VOcL0PNybwpfmV/N05zFAzwQ9USyEcX6t3UO+K5aqBQOIHw== @@ -7126,7 +6172,7 @@ minimatch@^9.0.0, minimatch@^9.0.1: dependencies: brace-expansion "^2.0.1" -minimist@^1.2.0, minimist@^1.2.6: +minimist@^1.2.6: version "1.2.7" resolved "https://registry.yarnpkg.com/minimist/-/minimist-1.2.7.tgz#daa1c4d91f507390437c6a8bc01078e7000c4d18" integrity sha512-bzfL1YUZsP41gmu/qjrEk0Q6i2ix/cVeAhbCbqH9u3zYutS1cLg00qhrD0M2MVdCcx4Sc0UpP2eBWo9rotpq6g== @@ -7221,7 +6267,7 @@ minizlib@^2.1.1, minizlib@^2.1.2: minipass "^3.0.0" yallist "^4.0.0" -mkdirp@^0.5.3, mkdirp@^0.5.5: +mkdirp@^0.5.3: version "0.5.6" resolved "https://registry.yarnpkg.com/mkdirp/-/mkdirp-0.5.6.tgz#7def03d2432dcae4ba1d611445c48396062255f6" integrity sha512-FP+p8RB8OWpF3YZBCrP5gtADmtXApB5AMLn+vdyA+PyxCjrCs00mjyUozssO33cwDeT3wNGdLxJ5M//YqtHAJw== @@ -7233,11 +6279,6 @@ mkdirp@^1.0.3, mkdirp@^1.0.4: resolved "https://registry.yarnpkg.com/mkdirp/-/mkdirp-1.0.4.tgz#3eb5ed62622756d79a5f0e2a221dfebad75c2f7e" integrity sha512-vVqVZQyf3WLx2Shd0qJ9xuvqgAyKPLAiqITEtqW0oIUjzo3PePDd6fW9iFz30ef7Ysp/oiWqbhszeGWW2T6Gzw== -moment@^2.15.2: - version "2.29.4" - resolved "https://registry.yarnpkg.com/moment/-/moment-2.29.4.tgz#3dbe052889fe7c1b2ed966fcb3a77328964ef108" - integrity sha512-5LC9SOxjSc2HF6vO2CyuTDNivEdoz2IvyJJGj6X8DJ0eFyfszE0QiEd+iXmBvUP3WHxSjFH/vIsA0EN00cgr8w== - mrmime@1.0.1, mrmime@^1.0.0: version "1.0.1" resolved "https://registry.yarnpkg.com/mrmime/-/mrmime-1.0.1.tgz#5f90c825fad4bdd41dc914eff5d1a8cfdaf24f27" @@ -7281,16 +6322,6 @@ nanoid@^3.3.6: resolved "https://registry.yarnpkg.com/nanoid/-/nanoid-3.3.6.tgz#443380c856d6e9f9824267d960b4236ad583ea4c" integrity sha512-BGcqMMJuToF7i1rt+2PWSNVnWIkGCU78jBG3RxO/bZlnZPK2Cmi2QaffxGO/2RvWi9sL+FAiRiXMgsyxQ1DIDA== -natural-compare-lite@^1.4.0: - version "1.4.0" - resolved "https://registry.yarnpkg.com/natural-compare-lite/-/natural-compare-lite-1.4.0.tgz#17b09581988979fddafe0201e931ba933c96cbb4" - integrity sha512-Tj+HTDSJJKaZnfiuw+iaF9skdPpTo2GtEly5JHnWV/hfv2Qj/9RKsGISQtLh2ox3l5EAGw487hnBee0sIJ6v2g== - -natural-compare@^1.4.0: - version "1.4.0" - resolved "https://registry.yarnpkg.com/natural-compare/-/natural-compare-1.4.0.tgz#4abebfeed7541f2c27acfb29bdbbd15c8d5ba4f7" - integrity sha512-OWND8ei3VtNC9h7V60qff3SVobHr996CTwgxubgyQYEpg290h9J0buyECNNJexkFm5sOajh5G116RYA1c8ZMSw== - needle@^3.1.0: version "3.2.0" resolved "https://registry.yarnpkg.com/needle/-/needle-3.2.0.tgz#07d240ebcabfd65c76c03afae7f6defe6469df44" @@ -7334,14 +6365,6 @@ ngx-json-viewer@^3.0.2: dependencies: tslib "^2.3.0" -ngx-logger@^5.0.7: - version "5.0.11" - resolved "https://registry.yarnpkg.com/ngx-logger/-/ngx-logger-5.0.11.tgz#cfbecfeb5c93424b74223405cec5dce63a8c8785" - integrity sha512-OP8qesmRPmu/FKGi0PYvxP4CSZMIzX+bN0UK6jtP3pOduqzCUlha91V57+tGY+lR1RNytdj2OjN2M1yfbiFtLQ== - dependencies: - tslib "^2.3.0" - vlq "^1.0.0" - nice-napi@^1.0.2: version "1.0.2" resolved "https://registry.yarnpkg.com/nice-napi/-/nice-napi-1.0.2.tgz#dc0ab5a1eac20ce548802fc5686eaa6bc654927b" @@ -7545,12 +6568,7 @@ nullthrows@^1.1.1: resolved "https://registry.yarnpkg.com/nullthrows/-/nullthrows-1.1.1.tgz#7818258843856ae971eae4208ad7d7eb19a431b1" integrity sha512-2vPPEi+Z7WqML2jZYddDIfy5Dqb0r2fze2zTxNNknZaFpVHU3mFB3R+DWeJWGVx0ecvttSGlJTI+WG+8Z4cDWw== -oauth-sign@~0.9.0: - version "0.9.0" - resolved "https://registry.yarnpkg.com/oauth-sign/-/oauth-sign-0.9.0.tgz#47a7b016baa68b5fa0ecf3dee08a85c679ac6455" - integrity sha512-fexhUFFPTGV8ybAtSIGbV6gOkSv8UtRbDBnAyLQw4QPKkgNlsH2ByPGtMUqdWkos6YCRmAqViwgZrJc/mRDzZQ== - -object-assign@^4, object-assign@^4.0.1, object-assign@^4.1.0, object-assign@^4.1.1: +object-assign@^4.1.0, object-assign@^4.1.1: version "4.1.1" resolved "https://registry.yarnpkg.com/object-assign/-/object-assign-4.1.1.tgz#2109adc7965887cfc05cbbd442cac8bfbb360863" integrity sha512-rJgTQnkUnH1sFw8yT6VSU3zD3sWmu6sZhIseY8VX+GRu3P6F7Fu+JNDoXfklElbLJSnc3FUQHVe4cU5hj+BcUg== @@ -7572,13 +6590,6 @@ on-finished@2.4.1: dependencies: ee-first "1.1.1" -on-finished@~2.3.0: - version "2.3.0" - resolved "https://registry.yarnpkg.com/on-finished/-/on-finished-2.3.0.tgz#20f1336481b083cd75337992a16971aa2d906947" - integrity sha512-ikqdkGAAyf/X/gPhXGvfgAytDZtDbr+bkNUJ0N9h5MI/dmdgCs3l6hoHrcUv41sRKew3jIwrp4qQDXiK99Utww== - dependencies: - ee-first "1.1.1" - on-headers@~1.0.2: version "1.0.2" resolved "https://registry.yarnpkg.com/on-headers/-/on-headers-1.0.2.tgz#772b0ae6aaa525c399e489adfad90c403eb3c28f" @@ -7629,18 +6640,6 @@ optimism@^0.16.2: "@wry/context" "^0.7.0" "@wry/trie" "^0.3.0" -optionator@^0.9.1: - version "0.9.1" - resolved "https://registry.yarnpkg.com/optionator/-/optionator-0.9.1.tgz#4f236a6373dae0566a6d43e1326674f50c291499" - integrity sha512-74RlY5FCnhq4jRxVUPKDaRwrVNXMqsGsiW6AJw4XK8hmtm10wC0ypZBLw5IIp85NZMr91+qd1RvvENwg7jjRFw== - dependencies: - deep-is "^0.1.3" - fast-levenshtein "^2.0.6" - levn "^0.4.1" - prelude-ls "^1.2.1" - type-check "^0.4.0" - word-wrap "^1.2.3" - ora@5.4.1, ora@^5.1.0, ora@^5.4.1: version "5.4.1" resolved "https://registry.yarnpkg.com/ora/-/ora-5.4.1.tgz#1b2678426af4ac4a509008e5e4ac9e9959db9e18" @@ -7656,12 +6655,12 @@ ora@5.4.1, ora@^5.1.0, ora@^5.4.1: strip-ansi "^6.0.0" wcwidth "^1.0.1" -os-tmpdir@~1.0.1, os-tmpdir@~1.0.2: +os-tmpdir@~1.0.2: version "1.0.2" resolved "https://registry.yarnpkg.com/os-tmpdir/-/os-tmpdir-1.0.2.tgz#bbe67406c79aa85c5cfec766fe5734555dfa1274" integrity sha512-D2FR03Vir7FIu45XBY20mTb+/ZSWB00sjU9jdQXt83gDrI4Ztz5Fs7/yy74g2N5SVQY4xY1qDr4rNddwYRVX0g== -p-limit@3.1.0, p-limit@^3.0.2: +p-limit@3.1.0: version "3.1.0" resolved "https://registry.yarnpkg.com/p-limit/-/p-limit-3.1.0.tgz#e1daccbe78d0d1388ca18c64fea38e3e57e3706b" integrity sha512-TYOanM3wGwNGsZN2cVTYPArw454xnXj5qmWF1bEoAc4+cU/ol7GVh7odevjp1FNHduHc3KZMcFduxU5Xc6uJRQ== @@ -7682,13 +6681,6 @@ p-locate@^4.1.0: dependencies: p-limit "^2.2.0" -p-locate@^5.0.0: - version "5.0.0" - resolved "https://registry.yarnpkg.com/p-locate/-/p-locate-5.0.0.tgz#83c8315c6785005e3bd021839411c9e110e6d834" - integrity sha512-LaNjtRWUBY++zB5nE/NwcaoMylSPk+S+ZHNB1TzdbMJMny6dynpAGt7X/tl/QYq3TIeE6nxHppbo2LGymrG5Pw== - dependencies: - p-limit "^3.0.2" - p-map@^4.0.0: version "4.0.0" resolved "https://registry.yarnpkg.com/p-map/-/p-map-4.0.0.tgz#bb2f95a5eda2ec168ec9274e06a747c3e2904d2b" @@ -7733,7 +6725,7 @@ pacote@15.2.0: ssri "^10.0.0" tar "^6.1.11" -pako@^1.0.3, pako@~1.0.2: +pako@^1.0.3: version "1.0.11" resolved "https://registry.yarnpkg.com/pako/-/pako-1.0.11.tgz#6c9599d340d54dfd3946380252a35705a6b992bf" integrity sha512-4hLB8Py4zZce5s4yd9XzopqwVv/yGNhV1Bl8NTmCq1763HeK2+EwVTv+leGeL13Dnh2wfbqowVPXCIO0z4taYw== @@ -7831,11 +6823,6 @@ path-is-absolute@^1.0.0: resolved "https://registry.yarnpkg.com/path-is-absolute/-/path-is-absolute-1.0.1.tgz#174b9268735534ffbc7ace6bf53a5a9e1b5c5f5f" integrity sha512-AVbw3UJ2e9bq64vSaS9Am0fje1Pa8pbGqTTsmXfaIiMpnr5DlDhfJOuLj9Sf95ZPVDAUerDfEk88MPmPe7UCQg== -path-is-inside@^1.0.1: - version "1.0.2" - resolved "https://registry.yarnpkg.com/path-is-inside/-/path-is-inside-1.0.2.tgz#365417dede44430d1c11af61027facf074bdfc53" - integrity sha512-DUWJr3+ULp4zXmol/SZkFf3JGsS9/SIv+Y3Rt93/UjPpDpklB5f1er4O3POIbUuUJ3FXgqte2Q7SrU6zAqwk8w== - path-key@^3.0.0, path-key@^3.1.0: version "3.1.1" resolved "https://registry.yarnpkg.com/path-key/-/path-key-3.1.1.tgz#581f6ade658cbba65a0d3380de7753295054f375" @@ -7876,11 +6863,6 @@ path-type@^4.0.0: resolved "https://registry.yarnpkg.com/path-type/-/path-type-4.0.0.tgz#84ed01c0a7ba380afe09d90a8c180dcd9d03043b" integrity sha512-gDKb8aZMDeD/tZWs9P6+q0J9Mwkdl6xMV8TjnGP3qJVJ06bdMgkbBlLU8IdfOsIsFz2BW1rNVT3XuNEl8zPAvw== -performance-now@^2.1.0: - version "2.1.0" - resolved "https://registry.yarnpkg.com/performance-now/-/performance-now-2.1.0.tgz#6309f4e0e5fa913ec1c69307ae364b4b377c9e7b" - integrity sha512-7EAHlyLHI56VEIdK57uwHdHKIaAGbnXPiw0yWbarQZOKaKpvUIgW0jWRVLiatnM+XXlSwsanIBH/hzGMJulMow== - picocolors@^1.0.0: version "1.0.0" resolved "https://registry.yarnpkg.com/picocolors/-/picocolors-1.0.0.tgz#cb5bdc74ff3f51892236eaf79d68bc44564ab81c" @@ -7891,28 +6873,11 @@ picomatch@2.3.1, picomatch@^2.0.4, picomatch@^2.2.1, picomatch@^2.3.1: resolved "https://registry.yarnpkg.com/picomatch/-/picomatch-2.3.1.tgz#3ba3833733646d9d3e4995946c1365a67fb07a42" integrity sha512-JU3teHTNjmE2VCGFzuY8EXzCDVwEqB2a8fsIvwaStHhAWJEeVd1o1QD80CU6+ZdEXXSLbSsuLwJjkCBWqRQUVA== -pify@^2.0.0: - version "2.3.0" - resolved "https://registry.yarnpkg.com/pify/-/pify-2.3.0.tgz#ed141a6ac043a849ea588498e7dca8b15330e90c" - integrity sha512-udgsAY+fTnvv7kI7aaxbqwWNb0AHiB0qBO89PZKPkoTmGOgdbrHDKD+0B2X4uTfJ/FT1R09r9gTsjUjNJotuog== - pify@^4.0.1: version "4.0.1" resolved "https://registry.yarnpkg.com/pify/-/pify-4.0.1.tgz#4b2cd25c50d598735c50292224fd8c6df41e3231" integrity sha512-uB80kBFb/tfd68bVleG9T5GGsGPjJrLAUpR5PZIrhBnIaRTQRjqdJSsIKkOP6OAIFbj7GOrcudc5pNjZ+geV2g== -pinkie-promise@^2.0.0: - version "2.0.1" - resolved "https://registry.yarnpkg.com/pinkie-promise/-/pinkie-promise-2.0.1.tgz#2135d6dfa7a358c069ac9b178776288228450ffa" - integrity sha512-0Gni6D4UcLTbv9c57DfxDGdr41XfgUjqWZu492f0cIGr16zDU06BWP/RAEvOuo7CQ0CNjHaLlM59YJJFm3NWlw== - dependencies: - pinkie "^2.0.0" - -pinkie@^2.0.0: - version "2.0.4" - resolved "https://registry.yarnpkg.com/pinkie/-/pinkie-2.0.4.tgz#72556b80cfa0d48a974e80e77248e80ed4f7f870" - integrity sha512-MnUuEycAemtSaeFSjXKW/aroV7akBbY+Sv+RkyqFjgAe73F+MR0TBWKBRDkmfWq/HiFmdavfZ1G7h4SPZXaCSg== - piscina@3.2.0: version "3.2.0" resolved "https://registry.yarnpkg.com/piscina/-/piscina-3.2.0.tgz#f5a1dde0c05567775690cccefe59d9223924d154" @@ -8009,11 +6974,6 @@ postcss@^8.4.21, postcss@^8.4.23: picocolors "^1.0.0" source-map-js "^1.0.2" -prelude-ls@^1.2.1: - version "1.2.1" - resolved "https://registry.yarnpkg.com/prelude-ls/-/prelude-ls-1.2.1.tgz#debc6489d7a6e6b0e7611888cec880337d316396" - integrity sha512-vkcDPrRZo1QZLbn5RLGPpg/WmIQ65qoWWhcGKf/b5eplkkarX0m9z8ppCat4mlOqUsWpyNuYgO3VRyrYHSzX5g== - prettier@^1.19.1: version "1.19.1" resolved "https://registry.yarnpkg.com/prettier/-/prettier-1.19.1.tgz#f7d7f5ff8a9cd872a7be4ca142095956a60797cb" @@ -8076,27 +7036,6 @@ prop-types@^15.7.2: object-assign "^4.1.1" react-is "^16.13.1" -protractor@^7.0.0: - version "7.0.0" - resolved "https://registry.yarnpkg.com/protractor/-/protractor-7.0.0.tgz#c3e263608bd72e2c2dc802b11a772711a4792d03" - integrity sha512-UqkFjivi4GcvUQYzqGYNe0mLzfn5jiLmO8w9nMhQoJRLhy2grJonpga2IWhI6yJO30LibWXJJtA4MOIZD2GgZw== - dependencies: - "@types/q" "^0.0.32" - "@types/selenium-webdriver" "^3.0.0" - blocking-proxy "^1.0.0" - browserstack "^1.5.1" - chalk "^1.1.3" - glob "^7.0.3" - jasmine "2.8.0" - jasminewd2 "^2.1.0" - q "1.4.1" - saucelabs "^1.5.0" - selenium-webdriver "3.6.0" - source-map-support "~0.4.0" - webdriver-js-extender "2.1.0" - webdriver-manager "^12.1.7" - yargs "^15.3.1" - proxy-addr@~2.0.7: version "2.0.7" resolved "https://registry.yarnpkg.com/proxy-addr/-/proxy-addr-2.0.7.tgz#f19fe69ceab311eeb94b42e70e8c2070f9ba1025" @@ -8110,12 +7049,7 @@ prr@~1.0.1: resolved "https://registry.yarnpkg.com/prr/-/prr-1.0.1.tgz#d3fc114ba06995a45ec6893f484ceb1d78f5f476" integrity sha512-yPw4Sng1gWghHQWj0B3ZggWUm4qVbPwPFcRG8KyxiU7J2OHFSoEHKS+EZ3fv5l1t9CyCiop6l/ZYeWbrgoQejw== -psl@^1.1.28: - version "1.9.0" - resolved "https://registry.yarnpkg.com/psl/-/psl-1.9.0.tgz#d0df2a137f00794565fcaf3b2c00cd09f8d5a5a7" - integrity sha512-E/ZsdU4HLs/68gYzgGTkMicWTLPdAftJLfJFlLUAAKZGkStNU72sZjT66SnMDVOfOWY/YAoiD7Jxa9iHvngcag== - -punycode@^2.1.0, punycode@^2.1.1: +punycode@^2.1.0: version "2.2.0" resolved "https://registry.yarnpkg.com/punycode/-/punycode-2.2.0.tgz#2092cc57cd2582c38e4e7e8bb869dc8d3148bc74" integrity sha512-LN6QV1IJ9ZhxWTNdktaPClrNfp8xdSAYS0Zk2ddX7XsXZAxckMHPCBcHRo0cTcEIgYPRiGEkmji3Idkh2yFtYw== @@ -8132,21 +7066,6 @@ pvutils@^1.1.3: resolved "https://registry.yarnpkg.com/pvutils/-/pvutils-1.1.3.tgz#f35fc1d27e7cd3dfbd39c0826d173e806a03f5a3" integrity sha512-pMpnA0qRdFp32b1sJl1wOJNxZLQ2cbQx+k6tjNtZ8CpvVhNqEPRgivZ2WOUev2YMajecdH7ctUPDvEe87nariQ== -q@1.4.1: - version "1.4.1" - resolved "https://registry.yarnpkg.com/q/-/q-1.4.1.tgz#55705bcd93c5f3673530c2c2cbc0c2b3addc286e" - integrity sha512-/CdEdaw49VZVmyIDGUQKDDT53c7qBkO6g5CefWz91Ae+l4+cRtcDYwMTXh6me4O8TMldeGHG3N2Bl84V78Ywbg== - -q@^1.4.1: - version "1.5.1" - resolved "https://registry.yarnpkg.com/q/-/q-1.5.1.tgz#7e32f75b41381291d04611f1bf14109ac00651d7" - integrity sha512-kV/CThkXo6xyFEZUugw/+pIOywXcDbFYgSct5cT3gqlbkBE1SJdwy6UQoZvodiWF/ckQLZyDE/Bu1M6gVu5lVw== - -qjobs@^1.2.0: - version "1.2.0" - resolved "https://registry.yarnpkg.com/qjobs/-/qjobs-1.2.0.tgz#c45e9c61800bd087ef88d7e256423bdd49e5d071" - integrity sha512-8YOJEHtxpySA3fFDyCRxA+UUV+fA+rTWnuWvylOK/NCjhY+b4ocCtmu8TtsWb+mYeU+GCHf/S66KZF/AsteKHg== - qs@6.11.0: version "6.11.0" resolved "https://registry.yarnpkg.com/qs/-/qs-6.11.0.tgz#fd0d963446f7a65e1367e01abd85429453f0c37a" @@ -8154,11 +7073,6 @@ qs@6.11.0: dependencies: side-channel "^1.0.4" -qs@~6.5.2: - version "6.5.3" - resolved "https://registry.yarnpkg.com/qs/-/qs-6.5.3.tgz#3aeeffc91967ef6e35c0e488ef46fb296ab76aad" - integrity sha512-qxXIEh4pCGfHICj1mAJQ2/2XVZkjCDTcEgfoSQxc/fYivUZxTkk7L3bDBJSoNrEzXI17oUO5Dp07ktqE5KzczA== - queue-microtask@^1.2.2: version "1.2.3" resolved "https://registry.yarnpkg.com/queue-microtask/-/queue-microtask-1.2.3.tgz#4929228bbc724dfac43e0efb058caf7b6cfb6243" @@ -8209,7 +7123,7 @@ read-package-json@^6.0.0: normalize-package-data "^5.0.0" npm-normalize-package-bin "^3.0.0" -readable-stream@^2.0.1, readable-stream@~2.3.6: +readable-stream@^2.0.1: version "2.3.7" resolved "https://registry.yarnpkg.com/readable-stream/-/readable-stream-2.3.7.tgz#1eca1cf711aef814c04f62252a36a62f6cb23b57" integrity sha512-Ebho8K4jIbHAxnuxi7o42OrZgF/ZTNcsZj6nRKyUmkhLFq8CHItp/fy6hQZuZmP/n3yZ9VBUbp4zz/mX8hmYPw== @@ -8272,11 +7186,6 @@ regex-parser@^2.2.11: resolved "https://registry.yarnpkg.com/regex-parser/-/regex-parser-2.2.11.tgz#3b37ec9049e19479806e878cabe7c1ca83ccfe58" integrity sha512-jbD/FT0+9MBU2XAZluI7w2OBs1RBi6p9M83nkoZayQXXU9e8Robt69FcZc7wU4eJD/YFTjn1JdCk3rbMJajz8Q== -regexpp@^3.2.0: - version "3.2.0" - resolved "https://registry.yarnpkg.com/regexpp/-/regexpp-3.2.0.tgz#0425a2768d8f23bad70ca4b90461fa2f1213e1b2" - integrity sha512-pq2bWo9mVD43nbts2wGv17XLiNLya+GklZ8kaDLV2Z08gDCsGpnKn9BFMepvWuHCbyVvY7J5o5+BVvoQbmlJLg== - regexpu-core@^5.2.1: version "5.2.2" resolved "https://registry.yarnpkg.com/regexpu-core/-/regexpu-core-5.2.2.tgz#3e4e5d12103b64748711c3aad69934d7718e75fc" @@ -8337,32 +7246,6 @@ remove-trailing-spaces@^1.0.6: resolved "https://registry.yarnpkg.com/remove-trailing-spaces/-/remove-trailing-spaces-1.0.8.tgz#4354d22f3236374702f58ee373168f6d6887ada7" integrity sha512-O3vsMYfWighyFbTd8hk8VaSj9UAGENxAtX+//ugIst2RMk5e03h6RoIS+0ylsFxY1gvmPuAY/PO4It+gPEeySA== -request@^2.87.0: - version "2.88.2" - resolved "https://registry.yarnpkg.com/request/-/request-2.88.2.tgz#d73c918731cb5a87da047e207234146f664d12b3" - integrity sha512-MsvtOrfG9ZcrOwAW+Qi+F6HbD0CWXEh9ou77uOb7FM2WPhwT7smM833PzanhJLsgXjN89Ir6V2PczXNnMpwKhw== - dependencies: - aws-sign2 "~0.7.0" - aws4 "^1.8.0" - caseless "~0.12.0" - combined-stream "~1.0.6" - extend "~3.0.2" - forever-agent "~0.6.1" - form-data "~2.3.2" - har-validator "~5.1.3" - http-signature "~1.2.0" - is-typedarray "~1.0.0" - isstream "~0.1.2" - json-stringify-safe "~5.0.1" - mime-types "~2.1.19" - oauth-sign "~0.9.0" - performance-now "^2.1.0" - qs "~6.5.2" - safe-buffer "^5.1.2" - tough-cookie "~2.5.0" - tunnel-agent "^0.6.0" - uuid "^3.3.2" - require-directory@^2.1.1: version "2.1.1" resolved "https://registry.yarnpkg.com/require-directory/-/require-directory-2.1.1.tgz#8c64ad5fd30dab1c976e2344ffe7f792a6a6df42" @@ -8455,14 +7338,7 @@ rfdc@^1.3.0: resolved "https://registry.yarnpkg.com/rfdc/-/rfdc-1.3.0.tgz#d0b7c441ab2720d05dc4cf26e01c89631d9da08b" integrity sha512-V2hovdzFbOi77/WajaSMXk2OLm+xNIeQdMMuB7icj7bk6zi2F8GGAxigcnDFpJHbNyNcgyJDiP+8nOrY5cZGrA== -rimraf@^2.2.8, rimraf@^2.5.2, rimraf@^2.5.4: - version "2.7.1" - resolved "https://registry.yarnpkg.com/rimraf/-/rimraf-2.7.1.tgz#35797f13a7fdadc566142c29d4f07ccad483e3ec" - integrity sha512-uWjbaKIK3T1OSVptzX7Nl6PvQ3qAGtKEtVRjRuazjfL3Bx5eI409VZSqgND+4UNnmzLVdPj9FqFJNPqBZFve4w== - dependencies: - glob "^7.1.3" - -rimraf@^3.0.0, rimraf@^3.0.2: +rimraf@^3.0.2: version "3.0.2" resolved "https://registry.yarnpkg.com/rimraf/-/rimraf-3.0.2.tgz#f1a5402ba6220ad52cc1282bac1ae3aa49fd061a" integrity sha512-JZkJMZkAGFFPP2YqXZXPbMlMBgsxzE8ILs4lMIX/2o0L9UBw9O/Y3o6wFw/i9YLapcUJWwqbi3kdxIPdC62TIA== @@ -8539,12 +7415,12 @@ safe-buffer@5.1.2, safe-buffer@~5.1.0, safe-buffer@~5.1.1: resolved "https://registry.yarnpkg.com/safe-buffer/-/safe-buffer-5.1.2.tgz#991ec69d296e0313747d59bdfd2b745c35f8828d" integrity sha512-Gd2UZBJDkXlY7GbJxfsE8/nvKkUEU1G38c1siN6QP6a9PT9MmHB8GnpscSmMJSoF8LOIrt8ud/wPtojys4G6+g== -safe-buffer@5.2.1, safe-buffer@>=5.1.0, safe-buffer@^5.0.1, safe-buffer@^5.1.0, safe-buffer@^5.1.2, safe-buffer@~5.2.0: +safe-buffer@5.2.1, safe-buffer@>=5.1.0, safe-buffer@^5.0.1, safe-buffer@^5.1.0, safe-buffer@~5.2.0: version "5.2.1" resolved "https://registry.yarnpkg.com/safe-buffer/-/safe-buffer-5.2.1.tgz#1eaf9fa9bdb1fdd4ec75f58f9cdb4e6b7827eec6" integrity sha512-rp3So07KcdmmKbGvgaNxQSJr7bGVSVk5S9Eq1F+ppbRo70+YeaDxkw5Dd8NPN+GD6bjnYm2VuPuCXmpuYvmCXQ== -"safer-buffer@>= 2.1.2 < 3", "safer-buffer@>= 2.1.2 < 3.0.0", safer-buffer@^2.0.2, safer-buffer@^2.1.0, safer-buffer@~2.1.0: +"safer-buffer@>= 2.1.2 < 3", "safer-buffer@>= 2.1.2 < 3.0.0": version "2.1.2" resolved "https://registry.yarnpkg.com/safer-buffer/-/safer-buffer-2.1.2.tgz#44fa161b0187b9549dd84bb91802f9bd8385cd6a" integrity sha512-YZo3K82SD7Riyi0E1EQPojLz7kpepnSQI9IyPbHHg1XXXevb5dJI7tpyN2ADxGcQbHG7vcyRHk0cbwqcQriUtg== @@ -8566,14 +7442,7 @@ sass@1.63.2: immutable "^4.0.0" source-map-js ">=0.6.2 <2.0.0" -saucelabs@^1.5.0: - version "1.5.0" - resolved "https://registry.yarnpkg.com/saucelabs/-/saucelabs-1.5.0.tgz#9405a73c360d449b232839919a86c396d379fd9d" - integrity sha512-jlX3FGdWvYf4Q3LFfFWS1QvPg3IGCGWxIc8QBFdPTbpTJnt/v17FHXYVAn7C8sHf1yUXo2c7yIM0isDryfYtHQ== - dependencies: - https-proxy-agent "^2.2.1" - -sax@>=0.6.0, sax@^1.2.4: +sax@^1.2.4: version "1.2.4" resolved "https://registry.yarnpkg.com/sax/-/sax-1.2.4.tgz#2816234e2378bddc4e5354fab5caa895df7100d9" integrity sha512-NqVDv9TpANUjFm0N8uM5GxL36UgKi9/atZw+x7YFnQ8ckwFGKrl4xX4yWtrey3UJm5nP1kUbnYgLopqWNSRhWw== @@ -8616,16 +7485,6 @@ select-hose@^2.0.0: resolved "https://registry.yarnpkg.com/select-hose/-/select-hose-2.0.0.tgz#625d8658f865af43ec962bfc376a37359a4994ca" integrity sha512-mEugaLK+YfkijB4fx0e6kImuJdCIt2LxCRcbEYPqRGCs4F2ogyfZU5IAZRdjCP8JPq2AtdNoC/Dux63d9Kiryg== -selenium-webdriver@3.6.0, selenium-webdriver@^3.0.1: - version "3.6.0" - resolved "https://registry.yarnpkg.com/selenium-webdriver/-/selenium-webdriver-3.6.0.tgz#2ba87a1662c020b8988c981ae62cb2a01298eafc" - integrity sha512-WH7Aldse+2P5bbFBO4Gle/nuQOdVwpHMTL6raL3uuBj/vPG07k6uzt3aiahu352ONBr5xXh0hDlM3LhtXPOC4Q== - dependencies: - jszip "^3.1.3" - rimraf "^2.5.4" - tmp "0.0.30" - xml2js "^0.4.17" - selfsigned@^2.1.1: version "2.1.1" resolved "https://registry.yarnpkg.com/selfsigned/-/selfsigned-2.1.1.tgz#18a7613d714c0cd3385c48af0075abf3f266af61" @@ -8650,7 +7509,7 @@ semver@^6.0.0, semver@^6.3.0, semver@^6.3.1: resolved "https://registry.yarnpkg.com/semver/-/semver-6.3.1.tgz#556d2ef8689146e46dcea4bfdd095f3434dffcb4" integrity sha512-BR7VvDCVHO+q2xBEWskxS6DJE1qRnb7DxzUrogb71CWoSficBxYsiAGd+Kl0mmq/MprG9yArRkyrQxTO6XjMzA== -semver@^7.0.0, semver@^7.1.1, semver@^7.3.5, semver@^7.3.7, semver@^7.3.8: +semver@^7.0.0, semver@^7.1.1, semver@^7.3.5, semver@^7.3.8: version "7.5.4" resolved "https://registry.yarnpkg.com/semver/-/semver-7.5.4.tgz#483986ec4ed38e1c6c48c34894a9182dbff68a6e" integrity sha512-1bCSESV6Pv+i21Hvpxp3Dx+pSD8lIPt8uVjRrxAUt/nbswYc+tK6Y2btiULjd4+fnq15PX+nqQDC7Oft7WkwcA== @@ -8847,31 +7706,6 @@ snake-case@^3.0.4: dot-case "^3.0.4" tslib "^2.0.3" -socket.io-adapter@~2.4.0: - version "2.4.0" - resolved "https://registry.yarnpkg.com/socket.io-adapter/-/socket.io-adapter-2.4.0.tgz#b50a4a9ecdd00c34d4c8c808224daa1a786152a6" - integrity sha512-W4N+o69rkMEGVuk2D/cvca3uYsvGlMwsySWV447y99gUPghxq42BxqLNMndb+a1mm/5/7NeXVQS7RLa2XyXvYg== - -socket.io-parser@~4.2.1: - version "4.2.3" - resolved "https://registry.yarnpkg.com/socket.io-parser/-/socket.io-parser-4.2.3.tgz#926bcc6658e2ae0883dc9dee69acbdc76e4e3667" - integrity sha512-JMafRntWVO2DCJimKsRTh/wnqVvO4hrfwOqtO7f+uzwsQMuxO6VwImtYxaQ+ieoyshWOTJyV0fA21lccEXRPpQ== - dependencies: - "@socket.io/component-emitter" "~3.1.0" - debug "~4.3.1" - -socket.io@^4.4.1: - version "4.5.4" - resolved "https://registry.yarnpkg.com/socket.io/-/socket.io-4.5.4.tgz#a4513f06e87451c17013b8d13fdfaf8da5a86a90" - integrity sha512-m3GC94iK9MfIEeIBfbhJs5BqFibMtkRk8ZpKwG2QwxV0m/eEhPIV4ara6XCF1LWNAus7z58RodiZlAH71U3EhQ== - dependencies: - accepts "~1.3.4" - base64id "~2.0.0" - debug "~4.3.2" - engine.io "~6.2.1" - socket.io-adapter "~2.4.0" - socket.io-parser "~4.2.1" - sockjs@^0.3.24: version "0.3.24" resolved "https://registry.yarnpkg.com/sockjs/-/sockjs-0.3.24.tgz#c9bc8995f33a111bea0395ec30aa3206bdb5ccce" @@ -8920,13 +7754,6 @@ source-map-support@0.5.21, source-map-support@^0.5.5, source-map-support@~0.5.20 buffer-from "^1.0.0" source-map "^0.6.0" -source-map-support@~0.4.0: - version "0.4.18" - resolved "https://registry.yarnpkg.com/source-map-support/-/source-map-support-0.4.18.tgz#0286a6de8be42641338594e97ccea75f0a2c585f" - integrity sha512-try0/JqxPLF9nOjvSta7tVondkP5dwgyLDjVoyMDlmjugT2lRZ1OfsrYTkCd2hkDnJTKRbO/Rl3orm8vlsUzbA== - dependencies: - source-map "^0.5.6" - source-map@0.5.6: version "0.5.6" resolved "https://registry.yarnpkg.com/source-map/-/source-map-0.5.6.tgz#75ce38f52bf0733c5a7f0c118d81334a2bb5f412" @@ -8942,11 +7769,6 @@ source-map@0.7.4: resolved "https://registry.yarnpkg.com/source-map/-/source-map-0.7.4.tgz#a9bbe705c9d8846f4e08ff6765acf0f1b0898656" integrity sha512-l3BikUxvPOcn5E74dZiq5BGsTb5yEwhaTSzccU6t4sDOH8NWJCstKO5QT2CvtFoK6F0saL7p9xHAqHOlCPJygA== -source-map@^0.5.6: - version "0.5.7" - resolved "https://registry.yarnpkg.com/source-map/-/source-map-0.5.7.tgz#8a039d2d1021d22d1ea14c80d8ea468ba2ef3fcc" - integrity sha512-LbrmJOMUSdEVxIKvdcJzQC+nQhe8FUZQTXQy6+I75skNgn3OoQ0DZA8YnFa7gp8tqtL3KPf1kmo0R5DoApeSGQ== - spdx-correct@^3.0.0: version "3.1.1" resolved "https://registry.yarnpkg.com/spdx-correct/-/spdx-correct-3.1.1.tgz#dece81ac9c1e6713e5f7d1b6f17d468fa53d89a9" @@ -9008,21 +7830,6 @@ sprintf-js@~1.0.2: resolved "https://registry.yarnpkg.com/sprintf-js/-/sprintf-js-1.0.3.tgz#04e6926f662895354f3dd015203633b857297e2c" integrity sha512-D9cPgkvLlV3t3IzL0D0YLvGA9Ahk4PcvVwUbN0dSGr1aP0Nrt4AEnTUbuGvquEC0mA64Gqt1fzirlRs5ibXx8g== -sshpk@^1.7.0: - version "1.17.0" - resolved "https://registry.yarnpkg.com/sshpk/-/sshpk-1.17.0.tgz#578082d92d4fe612b13007496e543fa0fbcbe4c5" - integrity sha512-/9HIEs1ZXGhSPE8X6Ccm7Nam1z8KcoCqPdI7ecm1N33EzAetWahvQWVqLZtaZQ+IDKX4IyA2o0gBzqIMkAagHQ== - dependencies: - asn1 "~0.2.3" - assert-plus "^1.0.0" - bcrypt-pbkdf "^1.0.0" - dashdash "^1.12.0" - ecc-jsbn "~0.1.1" - getpass "^0.1.1" - jsbn "~0.1.0" - safer-buffer "^2.0.2" - tweetnacl "~0.14.0" - ssri@^10.0.0: version "10.0.1" resolved "https://registry.yarnpkg.com/ssri/-/ssri-10.0.1.tgz#c61f85894bbc6929fc3746f05e31cf5b44c030d5" @@ -9060,20 +7867,11 @@ statuses@2.0.1: resolved "https://registry.yarnpkg.com/statuses/-/statuses-2.0.1.tgz#55cb000ccf1d48728bd23c685a063998cf1a1b63" integrity sha512-RwNA9Z/7PrK06rYLIzFMlaF+l73iwpzsqRIFgbMLbTcLD6cOao82TaWefPXQvB2fOC4AjuYSEndS7N/mTCbkdQ== -"statuses@>= 1.4.0 < 2", statuses@~1.5.0: +"statuses@>= 1.4.0 < 2": version "1.5.0" resolved "https://registry.yarnpkg.com/statuses/-/statuses-1.5.0.tgz#161c7dac177659fd9811f43771fa99381478628c" integrity sha512-OpZ3zP+jT1PI7I8nemJX4AKmAX070ZkYPVWV/AaKTJl+tXCTGyVdC1a4SL8RUQYEwk/f34ZX8UTykN68FwrqAA== -streamroller@^3.1.3: - version "3.1.4" - resolved "https://registry.yarnpkg.com/streamroller/-/streamroller-3.1.4.tgz#844a18e795d39c1089a8216e66a1cf1151271df0" - integrity sha512-Ha1Ccw2/N5C/IF8Do6zgNe8F3jQo8MPBnMBGvX0QjNv/I97BcNRzK6/mzOpZHHK7DjMLTI3c7Xw7Y1KvdChkvw== - dependencies: - date-format "^4.0.14" - debug "^4.3.4" - fs-extra "^8.1.0" - streamsearch@^1.1.0: version "1.1.0" resolved "https://registry.yarnpkg.com/streamsearch/-/streamsearch-1.1.0.tgz#404dd1e2247ca94af554e841a8ef0eaa238da764" @@ -9123,13 +7921,6 @@ string_decoder@~1.1.1: dependencies: ansi-regex "^5.0.1" -strip-ansi@^3.0.0: - version "3.0.1" - resolved "https://registry.yarnpkg.com/strip-ansi/-/strip-ansi-3.0.1.tgz#6a385fb8853d952d5ff05d0e8aaf94278dc63dcf" - integrity sha512-VhumSSbBqDTP8p2ZLKj40UjBCV4+v8bUSEpUb4KjRgWk9pbqGF4REFj6KEagidb2f/M6AzC0EmFyDNGaw9OCzg== - dependencies: - ansi-regex "^2.0.0" - strip-ansi@^7.0.1: version "7.1.0" resolved "https://registry.yarnpkg.com/strip-ansi/-/strip-ansi-7.1.0.tgz#d5b6568ca689d8561370b0707685d22434faff45" @@ -9142,16 +7933,6 @@ strip-final-newline@^2.0.0: resolved "https://registry.yarnpkg.com/strip-final-newline/-/strip-final-newline-2.0.0.tgz#89b852fb2fcbe936f6f4b3187afb0a12c1ab58ad" integrity sha512-BrpvfNAE3dcvq7ll3xVumzjKjZQ5tI1sEUIKr3Uoks0XUl45St3FlatVqef9prk4jRDzhW6WZg+3bk93y6pLjA== -strip-json-comments@^3.1.0, strip-json-comments@^3.1.1: - version "3.1.1" - resolved "https://registry.yarnpkg.com/strip-json-comments/-/strip-json-comments-3.1.1.tgz#31f1281b3832630434831c310c01cccda8cbe006" - integrity sha512-6fPc+R4ihwqP6N/aIv2f1gMH8lOVtWQHoqC4yK6oSDVVocumAsfCqjkXnqiYMhmMwS/mEHLp7Vehlt3ql6lEig== - -supports-color@^2.0.0: - version "2.0.0" - resolved "https://registry.yarnpkg.com/supports-color/-/supports-color-2.0.0.tgz#535d045ce6b6363fa40117084629995e9df324c7" - integrity sha512-KKNVtd6pCYgPIKU4cp2733HWYCpplQhddZLBUryaAHou723x+FRzQ5Df824Fj+IyyuiQTRoub4SnIFfIcrp70g== - supports-color@^5.3.0: version "5.5.0" resolved "https://registry.yarnpkg.com/supports-color/-/supports-color-5.5.0.tgz#e2e69a44ac8772f78a1ec0b35b689df6530efc8f" @@ -9290,7 +8071,7 @@ test-exclude@^6.0.0: glob "^7.1.4" minimatch "^3.0.4" -text-table@0.2.0, text-table@^0.2.0: +text-table@0.2.0: version "0.2.0" resolved "https://registry.yarnpkg.com/text-table/-/text-table-0.2.0.tgz#7f5ee823ae805207c00af2df4a84ec3fcfa570b4" integrity sha512-N+8UisAXDGk8PFXP4HAzVR9nbfmVJ3zYLAWiTIoqC5v5isinhr+r5uaO8+7r3BMfuNIufIsA7RdpVgacC2cSpw== @@ -9312,13 +8093,6 @@ title-case@^3.0.3: dependencies: tslib "^2.0.3" -tmp@0.0.30: - version "0.0.30" - resolved "https://registry.yarnpkg.com/tmp/-/tmp-0.0.30.tgz#72419d4a8be7d6ce75148fd8b324e593a711c2ed" - integrity sha512-HXdTB7lvMwcb55XFfrTM8CPr/IYREk4hVBFaQ4b/6nInrluSL86hfHm7vu0luYKCfyBZp2trCjpc8caC3vVM3w== - dependencies: - os-tmpdir "~1.0.1" - tmp@^0.0.33: version "0.0.33" resolved "https://registry.yarnpkg.com/tmp/-/tmp-0.0.33.tgz#6d34335889768d21b2bcda0aa277ced3b1bfadf9" @@ -9326,13 +8100,6 @@ tmp@^0.0.33: dependencies: os-tmpdir "~1.0.2" -tmp@^0.2.1: - version "0.2.1" - resolved "https://registry.yarnpkg.com/tmp/-/tmp-0.2.1.tgz#8457fc3037dcf4719c251367a1af6500ee1ccf14" - integrity sha512-76SUhtfqR2Ijn+xllcI5P1oyannHNHByD80W1q447gU3mp9G9PSpGdWmjUOHRDPiHYacIk66W7ubDTuPF3BEtQ== - dependencies: - rimraf "^3.0.0" - to-fast-properties@^2.0.0: version "2.0.0" resolved "https://registry.yarnpkg.com/to-fast-properties/-/to-fast-properties-2.0.0.tgz#dc5e698cbd079265bc73e0377681a4e4e83f616e" @@ -9355,14 +8122,6 @@ totalist@^1.0.0: resolved "https://registry.yarnpkg.com/totalist/-/totalist-1.1.0.tgz#a4d65a3e546517701e3e5c37a47a70ac97fe56df" integrity sha512-gduQwd1rOdDMGxFG1gEvhV88Oirdo2p+KjoYFU7k2g+i7n6AFFbDQ5kMPUsW0pNbfQsB/cwXvT1i4Bue0s9g5g== -tough-cookie@~2.5.0: - version "2.5.0" - resolved "https://registry.yarnpkg.com/tough-cookie/-/tough-cookie-2.5.0.tgz#cd9fb2a0aa1d5a12b473bd9fb96fa3dcff65ade2" - integrity sha512-nlLsUzgm1kfLXSXfRZMc1KLAugd4hqJHDTvc2hDIwS3mZAfMEuMbc03SujMF+GEcpaX/qboeycw6iO8JwVv2+g== - dependencies: - psl "^1.1.28" - punycode "^2.1.1" - tr46@~0.0.3: version "0.0.3" resolved "https://registry.yarnpkg.com/tr46/-/tr46-0.0.3.tgz#8184fd347dac9cdc185992f3a6622e14b9d9ab6a" @@ -9455,13 +8214,6 @@ tsutils@^2.29.0: dependencies: tslib "^1.8.1" -tsutils@^3.21.0: - version "3.21.0" - resolved "https://registry.yarnpkg.com/tsutils/-/tsutils-3.21.0.tgz#b48717d394cea6c1e096983eed58e9d61715b623" - integrity sha512-mHKK3iUXL+3UF6xL5k0PEhKRUBKPBCv/+RkEOpjRWxxx27KKRBmmA60A9pgOUvMi8GKhRMPEmjBRPzs2W7O1OA== - dependencies: - tslib "^1.8.1" - tuf-js@^1.1.7: version "1.1.7" resolved "https://registry.yarnpkg.com/tuf-js/-/tuf-js-1.1.7.tgz#21b7ae92a9373015be77dfe0cb282a80ec3bbe43" @@ -9471,30 +8223,6 @@ tuf-js@^1.1.7: debug "^4.3.4" make-fetch-happen "^11.1.1" -tunnel-agent@^0.6.0: - version "0.6.0" - resolved "https://registry.yarnpkg.com/tunnel-agent/-/tunnel-agent-0.6.0.tgz#27a5dea06b36b04a0a9966774b290868f0fc40fd" - integrity sha512-McnNiV1l8RYeY8tBgEpuodCC1mLUdbSN+CYBL7kJsJNInOP8UjDDEwdk6Mw60vdLLrr5NHKZhMAOSrR2NZuQ+w== - dependencies: - safe-buffer "^5.0.1" - -tweetnacl@^0.14.3, tweetnacl@~0.14.0: - version "0.14.5" - resolved "https://registry.yarnpkg.com/tweetnacl/-/tweetnacl-0.14.5.tgz#5ae68177f192d4456269d108afa93ff8743f4f64" - integrity sha512-KXXFFdAbFXY4geFIwoyNK+f5Z1b7swfXABfL7HXCmoIWMKU3dmS26672A4EeQtDzLKy7SXmfBu51JolvEKwtGA== - -type-check@^0.4.0, type-check@~0.4.0: - version "0.4.0" - resolved "https://registry.yarnpkg.com/type-check/-/type-check-0.4.0.tgz#07b8203bfa7056c0657050e3ccd2c37730bab8f1" - integrity sha512-XleUoc9uwGXqjWwXaUTZAmzMcFZ5858QA2vvx1Ur5xIcixXIP+8LnFDgRplU30us6teqdlskFfu+ae4K79Ooew== - dependencies: - prelude-ls "^1.2.1" - -type-fest@^0.20.2: - version "0.20.2" - resolved "https://registry.yarnpkg.com/type-fest/-/type-fest-0.20.2.tgz#1bf207f4b28f91583666cb5fbd327887301cd5f4" - integrity sha512-Ne+eE4r0/iWnpAxD852z3A+N0Bt5RN//NjJwRd2VFHEmrywxf5vsZlh4R6lixl6B+wz/8d+maTSAkN1FIkI3LQ== - type-fest@^0.21.3: version "0.21.3" resolved "https://registry.yarnpkg.com/type-fest/-/type-fest-0.21.3.tgz#d260a24b0198436e133fa26a524a6d65fa3b2e37" @@ -9586,11 +8314,6 @@ unique-slug@^4.0.0: dependencies: imurmurhash "^0.1.4" -universalify@^0.1.0: - version "0.1.2" - resolved "https://registry.yarnpkg.com/universalify/-/universalify-0.1.2.tgz#b646f69be3942dabcecc9d6639c80dc105efaa66" - integrity sha512-rBJeI5CXAlmy1pV+617WB9J63U6XcazHHF2f2dbJix4XzpUF0RS3Zbj0FGIOCAva5P/d/GBOYaACQ1w+0azUkg== - unixify@^1.0.0: version "1.0.0" resolved "https://registry.yarnpkg.com/unixify/-/unixify-1.0.0.tgz#3a641c8c2ffbce4da683a5c70f03a462940c2090" @@ -9657,11 +8380,6 @@ utils-merge@1.0.1: resolved "https://registry.yarnpkg.com/utils-merge/-/utils-merge-1.0.1.tgz#9f95710f50a267947b2ccc124741c1028427e713" integrity sha512-pMZTvIkT1d+TFGvDOqodOclx0QWkkgi6Tdoa8gC8ffGAAqz9pzPTZWAybbsHHoED/ztMtkv/VoYTYyShUn81hA== -uuid@^3.3.2: - version "3.4.0" - resolved "https://registry.yarnpkg.com/uuid/-/uuid-3.4.0.tgz#b23e4358afa8a202fe7a100af1f5f883f02007ee" - integrity sha512-HjSDRw6gZE5JMggctHBcjVak08+KEVhSIiDzFnT9S9aegmp85S/bReBVTb4QTFaRNptJ9kuYaNhnbNEOkbKb/A== - uuid@^8.3.2: version "8.3.2" resolved "https://registry.yarnpkg.com/uuid/-/uuid-8.3.2.tgz#80d5b5ced271bb9af6c445f21a1a04c606cefbe2" @@ -9697,20 +8415,11 @@ value-or-promise@1.0.12, value-or-promise@^1.0.11: resolved "https://registry.yarnpkg.com/value-or-promise/-/value-or-promise-1.0.12.tgz#0e5abfeec70148c78460a849f6b003ea7986f15c" integrity sha512-Z6Uz+TYwEqE7ZN50gwn+1LCVo9ZVrpxRPOhOLnncYkY1ZzOYtrX8Fwf/rFktZ8R5mJms6EZf5TqNOMeZmnPq9Q== -vary@^1, vary@~1.1.2: +vary@~1.1.2: version "1.1.2" resolved "https://registry.yarnpkg.com/vary/-/vary-1.1.2.tgz#2299f02c6ded30d4a5961b0b9f74524a18f634fc" integrity sha512-BNGbWLfd0eUPabhkXUVm0j8uuvREyTh5ovRa/dyow/BqAbZJyC+5fU+IzQOzmAKzYqYRAISoRhdQr3eIZ/PXqg== -verror@1.10.0: - version "1.10.0" - resolved "https://registry.yarnpkg.com/verror/-/verror-1.10.0.tgz#3a105ca17053af55d6e270c1f8288682e18da400" - integrity sha512-ZZKSmDAEFOijERBLkmYfJ+vmk3w+7hOLYDNkRCuRuMJGEmqYNCNLyBBFwWKVMhfwaEF3WOd0Zlw86U/WC/+nYw== - dependencies: - assert-plus "^1.0.0" - core-util-is "1.0.2" - extsprintf "^1.2.0" - vite@4.3.9: version "4.3.9" resolved "https://registry.yarnpkg.com/vite/-/vite-4.3.9.tgz#db896200c0b1aa13b37cdc35c9e99ee2fdd5f96d" @@ -9722,16 +8431,6 @@ vite@4.3.9: optionalDependencies: fsevents "~2.3.2" -vlq@^1.0.0: - version "1.0.1" - resolved "https://registry.yarnpkg.com/vlq/-/vlq-1.0.1.tgz#c003f6e7c0b4c1edd623fd6ee50bbc0d6a1de468" - integrity sha512-gQpnTgkubC6hQgdIcRdYGDSDc+SaujOdyesZQMv6JlfQee/9Mp0Qhnys6WxDWvQnL5WZdT7o2Ul187aSt0Rq+w== - -void-elements@^2.0.0: - version "2.0.1" - resolved "https://registry.yarnpkg.com/void-elements/-/void-elements-2.0.1.tgz#c066afb582bb1cb4128d60ea92392e94d5e9dbec" - integrity sha512-qZKX4RnBzH2ugr8Lxa7x+0V6XD9Sb/ouARtiasEQCHB1EVU4NXtmHsDDrx1dO4ne5fc3J6EW05BP1Dl0z0iung== - watchpack@^2.4.0: version "2.4.0" resolved "https://registry.yarnpkg.com/watchpack/-/watchpack-2.4.0.tgz#fa33032374962c78113f93c7f2fb4c54c9862a5d" @@ -9775,31 +8474,6 @@ webcrypto-core@^1.7.4: pvtsutils "^1.3.2" tslib "^2.4.0" -webdriver-js-extender@2.1.0: - version "2.1.0" - resolved "https://registry.yarnpkg.com/webdriver-js-extender/-/webdriver-js-extender-2.1.0.tgz#57d7a93c00db4cc8d556e4d3db4b5db0a80c3bb7" - integrity sha512-lcUKrjbBfCK6MNsh7xaY2UAUmZwe+/ib03AjVOpFobX4O7+83BUveSrLfU0Qsyb1DaKJdQRbuU+kM9aZ6QUhiQ== - dependencies: - "@types/selenium-webdriver" "^3.0.0" - selenium-webdriver "^3.0.1" - -webdriver-manager@^12.1.7: - version "12.1.8" - resolved "https://registry.yarnpkg.com/webdriver-manager/-/webdriver-manager-12.1.8.tgz#5e70e73eaaf53a0767d5745270addafbc5905fd4" - integrity sha512-qJR36SXG2VwKugPcdwhaqcLQOD7r8P2Xiv9sfNbfZrKBnX243iAkOueX1yAmeNgIKhJ3YAT/F2gq6IiEZzahsg== - dependencies: - adm-zip "^0.4.9" - chalk "^1.1.1" - del "^2.2.0" - glob "^7.0.3" - ini "^1.3.4" - minimist "^1.2.0" - q "^1.4.1" - request "^2.87.0" - rimraf "^2.5.2" - semver "^5.3.0" - xml2js "^0.4.17" - webidl-conversions@^3.0.0: version "3.0.1" resolved "https://registry.yarnpkg.com/webidl-conversions/-/webidl-conversions-3.0.1.tgz#24534275e2a7bc6be7bc86611cc16ae0a5654871" @@ -9960,13 +8634,6 @@ which-module@^2.0.0: resolved "https://registry.yarnpkg.com/which-module/-/which-module-2.0.0.tgz#d9ef07dce77b9902b8a3a8fa4b31c3e3f7e6e87a" integrity sha512-B+enWhmw6cjfVC7kS8Pj9pCrKSc5txArRyaYGe088shv/FGWH+0Rjx/xPgtsWfsUtS27FkP697E4DDhgrgoc0Q== -which@^1.2.1: - version "1.3.1" - resolved "https://registry.yarnpkg.com/which/-/which-1.3.1.tgz#a45043d54f5805316da8d62f9f50918d3da70b0a" - integrity sha512-HxJdYWq1MTIQbJ3nw0cqssHoTNU267KlrDuGZ1WYlxDStUtKUhOaJmh112/TZmHxxUfuJqPXSOm7tDyas0OSIQ== - dependencies: - isexe "^2.0.0" - which@^2.0.1, which@^2.0.2: version "2.0.2" resolved "https://registry.yarnpkg.com/which/-/which-2.0.2.tgz#7c6a8dd0a636a0327e10b59c9286eee93f3f51b1" @@ -9993,11 +8660,6 @@ wildcard@^2.0.0: resolved "https://registry.yarnpkg.com/wildcard/-/wildcard-2.0.0.tgz#a77d20e5200c6faaac979e4b3aadc7b3dd7f8fec" integrity sha512-JcKqAHLPxcdb9KM49dufGXn2x3ssnfjbcaQdLlfZsL9rH9wgDQjUtDxbo8NE0F6SFvydeu1VhZe7hZuHsB2/pw== -word-wrap@^1.2.3: - version "1.2.3" - resolved "https://registry.yarnpkg.com/word-wrap/-/word-wrap-1.2.3.tgz#610636f6b1f703891bd34771ccb17fb93b47079c" - integrity sha512-Hz/mrNwitNRh/HUAtM/VT/5VH+ygD6DV7mYKZAtHOrbs8U7lvPS6xf7EJKMF0uW1KJCl0H701g3ZGus+muE5vQ== - "wrap-ansi-cjs@npm:wrap-ansi@^7.0.0", wrap-ansi@^7.0.0: version "7.0.0" resolved "https://registry.yarnpkg.com/wrap-ansi/-/wrap-ansi-7.0.0.tgz#67e145cff510a6a6984bdf1152911d69d2eb9e43" @@ -10045,24 +8707,6 @@ ws@^8.13.0: resolved "https://registry.yarnpkg.com/ws/-/ws-8.13.0.tgz#9a9fb92f93cf41512a0735c8f4dd09b8a1211cd0" integrity sha512-x9vcZYTrFPC7aSIbj7sRCYo7L/Xb8Iy+pW0ng0wt2vCJv7M9HOMy0UoN3rr+IFC7hb7vXoqS+P9ktyLLLhO+LA== -ws@~8.2.3: - version "8.2.3" - resolved "https://registry.yarnpkg.com/ws/-/ws-8.2.3.tgz#63a56456db1b04367d0b721a0b80cae6d8becbba" - integrity sha512-wBuoj1BDpC6ZQ1B7DWQBYVLphPWkm8i9Y0/3YdHjHKHiohOJ1ws+3OccDWtH+PoC9DZD5WOTrJvNbWvjS6JWaA== - -xml2js@^0.4.17: - version "0.4.23" - resolved "https://registry.yarnpkg.com/xml2js/-/xml2js-0.4.23.tgz#a0c69516752421eb2ac758ee4d4ccf58843eac66" - integrity sha512-ySPiMjM0+pLDftHgXY4By0uswI3SPKLDw/i3UXbnO8M/p28zqexCUoPmQFrYD+/1BzhGJSs2i1ERWKJAtiLrug== - dependencies: - sax ">=0.6.0" - xmlbuilder "~11.0.0" - -xmlbuilder@~11.0.0: - version "11.0.1" - resolved "https://registry.yarnpkg.com/xmlbuilder/-/xmlbuilder-11.0.1.tgz#be9bae1c8a046e76b31127726347d0ad7002beb3" - integrity sha512-fDlsI/kFEx7gLvbecc0/ohLG50fugQp8ryHzMTuW9vSa1GJ0XYWKnhsUx7oie3G98+r56aTQIUB4kht42R3JvA== - y18n@^4.0.0: version "4.0.3" resolved "https://registry.yarnpkg.com/y18n/-/y18n-4.0.3.tgz#b5f259c82cd6e336921efd7bfd8bf560de9eeedf" @@ -10101,11 +8745,6 @@ yargs-parser@^18.1.2: camelcase "^5.0.0" decamelize "^1.2.0" -yargs-parser@^20.2.2: - version "20.2.9" - resolved "https://registry.yarnpkg.com/yargs-parser/-/yargs-parser-20.2.9.tgz#2eb7dc3b0289718fc295f362753845c41a0c94ee" - integrity sha512-y11nGElTIV+CT3Zv9t7VKl+Q3hTQoT9a1Qzezhhl6Rp21gJ/IVTW7Z3y9EWXhuUBC2Shnf+DX0antecpAwSP8w== - yargs-parser@^21.1.1: version "21.1.1" resolved "https://registry.yarnpkg.com/yargs-parser/-/yargs-parser-21.1.1.tgz#9096bceebf990d21bb31fa9516e0ede294a77d35" @@ -10141,19 +8780,6 @@ yargs@^15.3.1: y18n "^4.0.0" yargs-parser "^18.1.2" -yargs@^16.1.1: - version "16.2.0" - resolved "https://registry.yarnpkg.com/yargs/-/yargs-16.2.0.tgz#1c82bf0f6b6a66eafce7ef30e376f49a12477f66" - integrity sha512-D1mvvtDG0L5ft/jGWkLpG1+m0eQxOfaBvTNELraWj22wSVUMWxZUvYgJYcKh6jGGIkJFhH4IZPQhR4TKpc8mBw== - dependencies: - cliui "^7.0.2" - escalade "^3.1.1" - get-caller-file "^2.0.5" - require-directory "^2.1.1" - string-width "^4.2.0" - y18n "^5.0.5" - yargs-parser "^20.2.2" - yargs@^17.0.0, yargs@^17.2.1: version "17.6.2" resolved "https://registry.yarnpkg.com/yargs/-/yargs-17.6.2.tgz#2e23f2944e976339a1ee00f18c77fedee8332541"